0001193125-23-199175.txt : 20230731 0001193125-23-199175.hdr.sgml : 20230731 20230731163601 ACCESSION NUMBER: 0001193125-23-199175 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230731 DATE AS OF CHANGE: 20230731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 231127833 BUSINESS ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 10-Q 1 d515836d10q.htm FORM 10-Q Form 10-Q
Table of Contents
falseQ20001613780--12-3100-0000000 0001613780 2023-06-30 0001613780 2022-12-31 0001613780 2022-04-01 2022-06-30 0001613780 2023-01-01 2023-06-30 0001613780 2022-01-01 2022-06-30 0001613780 2023-04-01 2023-06-30 0001613780 2023-07-31 0001613780 2022-01-01 2022-03-31 0001613780 2023-01-01 2023-03-31 0001613780 2021-12-31 0001613780 2022-03-31 0001613780 2022-06-30 0001613780 2023-03-31 0001613780 us-gaap:CommonStockMember 2022-12-31 0001613780 us-gaap:RealEstateMember 2022-12-31 0001613780 dbvt:OtherAssetMember 2022-12-31 0001613780 dbvt:TaxLiabilitiesMember 2022-12-31 0001613780 dbvt:OtherDebtsMember 2022-12-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2022-12-31 0001613780 dbvt:DeferredRevenueMember 2022-12-31 0001613780 us-gaap:CommonStockMember 2023-06-30 0001613780 us-gaap:RealEstateMember 2023-06-30 0001613780 dbvt:OtherAssetMember 2023-06-30 0001613780 dbvt:TaxLiabilitiesMember 2023-06-30 0001613780 dbvt:OtherDebtsMember 2023-06-30 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2023-06-30 0001613780 dbvt:DeferredRevenueMember 2023-06-30 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2023-06-30 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2023-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2023-06-30 0001613780 dbvt:AmericanDepositarySharesMember 2023-06-30 0001613780 dbvt:ShareCapitalMember 2023-06-30 0001613780 dbvt:ExpensesByFunctionMember 2022-01-01 2022-06-30 0001613780 dbvt:ExpensesByNatureMember 2022-01-01 2022-06-30 0001613780 dbvt:NonemployeewarrantsMember 2022-01-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001613780 dbvt:PrefundedWarrantsMember 2022-01-01 2022-06-30 0001613780 dbvt:RentExpensesMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001613780 dbvt:ExpensesByFunctionMember 2022-04-01 2022-06-30 0001613780 dbvt:ExpensesByNatureMember 2022-04-01 2022-06-30 0001613780 dbvt:NonemployeewarrantsMember 2022-04-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001613780 dbvt:PrefundedWarrantsMember 2022-04-01 2022-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0001613780 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001613780 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001613780 dbvt:ExpensesByFunctionMember 2023-01-01 2023-06-30 0001613780 dbvt:ExpensesByNatureMember 2023-01-01 2023-06-30 0001613780 dbvt:NonemployeewarrantsMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 dbvt:PrefundedWarrantsMember 2023-01-01 2023-06-30 0001613780 dbvt:RentExpensesMember 2023-01-01 2023-06-30 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2023-01-01 2023-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2023-01-01 2023-06-30 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 dei:AdrMember 2023-01-01 2023-06-30 0001613780 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001613780 dbvt:CollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001613780 dbvt:IncreaseInCurrentTradePayablesMember 2023-01-01 2023-06-30 0001613780 us-gaap:ResearchMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 dbvt:ExpensesByFunctionMember 2023-04-01 2023-06-30 0001613780 dbvt:ExpensesByNatureMember 2023-04-01 2023-06-30 0001613780 dbvt:NonemployeewarrantsMember 2023-04-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001613780 dbvt:PrefundedWarrantsMember 2023-04-01 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0001613780 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001613780 us-gaap:TreasuryStockMember 2023-04-01 2023-06-30 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001613780 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001613780 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001613780 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001613780 us-gaap:TreasuryStockMember 2023-01-01 2023-03-31 0001613780 srt:MinimumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember srt:MaximumMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:AmericanDepositarySharesMember 2023-06-01 2023-06-30 0001613780 us-gaap:ResearchMember 2022-01-01 2022-12-31 0001613780 us-gaap:CommonStockMember 2022-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001613780 us-gaap:TreasuryStockMember 2022-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2022-12-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2022-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001613780 dbvt:BSAWarrantsMember 2022-12-31 0001613780 dbvt:BSAWarrantsMember 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-12-31 0001613780 us-gaap:EmployeeStockOptionMember 2023-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001613780 us-gaap:TreasuryStockMember 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2023-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001613780 us-gaap:CommonStockMember 2021-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001613780 us-gaap:TreasuryStockMember 2021-12-31 0001613780 us-gaap:RetainedEarningsMember 2021-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001613780 us-gaap:CommonStockMember 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001613780 us-gaap:TreasuryStockMember 2022-03-31 0001613780 us-gaap:RetainedEarningsMember 2022-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001613780 us-gaap:TreasuryStockMember 2022-12-31 0001613780 us-gaap:RetainedEarningsMember 2022-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001613780 us-gaap:CommonStockMember 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001613780 us-gaap:TreasuryStockMember 2023-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 iso4217:USD xbrli:shares utr:Year utr:Month xbrli:pure iso4217:EUR iso4217:EUR xbrli:shares iso4217:USD xbrli:shares

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
or
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
                    
to
                    
Commission file number
001-36697
 
 
DBV TECHNOLOGIES S.A.
(Exact name of registrant as specified in its charter)
 
 
 
France
 
Not applicable
State or other jurisdiction of
incorporation or organization
 
(I.R.S. Employer
Identification No.)
   
177-181
avenue Pierre Brossolette
92120 Montrouge France
 
N/A
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code +33 1 55 42 78 78
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
American Depositary Shares, each representing
one-half
of one ordinary share, nominal value €0.10 per share
 
DBVT
 
The Nasdaq Stock Market LLC
Ordinary shares, nominal value €0.10 per share*
 
n/a
 
The Nasdaq Stock Market LLC
 
*
Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered pursuant to section 12(g) of the Act: None.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒    Yes                ☐    No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒    Yes                ☐    No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.

Large accelerated filer     Accelerated filer  
       
Non-accelerated
filer
    Smaller reporting company  
       
        Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Act).    ☐  Yes      No
As of July 31, 2023, the registrant had 96,250,954 ordinary shares, nominal value €0.10 per share, outstanding including treasury shares.
 
 
 


Table of Contents

Table of contents

 

Part I

  Financial information      3  

Item 1

  Condensed Consolidated Statements of Financial Position (Unaudited) as of June 30, 2023 and December 31, 2022      3  
  Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three and Six Months Ended June 30, 2023 and 2022      4  
  Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2023 and 2022      5  
  Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) for the Six Months Ended June 30, 2023 and 2022      6  
  Notes to the Condensed Consolidated Financial Statements (Unaudited)      7  

Item 2

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      17  

Item 3

  Quantitative and Qualitative Disclosures About Market Risk      24  

Item 4

  Controls and Procedures      24  

Part II

  Other Information      24  

Item 1

  Legal Proceedings      24  

Item 1A

  Risk Factors      25  

Item 2

  Unregistered Sales of Equity Securities and Use of Proceeds      25  

Item 3

  Defaults Upon Senior Securities      25  

Item 4

  Mine Safety Disclosures      25  

Item 5

  Other Information      25  

Item 6

  Exhibits      25  

Unless the context otherwise requires, we use the terms “DBV”, “DBV Technologies,” the “Company,” “we,” “us” and “our” in this Quarterly Report on Form 10-Q, or Quarterly Report, to refer to DBV Technologies S.A. and, where appropriate, its consolidated subsidiaries. “Viaskin”, “EPIT” and our other registered and common law trade names, trademarks and service marks are the property of DBV Technologies S.A. or our subsidiaries. All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the ® and  symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.


Table of Contents

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS.

This Quarterly Report contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things:

 

   

our expectations regarding the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated re-submission of a Biologics License Application, or a BLA, for ViaskinTM Peanut to the U.S. Food and Drug Administration, or the FDA;

 

   

the timing and anticipated results of interactions with regulatory agencies;

 

   

the initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;

 

   

the sufficiency of existing capital resources;

 

   

our business model and our other strategic plans for our business, product candidates and technology;

 

   

our ability to manufacture clinical and commercial supplies of our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates;

 

   

our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Viaskin Peanut and/or our other product candidates, if approved;

 

   

the commercialization of our product candidates, if approved;

 

   

our expectations regarding the potential market size and the size of the patient populations for Viaskin Peanut and/or our other product candidates, if approved, and our ability to serve such markets;

 

   

the pricing and reimbursement of our product candidates, if approved;

 

   

the rate and degree of market acceptance of Viaskin Peanut and/or our other product candidates, if approved, by physicians, patients, third-party payors and others in the medical community;

 

   

our ability to advance product candidates into, and successfully complete, clinical trials;

 

   

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

 

   

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

 

   

the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;

 

   

our ability to maintain and establish collaborations or obtain additional grant funding;

 

   

our financial performance;

 

   

developments relating to our competitors and our industry, including competing therapies;

 

   

the impact of the COVID-19 pandemic and its effects on our operations, research and development, clinical trials and ability to obtain financing and potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers and collaborators with whom we conduct business; and

 

   

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption “Risk Factors” in Part I. Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission, or the SEC on March 2, 2023. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Undue reliance should not be placed on any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.

 

1


Table of Contents

In addition, any forward-looking statement in this Quarterly Report, including statements that “we believe” and similar statements, reflect our beliefs and opinions on the relevant subject and represents our views only as of the date of this Quarterly Report and should not be relied upon as representing our views as of any subsequent date. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

 

 

2


Table of Contents
Part I – Financial Information
Item 1. Financial Statements
DBV
Technologies S.A.
Condensed Consolidated Statements of Financial Position (unaudited)
(amounts in thousands, except share and per share data)
 
           
June 30,
   
December 31,
 
    
Note
    
2023
   
2022
 
Assets
                         
Current assets:
                         
Cash and cash equivalents
  
 
3
 
   $ 173,961     $ 209,194  
Other current assets
  
 
4
 
     21,578       13,880  
             
 
 
   
 
 
 
Total current assets
           
 
195,539
 
 
 
223,074
 
Property, plant, and equipment, net
              14,135       15,096  
Right-of-use
assets related to operating leases
  
 
5
 
     1,832       2,513  
Intangible assets
              68       10  
Other
non-current
assets
              5,944       5,824  
             
 
 
   
 
 
 
Total
non-current
assets
           
 
21,979
 
 
 
23,444
 
             
 
 
   
 
 
 
Total Assets
           
$
217,518
 
 
$
246,518
 
             
 
 
   
 
 
 
Liabilities and shareholders’ equity
                         
Current liabilities:
                         
Trade payables
  
 
6
 
   $ 19,094     $ 14,473  
Short-term operating leases
  
 
5
 
     1,944       1,894  
Current contingencies
  
 
9
 
     5,076       3,944  
Other current liabilities
  
 
6
 
     7,258       9,210  
             
 
 
   
 
 
 
Total current liabilities
           
 
33,373
 
 
 
29,521
 
             
 
 
   
 
 
 
Long-term operating leases
  
 
5
 
     187       1,127  
Non-current
contingencies
  
 
9
 
     15,731       16,680  
Other
non-current
liabilities
  
 
6
 
     3,987       4,735  
             
 
 
   
 
 
 
Total
non-current
liabilities
           
 
19,905
 
 
 
22,543
 
             
 
 
   
 
 
 
Total Liabilities
           
$
53,277
 
 
$
52,064
 
             
 
 
   
 
 
 
Shareholders’ equity:
                         
Ordinary shares, €0.10 par value; 96,250,954 and 94,137,145 shares authorized, and issued as
of
 June 30, 2023 and December 31, 2022, respectively
            $ 10,952     $ 10,720  
Additional
paid-in
capital
              375,759       458,221  
Treasury stock, 149,972 and 149,793 ordinary shares as of June 30, 2023 and December 31, 2022, respectively, at cost
              (1,082     (1,109
Accumulated deficit
              (210,940     (259,578
Accumulated other comprehensive income
              687       781  
Accumulated currency translation effect
              (11,136     (14,581
             
 
 
   
 
 
 
Total Shareholders’ equity
  
 
7
 
  
$
164,240
 
 
$
194,453
 
             
 
 
   
 
 
 
Total Liabilities and Shareholders’ equity
           
$
217,518
 
 
$
246,518
 
             
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
3

DBV Technologies S.A.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(amounts in thousands, except share and per share data)
 
           
Three Months Ended June 30,
   
Six Months Ended
June 30,
 
    
Note
    
2023
   
2022
   
2023
   
2022
 
Operating income
  
 
10
 
  
$
2,288
 
 
$
1,529
 
 
$
4,482
 
 
$
4,074
 
Operating expenses
                                         
Research and development expenses
              (17,616     (18,611     (33,653     (30,834
Sales and marketing expenses
              (516     (1,037     (950     (1,500
General and administrative expenses
              (9,231     (5,704     (16,120     (12,334
             
 
 
   
 
 
   
 
 
   
 
 
 
Total Operating expenses
           
 
(27,364
 
 
(25,352
 
 
(50,723
 
 
(44,669
             
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
           
 
(25,076
 
 
(23,823
 
 
(46,242
 
 
(40,595
             
 
 
   
 
 
   
 
 
   
 
 
 
Financial income (expenses)
              846       784       1,450       936  
             
 
 
   
 
 
   
 
 
   
 
 
 
Loss before taxes
           
 
(24,230
 
 
(23,039
 
 
(44,791
 
 
(39,659
             
 
 
   
 
 
   
 
 
   
 
 
 
Income tax
              (13           (13     (87
             
 
 
   
 
 
   
 
 
   
 
 
 
Net loss
           
$
(24,243
 
$
(23,039
 
$
(44,804
 
$
(39,746
             
 
 
   
 
 
   
 
 
   
 
 
 
Foreign currency translation differences, net of taxes
              (221     (11,394     3,445       (13,327
Actuarial gains (losses) on employee benefits, net of taxes
              (10     200       (92     224  
             
 
 
   
 
 
   
 
 
   
 
 
 
Total comprehensive loss
           
$
(24,475
 
$
(34,234
 
$
(41,452
 
$
(52,849
             
 
 
   
 
 
   
 
 
   
 
 
 
Basic/diluted net loss per share attributable to shareholders
  
 
14
 
  
$
(0.26
 
$
(0.35
 
$
(0.48
 
$
(0.66
Weighted average shares outstanding used in computing per share amounts:
              94,324,889       66,047,949       94,150,141       60,490,075  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
4

DBV Technologies S.A.
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
 
           
Six Months
Ended June 30,
 
    
Notes
    
2023
   
2022
 
Net loss for the period
           
$
(44,804
 
$
(39,746
Adjustments to reconcile net loss to net cash flow provided by (used in) operating activities:
                         
Depreciation, amortization and accrued contingencies
              369       1,249  
Retirement pension obligations
              11       14  
Expenses related to share-based payments
  
 
8
 
     3,446       2,441  
Other elements
              23       (3
Changes in operating assets and liabilities:
                         
Decrease (increase) in other current assets
              (6,481     23,436  
(Decrease) increase in trade payables
              3,419       5,894  
(Decrease) increase in other current and
non-current
liabilities
              (2,913     (3,040
Change in operating lease liabilities and right of use assets
              535       (1,979
Net cash flow provided by (used in) operating activities
           
 
(46,394
 
 
(11,733
             
 
 
   
 
 
 
Cash flows provided by (used in) investing activities:
                         
Acquisitions of property, plant, and equipment, net from proceeds
              (275     (369
Proceeds from property, plant, and equipment dispositions
                       3  
Acquisitions of
non-current
financial assets
              (27     (279
Proceeds from
non-current
financial assets dispositions
              4       426  
             
 
 
   
 
 
 
Net cash flows provided by (used in) investing activities
           
 
(299
 
 
(218
             
 
 
   
 
 
 
Cash flows provided by (used in) financing activities:
                         
Decrease in conditional advances
                       (328
Treasury shares
              27       279  
Capital increases, net of transaction costs
              7,766       195,270  
Other cash flows related to financing activities
                           
             
 
 
   
 
 
 
Net cash flows provided by (used in) financing activities
           
 
7,793
 
 
 
195,221
 
             
 
 
   
 
 
 
Effect of exchange rate changes on cash and cash equivalents
              3,668       (12,600
             
 
 
   
 
 
 
Net increase (decrease) in cash and cash equivalents
           
 
(35,232
 
 
170,670
 
             
 
 
   
 
 
 
Net Cash and cash equivalents at the beginning of the period
              209,194       77,301  
             
 
 
   
 
 
 
Net cash and cash equivalents at the end of the period
  
 
3
 
  
$
173,961
 
 
$
247,971
 
             
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
5

DBV Technologies S.A.
Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)
(amounts in thousands, except share and per share data)
 
    
Ordinary shares
                                       
    
Number of
Shares
    
Amount
    
Additional
paid-in

capital
   
Treasury
stock
   
Accumulated
deficit
   
Accumulated
other
comprehensive
income (loss)
    
Accumulated
currency
translation
effect
   
Total
Shareholders’
Equity
 
Balance at January 1, 2022
  
 
55,095,762
 
  
$
6,538
 
  
$
358,115
 
 
$
(1,232
 
$
(258,528
 
$
519
 
  
$
(6,137
 
$
99,274
 
Net (loss)
     —          —          —         —         (16,706     —          —         (16,706
Other comprehensive income (loss)
     —          —          —         —         —         24        (1,933     (1,909
Issuance of ordinary shares
     775        1                 —         —         —          —         1  
Treasury shares
     —          —          —         40       —         —          —         40  
Share-based payments
     —          —          1,363       —         —         —          —         1,363  
Other change in equity
     —          —          —         —         15       —          (15     —    
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
    
 
 
   
 
 
 
Balance at March 31, 2022
  
 
55,096,537
 
  
$
6,539
 
  
$
359,478
 
 
$
(1,193
 
$
(275,219
 
$
543
 
  
$
(8,086
 
$
82,062
 
Net (loss)
     —          —          —         —         (23,039     —          —         (23,039
Other comprehensive income (loss)
     —          —          —         —         —         200        (11,394     (11,194
Issuance of ordinary shares
     38,926,142        4,170        103,007       —         —         —          —         107,176  
Issuance of warrants
     —          —          88,094       —         —         —          —         88,094  
Treasury shares
     —          —          —         240       —         —          —         240  
Share-based payments
     —          —          1,078       —         —         —          —         1,078  
Allocation of accumulated net losses
     —          —          (95,209     —         95,209       —          —         —    
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
    
 
 
   
 
 
 
Balance at June 30, 2022
  
 
94,022,679
 
  
$
10,708
 
  
$
456,447
 
 
$
(953
 
$
(203,050
 
$
743
 
  
$
(19,480
 
$
244,416
 
 
    
Ordinary shares
                                      
    
Number of
Shares
    
Amount
    
Additional
paid-in

capital
   
Treasury
stock
   
Accumulated
deficit
   
Accumulated
other
comprehensive
income (loss)
   
Accumulated
currency
translation
effect
   
Total
Shareholders’
Equity
 
Balance at January 1, 2023
  
 
94,137,145
 
  
$
10,720
 
  
$
458,221
 
 
$
(1,109
 
$
(259,578
 
$
781
 
 
$
(14,581
 
$
194,453
 
Net (loss)
     —          —          —         —         (20,561     —         —         (20,561
Other comprehensive income (loss)
     —          —          —         —         —         (82     3,666       3,584  
Issuance of ordinary shares
     10,174        1        (1     —         —         —         —             
Treasury shares
     —          —          —         (14     —         —         —         (14
Share-based payments
     —          —          1,632       —         —         —         —         1,632  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at March 31, 2023
  
 
94,147,319
 
  
$
10,721
 
  
$
459,852
 
 
$
(1,123
 
$
(280,138
 
$
698
 
 
$
(10,915
 
$
179,094
 
Net (loss)
     —          —          —         —         (24,243     —         —         (24,243
Other comprehensive income (loss)
     —          —          —         —         —         (10     (221     (232
Issuance of ordinary shares
     2,103,635        231        7,535       —         —         —         —         7,766  
Treasury shares
     —          —          —         42       —         —         —         42  
Share-based payments
     —          —          1,814       —         —         —         —         1,814  
Allocation of accumulated net losses
     —          —          (93,441     —         93,441       —         —         —    
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at June 30, 2023
  
 
96,250,954
 
  
$
10,952
 
  
$
375,759
 
 
$
(1,082
 
$
(210,940
 
$
687
 
 
$
(11,136
 
$
164,240
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
6

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1: The Company
Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”, or the “group”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin
. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT
, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin
.
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form
10-K
filed with the SEC on March 2, 2023 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2022 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2022.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2023, or any other future period.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an
on-going
basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of
right-of-use
assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies, and (8) estimate of employee benefits obligations.
Accounting Pronouncements adopted in 2023
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU
2016-13—Financial
Instruments—Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU
2019-10
which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Adoption of this new standard did not have a material impact on the consolidated financial statements.
In October 2021, the FASB issued ASU
2021-08,
which amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. This amendment is effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption of this new standard has no impact on the consolidated financial statements.
 
7

Accounting Pronouncements issued not yet adopted
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
Note 2: Significant Events and Transactions
Clinical programs
United States Regulatory History and Current Status
In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following receipt of the Complete Response Letter. The FDA agreed with its position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of one peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and a modified patch, FDA requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages
4-11.
The Company named that assessment EQUAL, which stands for Equivalence in Uptake of ALlergen. The FDA also recommended conducting a
6-month,
well-controlled safety and adhesion trial to assess a modified Viaskin Peanut patch in the intended patient population. The Company later named this study STAMP, which stands for Safety, Tolerability, and Adhesion of Modified Patches.
Based on the January 2021 FDA feedback, the Company defined three parallel workstreams:
 
  1.
Identify a modified Viaskin patch (which the Company calls “mVP”).
 
  2.
Generate the
6-month
safety and adhesion clinical data FDA requested via STAMP, which the Company expected to be the longest component of the mVP clinical plan. The Company prioritized the STAMP protocol submission so the Company could begin the study as soon as possible.
 
  3.
Demonstrate the equivalence in allergen uptake between the current and modified patches in the intended patient population via EQUAL. The complexity of EQUAL hinged on the lack of established clinical and regulatory criteria to characterize allergen uptake via an epicutaneous patch. To support those exchanges, the Company outlined its proposed approach to demonstrate allergen uptake equivalence between the two patches, and allotted time to generate informative data through two additional Phase 1 clinical trials in healthy adult volunteers:
 
  a.
PREQUAL, a Phase 1 study with adult healthy volunteers to optimize the allergen sample collection methodologies and validate the assays we intend to use in EQUAL
.
The data collection phase of the trial is complete, and the data analysis phase is ongoing.
 
  b.
‘EQUAL in adults’—a second Phase I study with adult healthy volunteers to compare the allergen uptake of cVP and mVP;
In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches. The Company completed CHAMP in the second quarter of 2021. All modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the then-current Viaskin Peanut patch, and the Company then selected two modified patches that performed best out of the five modified patches studied for further development. The Company then selected the circular patch for further development, which is larger in size relative to the current patch and circular in shape.
In May 2021, the Company submitted its proposed STAMP protocol to the FDA, and on October 14, 2021, the Company received an Advice/Information Request letter from the FDA. In this letter, the FDA requested a stepwise approach to the modified Viaskin patch development program and provided partial feedback on the STAMP protocol. Specifically, the FDA requested that the Company conduct allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL), and submit the allergen uptake comparison data for FDA review and feedback prior to starting the STAMP study. The FDA’s explanation was that the results from the allergen uptake studies might affect the design of the STAMP study.
After careful review of the FDA’s information requests, in December 2021, the Company decided not to pursue the sequential approach to the development plans for Viaskin Peanut as requested by the FDA in the October 2021 feedback. The Company estimated that the FDA’s newly proposed sequential approach would require at least five rounds of exchanges that necessitate FDA alignment prior to initiating STAMP, the
6-month
safety and adhesion study. As such, in December 2021, the Company announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. The Company considers this approach the most straightforward to potentially demonstrate effectiveness, safety, and improved in vivo adhesion of the modified Viaskin Peanut system. The FDA confirmed the Company’s change in strategy is agreeable via oral and written
exchanges.
 
8

In 2022, the Company announced the new Phase 3 pivotal study for modified Viaskin Peanut (mVP) patch would be in younger
(4-7
years old) and more sensitive children with peanut allergy.
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institution
al
Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced it received feedback from the U.S. FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol.
On March 2, 2023, the Company announced the completion of EVOLVE, a
12-week
caregiver and patient user experience study of the mVP patch in 50 peanut allergic children ages
4–11-years
old. The objective of EVOLVE was to evaluate the Instructions for Use (IFU) and ease of use for the mVP patch. The study concluded that the updated IFU supported correct patch application, which included no lifting of the patch edges or detachment directly after application. Furthermore, EVOLVE concluded that the majority of parents/caregivers reported a positive ease of use experience with the mVP patch. In EVOLVE, DBV also tested the functionality of an electronic patient diary (eDiary) to collect information on activities of daily living and patch adhesion scores. EVOLVE verified that the eDiary tool can be used by caregivers in VITESSE to capture the adhesion data in support of a potential BLA.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE study. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025.
On April 19, 2023, the Company outlined
the
regulatory path for Viaskin Peanut in children
1-3
years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the
pre-specified
criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.
Viaskin Peanut for children ages
4-11—European
Union Regulatory History and Current Status
On August 2, 2021, the Company announced it received from the European Medicines Agency (“EMA”) of the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. It is a letter that is meant to include any remaining questions or objections at that stage in the process. The EMA indicated many of their objections and major objections from the Day 120 list of questions had been answered. One major objection remained at Day 180. The Major Objection questioned the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.
On December 20, 2021, the Company announced it had withdrawn the Marketing Authorization Application (“MAA”) for Viaskin Peanut and formally notified the EMA of our decision. The initial filing was supported by data from a single, placebo-controlled Phase 3 pivotal trial known as PEPITES
(V712-301).
The decision to withdraw was based on the view of EMA Committee for Medicinal Products for Human Use (CHMP) that the data available to date from a single pivotal clinical trial were not sufficient to preclude a Major Objection at Day 180 in the review cycle. The Company believes data from a second Viaskin Peanut pivotal clinical trial will support a more robust path for licensure of Viaskin Peanut in the EU. The Company intends to resubmit the MAA when that data set is available.
Viaskin Peanut for children ages
1-3
In June 2020, the Company announced that in Part A, patients in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigation of the 250 µg dose in this age group, which is the dose being studied in Part B of the study. Enrollment for Part B of EPITOPE was completed in the first quarter
of 2021.
 
9

In June 2022, the Company announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms respectively. Enrollment was balance for age and baseline disease characteristics between the active and placebo treatment arms.
On April 19, 2023,
the Company announced it will begin a new safety study after it received confirmation from the FDA that the EPITOPE study meets the
 
pre-specified
 
criteria for success for the primary endpoint, with no additional efficacy study requested. This safety study will increase the safety data collected from EPITOPE in support of a BLA. It will also generate patch adhesion data and will include updated instructions for use.
On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut
exposure
by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages
1-3
years old with a confirmed peanut allergy.
Viaskin Peanut for Children ages
4-7
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced we had received feedback from the FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE trial. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025.
Financing
In June 2023, the Company issued and completed sales of new ordinary shares (the “Ordinary Shares”) in
the
form of American Depositary Shares (“ADSs”), for a total gross amount of $7.8 million, under the
At-The-Market
(“ATM”) program established in May 2022. In this context, 2,052,450 new Ordinary Shares in
the
form of ADS have been issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics (the “ATM Issuance”), at a unit subscription price of 1.90 dollar per ADS (i.e., a subscription price per Ordinary Share of 3.52 euro based on the USD/EUR exchange rate of 1.0809 dollar for 1 euro, as published by the European Central Bank on June 14, 2023) and each ADS giving the right to receive
one-half
of one ordinary share of the Company.
Legal Proceedings
From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings.
 
10

Note 3: Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Cash
     24,111        30,104  
Cash equivalents
     149,850        179,090  
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of financial position
  
 
173,961
 
  
 
209,194
 
    
 
 
    
 
 
 
Bank overdrafts
                   
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of cash flows
  
 
173,961
 
  
 
209,194
 
Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements.
Note 4 Other Current Assets
Other current assets consisted of the following:
 
 
  
June 30,
2023
 
  
December 31,
2022
 
Research tax credit
     9,662        5,792  
Other tax claims
     5,851        3,903  
Prepaid expenses
     4,494        2,680  
Other receivables
     1,571        1,504  
    
 
 
    
 
 
 
Total
  
 
21,578
 
  
 
13,880
 
    
 
 
    
 
 
 
Research tax credit
The variance in Research Tax Credit is presented as follows:
 
    
Amount in
thousands of US
Dollars
 
Opening research tax credit receivable as of January 1, 2023
  
 
5,792
 
+ Operating revenue
     3,741  
- Payment received
         
- Adjustment and currency translation effect
     130  
    
 
 
 
Closing research tax credit receivable as of June 30, 2023
  
 
9,662
 
    
 
 
 
Of which -
Non-current
portion
         
Of which - Current portion
     9,662  
Before currency translation effect, the balance in research tax credit as of June 30, 2023, consisted of $5.8 million research tax credit for the 2022 fiscal year filed with the tax authorities and yet to be reimbursed, and $3.7 million estimated research tax credit for the first six months of the 2023 fiscal year.
The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies.
 
11

Note 5 Lease contracts
Future minimum lease payments under the Company’s operating leases’ right of use as of June 30, 2023 and December 31, 2022, are as follows:
 
    
June 30, 2023
   
December 31, 2022
 
    
Real estate
   
Other
assets
   
Total
   
Real estate
   
Other
assets
   
Total
 
Current portion
     1,886       74       1,961       1,972       79       2,051  
Year 2
     291       43       334       1,168       74       1,243  
Year 3
              —                  65       6       71  
Thereafter
                                                      
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total minimum lease payments
  
 
2,177
 
 
 
118
 
 
 
2,295
 
 
 
3,204
 
 
 
160
 
 
 
3,364
 
Less: Effects of discounting
     (153     (10     (163     (325     (17     (343
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Present value of operating lease
  
 
2,024
 
 
 
107
 
 
 
2,131
 
 
 
2,879
 
 
 
143
 
 
 
3,021
 
Less: current portion
     (1,873     (72     (1,944     (1,823     (71     (1,894
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Long-term operating lease
  
 
151
 
 
 
36
 
 
 
187
 
 
 
1,055
 
 
 
72
 
 
 
1,127
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average remaining lease term (years)
     0.95       —                 1.40       —            
Weighted average discount rate
     2.90     2.50             3.00     2.45        
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:
 
    
June 30,
 
    
2023
    
2022
 
Operating lease expense / (income)
     1,543        950  
Net termination impact
     (920      (1,657
Supplemental cash flow information related to operating leases is as follows for the period June 30, 2023 and 2022:
 
    
June 30,
 
    
2023
    
2022
 
Cash paid for amounts included in the measurement of lease liabilities
                 
Operating cash outflows related to operating leases
     963        1,079  
Note 6: Trade Payables and Other Current Liabilities
6.1 Trade Payables
Trade payables increased by $4.6 million as of June 30, 2023, compared to December 31, 2022.
No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each period presented.
 
12

6.2 Other Liabilities
The following tables summarize the other liabilities as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
    
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total     
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total  
Employee related liabilities
     4,374                  4,374        5,872        45        5,917  
Deferred income
     2,264        3,987        6,251        2,137        4,690        6,828  
Tax liabilities
     187                  187        69                  69  
Other debts
     433                  433        1,131                  1,131  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,258
 
  
 
3,987
 
  
 
11,245
 
  
 
9,210
 
  
 
4,735
 
  
 
13,945
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The Employee related liabilities include short-term debt to employees including social welfare and tax agency obligations.
Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science.
Note 7: Shareholders’ equity
The share capital as of June 30, 2023 is set at the sum of €9,625,095.40 ($10,952 thousands converted at historical rates). It is divided into 96,250,954 fully authorized, subscribed and
paid-up
ordinary shares with a par value of €0.10.
Pursuant to the authorization granted by the General Meeting of the Shareholders held on April 12, 2023 (the “SH General Meeting”), the accumulated net losses of DBV Technologies S.A. after appropriation of the net result for the year ended December 31, 2022, have been allocated to additional
paid-in
capital.
Note 8: Share-Based Payments
The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and
non-employee
warrants (
Bons de Souscription d’Actions
or “BSA”).
During the six months ended June 30, 2023, the Company granted 59,200 stock options and 35,800 restricted stock units to employees. There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report. 
Change in Number of BSA/SO/RSU:
 
    
Number of outstanding
 
    
BSA
    
SO
    
RSUs
 
Balance as of December 31, 2022
  
 
251,693
 
  
 
5,306,569
 
  
 
1,589,081
 
Granted during the period
     —          59,200        35,800  
Forfeited during the period
     —          (75,200      (54,444
Exercised/released during the period
     —          —          (61,359
Expired during the period
     —          —          —    
    
 
 
    
 
 
    
 
 
 
Balance as of June 30, 2023
  
 
251,693
 
  
 
5,290,569
 
  
 
1,509,078
 
    
 
 
    
 
 
    
 
 
 
 
13

Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
 
           
Three Months
Ended June 30,
   
Six Months
Ended June 30,
 
           
2023
   
2022
   
2023
   
2022
 
Research & development
     SO        (465     (290     (894     (665
       RSU        (271     (185     (529     (393
Sales & marketing
     SO        (27     (38     (54     (33
       RSU        (8     (17     (17     (16
General & administrative
     SO        (925     (478     (1,722     (1,176
       RSU        (118     (70     (231     (157
             
 
 
   
 
 
   
 
 
   
 
 
 
Total share-based compensation (expense)
           
 
(1,814
 
 
(1,078
 
 
(3,446
 
 
(2,441
             
 
 
   
 
 
   
 
 
   
 
 
 
Note 9: Contingencies
The following tables summarize the contingencies as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Current contingencies
     5,076        3,944  
Non-current
contingencies
     15,731        16,680  
    
 
 
    
 
 
 
Total contingencies
  
 
20,807
 
  
 
20,625
 
    
 
 
    
 
 
 
The changes in contingencies are as follows:
 
    
Pension
retirement
obligations
    
Collaboration
agreement -
Loss at
completion
    
Other
contingencies
    
Total
 
At January 1, 2023
  
 
790
 
  
 
19,835
 
  
 
—  
 
  
 
20,625
 
Increases in liabilities
     11        —          780        791  
Used liabilities
     —          —          —              
Reversals of unused liabilities
     —          (1,083      —          (1,083
Net interest related to employee benefits, and unwinding of discount
     —          —          —              
Actuarial gains and losses on defined-benefit plans
     93        —          —          93  
Currency translation effect
     15        366                  381  
    
 
 
    
 
 
    
 
 
    
 
 
 
At June 30, 2023
  
 
909
 
  
 
19,118
 
  
 
780
 
  
 
20,807
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Of which Current
  
 
—  
 
  
 
4,296
 
  
 
780
 
  
 
5,076
 
Of which
Non-current
  
 
909
 
  
 
14,822
 
  
 
—  
 
  
 
15,731
 
The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report.
In 2022 and during the first six months of 2023, the Company updated its measurement of progress of the Phase 2 clinical trial (“PII”) conducted as part of the collaboration and license agreement with Nestlé Health Sciences and updated the cumulative income recognized. The Company recognized a reversal of $1.1 million of the loss for completion recorded in the amount of the excess between the Company’s current best estimates of costs yet to be incurred and income yet to be recognized for the completion of the PII.
The other contingencies mainly consisted of a provision for refurbishment amounting to the best estimate of costs to be incurred in case the Montrouge office lease agreement is not renewed at its July 2024 term.
 
14

Note 10: Operating income
The following table summarizes the operating income during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research tax credit
     1,975        1,491        3,741        3,060  
Other operating income
     312        37        741        1,014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
2,288
 
  
 
1,529
 
  
 
4,482
 
  
 
4,074
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The increase in operating income was primarily due to the increase in the research and development costs eligible to research tax credit in France.
The Company recognizes as other operating income accrued revenues based on its updated measurement of progress of the Phase 2 clinical trial conducted as part of the collaboration agreement with Nestlé. Moreover, the loss for completion recorded in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase 2 clinical trial was updated accordingly as of June 30, 2023 (see note 9 related to contingencies).
Note 11: Allocation of Personnel Expenses
The Company had an average of 88 employees during the six months ended June 30, 2023, in comparison with an average of 87 employees during the six months ended June 30, 2022.
The following table summarizes the allocation of personnel expenses by function during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research and Development expenses
     4,014        3,097        8,020        6,172  
Sales and Marketing expenses
     208        344        373        589  
General and Administrative expenses
     2,858        2,767        5,958        5,362  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total personnel expenses
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The following table summarizes the allocation of personnel expenses by nature during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Wages and salaries
     4,078        3,509        8,516        7,497  
Social security contributions
     1,185        1,256        1,884        1,507  
Expenses for pension commitments
     246        211        504        509  
Employer contribution to bonus shares
     (244      154               170  
Share-based payments
     1,814        1,078        3,446        2,441  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The increase in personnel expenses was mainly due to recruitment of US employees partially offset by the departure of
non-US
employees, and the increase of charges related to share-base payments.
Note 12: Commitments
There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the Annual Report.
 
15

Note 13: Relationships with Related Parties
The Company’s related parties exclusively consisted of the members of the Board of Directors and the members of the Executive Committee. As of June 30, 2023, the total amount of remuneration granted to the members of the Board of Directors and Executive Committee has not significantly changed since December 31, 2022.
There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.
Note 14: Loss Per Share
Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three- and
six-month
periods ended June 30, 2023 and 2022, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three and six months ended June 30, 2023 and 2022 indicated in number of potential shares:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Non-employee
warrants
     251,693        256,693        251,693        256,693  
Stock options
     5,290,569        3,442,358        5,290,569        3,442,358  
Restricted stock units
     1,509,078        1,145,223        1,509,078        1,145,223  
Prefunded warrants
     28,276,331        28,276,331        28,276,331        28,276,331  
Note 15: Events after the Close of the Period
The Company evaluated subsequent events that occurred after June 30, 2023, through the date the condensed consolidated financial statements were issued after their approval by the Board of Directors on July 28, 2023, and determined that there are no significant events that require adjustments or disclosure in such condensed consolidated financial statements.
 
16


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2022, included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 2, 2023, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.

Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPITTM, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat children suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. We believe Viaskin may offer convenient, self-administered, non-invasive immunotherapy to patients, if approved.

Our most advanced clinical program is Viaskin Peanut, which has been evaluated as a potential therapy for children with peanut allergy in nine clinical trials, including four Phase 2 trials and three completed Phase 3 trials. We recently completed a Phase 3 trial of Viaskin Peanut in children ages one to three with peanut allergy and we also have an ongoing Phase 3 trial of Viaskin Peanut in children ages four to seven with peanut allergy.

On March 7, 2023, the Company announced screening of the first patient in VITESSE. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025.

On April 19, 2023, the Company outlined the regulatory path for Viaskin Peanut in children 1-3 years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the pre-specified criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.

On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages 1-3 years old with a confirmed peanut allergy.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Consolidated Financial Statements in Part I, Item 1 of our Annual Report.

 

17


Table of Contents

Business trends and Results of Operations

Comparison of the Three Months Ended June 30, 2023 and 2022

The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the three months ended June 30, 2023 and 2022.

 

     Three months ended June 30,                
     2023      2022      $ change      % change  

Operating income

   $ 2,288      $ 1,529        759        50

Operating expenses

           

Research and development expenses

     (17,616      (18,611      995        (5 )% 

Sales and marketing expenses

     (516      (1,037      520        (50 )% 

General and administrative expenses

     (9,231      (5,704      (3,527      62
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Operating expenses

     (27,364      (25,352      (2,012      8
  

 

 

    

 

 

    

 

 

    

 

 

 

Financial income (expenses)

     846        784        62        8
  

 

 

    

 

 

    

 

 

    

 

 

 

Income tax

     (13      —          (13      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ (24,243    $ (23,039      (1,204 )       5
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic/diluted Net loss per share attributable to shareholders

   $ (0.26    $ (0.35      

Operating Income

The following table summarizes our operating income during the three months ended June 30, 2023 and 2022:

 

     Three months ended June 30,                
     2023      2022      $ change      % change  

Sales

     —          —          —          —    

Other income

     2,288        1,529        759        50

Research tax credit

     1,975        1,491        484        32

Other operating income

     312        37        275        734
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income

     2,288        1,529        759        50
  

 

 

    

 

 

    

 

 

    

 

 

 

Our operating income is primarily generated from the French research tax credit (Crédit d’Impôt Recherche, or “CIR”), and revenues recognized as part of our collaboration agreement with Nestlé Health Science. We generated operating income of $2.3 million during the three months ended June 30, 2023 compared to $1.5 million during the three months ended June 30, 2022.

The increase in operating income was primarily due to the increase by $0.5 million in French research tax credit as the eligible employee-related costs increased to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.

In addition, other operating income increased by $0.3 million for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, after we updated the measurement of progress of the Phase 2 clinical trial conducted as part of the Nestlé’s collaboration agreement.

Operating Expenses

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the three months ended June 30, 2023 and 2022:

 

18


Table of Contents
     Three Months Ended June 30,                
Research and Development expenses    2023      2022      $ change      % change  

External clinical-related expenses

     11,421        11,664        (243      (2 )% 

Employee-related costs (excl. share-based payments)

     3,278        2,622        656        25

Share-based payment expenses

     736        475        261        55

Depreciation, amortization and other costs

     2,181        3,850        (1,669      (43 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Research and Development expenses

     17,616        18,611        (995      50
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and Development expenses decreased by $1.0 million for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, primarily due to the reversal of $1.1 million of the loss at completion recorded as other costs on the Phase 2 clinical trial conducted as part of the collaboration agreement with Nestlé. During the three months ended June 30, 2022, the loss at completion was impacted by additional clinical and production costs following increasing timing to achieve upcoming milestones. During the three months ended June 30, 2023, there were no changes to the timing to completion.

In addition external clinical expenses decreased by $0.2 million as a result of differences in phasing of on-going clinical trials between the three months ended June 30, 2022 and the three months ended June 30, 2023.

Decreases in impacts of the loss at completion and in external clinical-related expenses were partially offset by the increase by $0.7 million in employee-related costs (excl. share-based payments) to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.

Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the three months ended June 30, 2023 and 2022:

 

     Three Months Ended June 30,                
Sales and Marketing expenses    2023      2022      $ change      % change  

External professional services

     80        399        (319      (80 )% 

Employee-related costs (excl. share-based payments)

     173        289        (116      (40 )% 

Share-based payment expenses

     35        55        (20      (36 )% 

Depreciation, amortization and other costs

     229        294        (65      (22 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Sales and Marketing expenses

     516        1,037        (520      (50 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Sales and marketing expenses decreased by $0.5 million for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, due to a decrease of external professional services and employee-related costs.

General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the three months ended June 30, 2023 and 2022:

 

     Three Months Ended June 30,                
General and Administrative expenses    2023      2022      $ change      % change  

External professional services

     3,806        1,771        2,034        115

Employee-related costs (excl. share-based payments)

     1,814        2,220        (405      (18 )% 

Share-based payment expenses

     1,043        548        496        91

Depreciation, amortization and other costs

     2,568        1,166        1,402        120
  

 

 

    

 

 

    

 

 

    

 

 

 

Total General and Administrative expenses

     9,231        5,704        3,527        62
  

 

 

    

 

 

    

 

 

    

 

 

 

General and Administrative expenses increased by $3.5 million for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, mainly due to one-time costs associated with financing activities, organizational planning, market research and planning activities. In addition, we recorded a provision amounting to $0.7 million as of June 30, 2023, as our best estimate of costs to be incurred if the Montrouge office lease agreement is not renewed at its July 2024 terms.

 

19


Table of Contents

Financial income (expense)

Our financial income was $0.8 million for the three months ended June 30, 2023, compared to a financial income of $0.8 million for the three months ended June 30, 2022. This item mainly includes the financial income on our financial assets.

Income tax

Our income tax expense was nil for the three months ended June 30, 2023 and June 30, 2022.

Net loss

Net loss was $24.2 million for the three months ended June 30, 2023, compared to $23 million for the three months ended June 30, 2022. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.26 and $0.35 for the three months ended June 30, 2023 and 2022, respectively.

Comparison of the Six Months Ended June 30, 2023 and 2022

The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the six months ended June 30, 2023 and 2022.

 

     Six months ended June 30,                
     2023      2022      $ change      % change  

Operating income

   $ 4,482      $ 4,074        407        10

Operating expenses

           

Research and development expenses

     (33,653      (30,834      (2,819      9

Sales and marketing expenses

     (950      (1,500      551        (37 )% 

General and administrative expenses

     (16,120      (12,334      (3,786      31
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Operating expenses

     (50,723      (44,669      (6,054      14
  

 

 

    

 

 

    

 

 

    

 

 

 

Financial income (expense)

     1,450        936        515        55
  

 

 

    

 

 

    

 

 

    

 

 

 

Income tax

     (13      (87      74        (85 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ (44,804    $ (39,746      (5,058      13
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic/diluted Net loss per share attributable to shareholders

   $ (0.48    $ (0.66      
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating Income

The following table summarizes our operating income during the six months ended June 30, 2023 and 2022:

 

     Six months ended June 30,                
     2023      2022      $ change      % change  

Sales

     —          —          

Other income

     4,482        4,074        407        10

Research tax credit

     3,741        3,060        680        22

Other operating income

     741        1,014        (273      (27 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income

     4,482        4,074        407        10
  

 

 

    

 

 

    

 

 

    

 

 

 

Our operating income consisted of the French research tax credit (Crédit d’Impôt Recherche, or “CIR”), and revenues recognized as part of our collaboration agreement with Nestlé Health Science. We generated operating income of $4.5 million during the six months ended June 30, 2023 compared to $4.1 million during the six months ended June 30, 2022.

The increase in operating income was due to the increase by $0.7 million in the French research tax credit as both eligible employee-related costs and eligible external clinical-related expenses increased to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.

 

20


Table of Contents

The increase in research tax credit was partially offset by the decrease by $0.3 million in other operating income for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, after we updated the measurement of progress of the Phase 2 clinical trial conducted as part of the Nestlé’s collaboration agreement.

Operating Expenses

Research and Development Expenses

The following table summarizes our R&D expenses incurred during the six months ended June 30, 2023 and 2022:

 

     Six Months Ended June 30,                
Research and Development expenses    2023      2022      $ change      % change  

External clinical-related expenses

     21,892        19,014        2,878        15

Employee-related costs (excl. share-based payments)

     6,598        5,114        1,484        29

Share-based payment expenses

     1,423        1,058        365        34

Depreciation, amortization and other costs

     3,741        5,648        (1,908      (34 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Research and Development expenses

     33,653        30,834        2,819        9
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and Development expenses increased by $2.8 million for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, primarily due to the increase by $2.9 million and by $1.5 million in external clinical-related expenses and in employee-related costs (excl. share-based payments) respectively, to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.

Increases in both external clinical-related expenses and employee-related costs were partially offset by the reversal of $1.1 million of the loss at completion recorded as other costs on the Phase 2 clinical trial conducted as part of the collaboration agreement with Nestlé. During the six months ended June 30, 2022, the loss at completion was impacted by additional clinical and production costs following increasing timing to achieve upcoming milestones. During the six months ended June 30, 2023, there were no changes to the timing to completion.

Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the six months ended June 30, 2023 and 2022:

 

     Six Months Ended June 30,                
Sales and Marketing expenses    2023      2022      $ change      % change  

External professional services

     348        521        (173      (33 )% 

Employee-related costs (excl. share-based payments)

     303        539        (237      (44 )% 

Share-based payment expenses

     70        49        21        41

Depreciation, amortization and other costs

     229        391        (162      (41 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Sales and Marketing expenses

     950        1,500        (551      (37 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Sales and marketing expenses decreased by $ 0.6 million for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, primarily due to a decrease of external professional services and employee-related costs.

General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the six months ended June 30, 2023 and 2022:

 

     Six Months Ended June 30,                
General and Administrative expenses    2023      2022      $ change      % change  

External professional services

     5,512        2,879        2,633        91

Employee-related costs (excl. share-based payments)

     4,005        4,029        (25      (1 )% 

Share-based payment expenses

     1,954        1,333        620        47

Depreciation, amortization and other costs

     4,650        4,093        557        14
  

 

 

    

 

 

    

 

 

    

 

 

 

Total General and Administrative expenses

     16,120        12,334        3,786        31
  

 

 

    

 

 

    

 

 

    

 

 

 

 

21


Table of Contents

General and Administrative expenses increased by $3.8 million for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, mainly due to one-time costs associated with financing activities, organizational planning, market research and planning activities. In addition, we recorded a provision amounting to $0.7 million as of June 30, 2023, as our best estimate of costs to be incurred if the Montrouge office lease agreement is not renewed at its July 2024 terms.

Financial income (expense)

Our financial income was $1.5 million for the six months ended June 30, 2023, compared to a financial income of $0.9 million for the six months ended June 30, 2022. This item mainly includes financial income on our financial assets.

Income tax

Our income tax expense was nil for the six months ended June 30, 2023 and June 30, 2022.

Net loss

Net loss was $ 44.8 million for the six months ended June 30, 2023, compared to $39.7 million for the six months ended June 30, 2022. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.48 and $0.66 for the six months ended June 30, 2023 and 2022, respectively.

Liquidity and Capital Resources

Financial Condition

On June 30, 2023, we had $174 million in cash and cash equivalents compared to $209.2 million of cash and cash equivalents on December 31, 2022. We have incurred operating losses and negative cash flows from operations since our inception. Net cash used for operating activities was $ 46.4 million and $11.7 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, we recorded a net loss of $ 44.8 million. Our net cash flows provided by financing activities decreased to $7.8 million during the six months ended June 30, 2023 from $195.2 million during the six months ended June 30, 2022 due to more important financing operations in first semester of 2022 (May 2022 ATM and June 2022 PIPE) compared to 2023 (June 2023 ATM).

Our condensed consolidated financial statements have been prepared on a going concern basis assuming that based on our current operations, as well as our plans and assumptions, we expect that our balance of cash and cash equivalents at closing date will be sufficient to fund our operations for at least the next 12 months. As such, no adjustments have been made to the condensed consolidated financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should we not be able to continue as a going concern.

Sources of Liquidity and Material Cash Requirements

We have incurred net losses each year since our inception. Substantially all of our net losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. We have not incurred any bank debt.

Payments associated with Research tax credits (Crédit d’Impôt Recherche) contribute to fund our short-term cash requirements. We intend to seek additional capital as we prepare for the launch of Viaskin Peanut, if approved, and continue other research and development efforts. We may seek to finance our future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings.

In May 2022, we established an At-The-Market (“ATM”) program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $100 million of American Depositary Shares (“ADSs”), each ADS representing one-half of one ordinary share of the Company. The ATM program is intended to be effective through the expiration of the Company’s existing registration statement registering the ADSs to be issued under the ATM program, i.e. until July 16, 2024, unless terminated prior to such date in accordance with the sales agreement or the maximum amount of the program has been reached. The Company’s intent is to use the net proceeds, if any, of sales of ADSs issued under the program, together with its existing cash and cash equivalents, primarily for activities associated with potential approval and launch of Viaskin Peanut, as well as to advance the development of the Company’s product candidates using its Viaskin Peanut platform and for working capital and other general corporate purposes.

Pursuant to the ATM program, the Company issued and completed sales of new Ordinary Shares in the form of ADSs for a total gross amount of $15.3 million on May 4, 2022, and of $7.8 million on June 14, 2023. Respectively, 6,036,238 and 2,052,450 new Ordinary Shares in the form of ADSs were issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics (the “ATM issuance”), at a unit subscription price of $1.27 and $1.90 per ADS, each ADS giving the right to receive one-half of one ordinary share of the Company.

 

22


Table of Contents

We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to us, including reduced ability to raise additional capital when needed or on acceptable terms, if at all. If we are not successful in our financing objectives, we could have to scale back our operations, notably by delaying or reducing the scope of our research and development efforts or obtain financing through arrangements with collaborators or others that may require us to relinquish rights to our product candidates that we might otherwise seek to develop or commercialize independently.

Operating leases

Our corporate headquarters are located in Montrouge, France. Our principal offices occupy a 4,470 square meter facility, pursuant to a lease agreement dated March 3, 2015, and represents a $0.8 million cash requirement as of June 30, 2023 which expires July 31, 2024.

Our primary U.S. office is located in Basking Ridge, New Jersey. In March 2022, we entered into a lease agreement, commencing on April 1, 2022 and effective for 38 months, for an office of 5,799 square feet in Basking Ridge, New Jersey. The Basking Ridge office represent a $0.1 million cash requirement as of June 30, 2023 which expires June 1, 2025.

There have been no material changes in our operating leases from those disclosed in the Annual Report.

Purchase obligations - Obligations Under the Terms of CRO Agreements

In connection with the launch of our clinical trials for Viaskin Peanut and Viaskin Milk, we signed agreements with several contract research organizations.

There have been no material changes in our purchase obligations from those disclosed in the Annual Report.

Summary Statement of Cash Flows

The table below summarizes our sources and uses of cash for the six months ended June 30, 2023 and 2022.

 

     Six months ended June 30,                
(Amounts in thousands of U.S. Dollars)    2023      2022      $ change      % of change  

Net cash flow used in operating activities

     (46,394      (11,733      (34,661      295

Net cash flow used in investing activities

     (299      (218      (80      37

Net cash flow provided by financing activities

     7,793        195,222        (187,429      (96 )% 

Effect of exchange rate changes on cash and cash equivalents

     3,668        (12,600      16,268        (129 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net (decrease) increase in cash and cash equivalents

     (35,232      170,670        (205,903      (121 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating Activities

Our net cash flows used in operating activities were $46.4 million and $11.7 million during the six months ended June 30, 2023 and 2022, respectively. Our net cash flows used in operating activities increased by $ 34.7 million, mainly due to the repayment in 2022 of the research tax credit receivable relating to fiscal years 2019 to 2021 for €24.8 million (corresponding to $28.1 million on the basis of 2021 closing exchange rate). The increase is also explained by the change in trade payables during the six months period ended June 30, 2023 compared to the six months period ended June 30, 2022.

Investing Activities

Our net cash flows used in investing activities were $0.3 million and $0.2 million during the six months ended June 30, 2023 and 2022, respectively.

Financing Activities

Our net cash flows provided by financing activities was $ 7.8 million during the six months ended June 30, 2023 that consisted of the ATM in June 2023 compared to $195.2 million during the six months ended June 30, 2022, that consisted of the May 2022 ATM and the June 2022 PIPE.

 

23


Table of Contents

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.

Smaller Reporting Company Status

We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on its evaluation as of June 30, 2023, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

PART II – Other information

Item 1. Legal Proceedings

See “Note 2: Significant Events and Transactions – Legal Proceedings” in the notes to the condensed consolidated financial statements included elsewhere in this Report.

 

24


Table of Contents

Item 1A. Risk Factors

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and trading price of our securities. In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report. There have been no material changes in our risk factors from those disclosed in the Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the six months ended June 30, 2023, we issued the following unregistered securities:

 

   

On March 23, 2023, the issuance of an aggregate of 10,174 ordinary shares to U.S. and non-U.S. employees upon settlement of RSUs;

 

   

On May 19, 2023, the issuance of an aggregate of 2,500 ordinary shares to a non-U.S. employee upon settlement of RSUs;

 

   

On May 22, 2023, the issuance of an aggregate of 14,364 ordinary shares to non-U.S. employees upon settlement of RSUs; and

 

   

On May 24, 2023, the issuance of an aggregate of 34,321 ordinary shares to U.S. and non-U.S. employees upon settlement of RSUs.

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Regulation S promulgated under Section 5 of the Securities Act, as transactions by an issuer not involving any public offering or as offerings made to non-U.S. resident employees pursuant to an employee benefit plan established and administered in accordance with the law of a country other than the United States (namely, the Republic of France) and in accordance with that country’s practices and documentation. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits.

Exhibit Index

 

Exhibit   

Description

   Incorporated by Reference  
          Schedule/
Form
     File
Number
     Exhibit      File
Date
 
3.1    By-laws (statuts) of the registrant (English translation)      10-Q        001-36697        3.1        5/04/23  
31.1    Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as Amended            
31.2    Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended            
32.1*    Certificate of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, as amended            
101.INS    XBRL Instance Document            
101.SCH    XBRL Taxonomy Extension Schema Document            
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document            

 

25


Table of Contents
Exhibit   

Description

   Incorporated by Reference  
          Schedule/
Form
     File
Number
     Exhibit      File
Date
 
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB    XBRL Taxonomy Extension Labels Linkbase Document            
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document            
104    Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.            

 

*

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporate language contained in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    DBV Technologies S.A.
    (Registrant)
Date: July 31, 2023     By:  

/s/ Daniel Tassé

      Daniel Tassé
      Chief Executive Officer
      (Principal Executive Officer)
Date: July 31, 2023     By:  

/s/ Sébastien Robitaille

      Sébastien Robitaille
      Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

 

26

EX-31.1 2 d515836dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification by the Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Daniel Tassé, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of DBV Technologies S.A.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 31, 2023

 

/s/ Daniel Tassé

Daniel Tassé
Chief Executive Officer
(Principal Executive Officer)

 

EX-31.2 3 d515836dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification by the Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Sébastien Robitaille, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of DBV Technologies S.A.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 31, 2023

 

/s/ Sébastien Robitaille

Sébastien Robitaille
Chief Financial Officer
(Principal Financial and Accounting Officer)

 

EX-32.1 4 d515836dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Daniel Tassé, Chief Executive Officer of DBV Technologies S.A. (the “Company”), and Sébastien Robitaille, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

 

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Exchange Act, and

 

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 31, 2023

 

/s/ Daniel Tassé

                 

/s/ Sébastien Robitaille

Daniel Tassé

Chief Executive Officer

(Principal Executive Officer)

    

Sébastien Robitaille

Chief Financial Officer

(Principal Financial and Accounting Officer)

This certification accompanies the Quarterly Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 5 dbvt-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Statements of Financial Position link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Statements of Financial Position (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - The Company link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Significant Events and Transactions link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Cash and Cash Equivalents link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Other Current Assets link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Lease contracts link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Trade Payables and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Shareholders' equity link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Share-Based Payments link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Operating Income link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Allocation of Personnel Expenses link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Relationships with Related Parties link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Events After the Close of the Period link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - The Company (Policies) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Lease contracts (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Trade Payables and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Operating Income (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Allocation of Personnel Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Significant Events and Transactions of the Periods - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Other Current Assets - Summary of Other Current Asset (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Other Current Assets - Summary Of Research Tax Credit (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Other Current Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Lease contracts - Summary of Rent expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Trade Payables and Other Current Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Shareholders' equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Share-Based Payments - Summary of RSU Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Share-Based Payments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Contingencies - Summary of Movement in Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Operating Income - Summary of Operating Income (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Commitments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Relationships with Related Parties - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 dbvt-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 dbvt-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 dbvt-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 dbvt-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jun. 30, 2023
Jul. 31, 2023
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Registrant Name DBV TECHNOLOGIES S.A.  
Entity Central Index Key 0001613780  
Entity File Number 001-36697  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Interactive Data Current Yes  
Entity Common Stock, Shares Outstanding   96,250,954
Document Quarterly Report true  
Document Transition Report false  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Address, Country FR  
Entity Small Business true  
Entity Incorporation, State or Country Code I0  
Entity Address, Address Line One 177-181 avenue Pierre Brossolette  
Entity Address, City or Town Montrouge  
Entity Address, Postal Zip Code 92120  
City Area Code 33  
Local Phone Number 1 55 42 78 78  
Entity Tax Identification Number 00-0000000  
American Depositary Share [Member]    
Document Information [Line Items]    
Title of 12(b) Security American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share  
Trading Symbol DBVT  
Security Exchange Name NASDAQ  
Ordinary Shares [Member]    
Document Information [Line Items]    
Title of 12(b) Security Ordinary shares, nominal value €0.10 per share  
Security Exchange Name NASDAQ  
No Trading Symbol Flag true  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Financial Position - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 173,961 $ 209,194
Other current assets 21,578 13,880
Total current assets 195,539 223,074
Non-Current assets    
Property, plant, and equipment, net 14,135 15,096
Right-of-use assets related to operating leases 1,832 2,513
Intangible assets 68 10
Other non-current assets 5,944 5,824
Total non-current assets 21,979 23,444
Total Assets 217,518 246,518
Current liabilities    
Trade payables 19,094 14,473
Short-term operating leases 1,944 1,894
Current contingencies 5,076 3,944
Other current liabilities 7,258 9,210
Total current liabilities 33,373 29,521
Non-Current liabilities    
Long-term operating leases 187 1,127
Non-current contingencies 15,731 16,680
Other non-current liabilities 3,987 4,735
Total non-current liabilities 19,905 22,543
Total Liabilities 53,277 52,064
Shareholders' equity:    
Ordinary shares, €0.10 par value; 96,250,954 and 94,137,145 shares authorized, and issued as at June 30, 2023 and December 31, 2022, respectively 10,952 10,720
Additional paid-in capital 375,759 458,221
Treasury stock, 149,972 and 149,793 ordinary shares as of June 30, 2023 and December 31, 2022, respectively, at cost (1,082) (1,109)
Accumulated deficit (210,940) (259,578)
Accumulated other comprehensive income 687 781
Accumulated currency translation effect (11,136) (14,581)
Total shareholders' equity 164,240 194,453
Total Liabilities and Shareholders' equity $ 217,518 $ 246,518
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Financial Position (Parenthetical) - € / shares
Jun. 30, 2023
Dec. 31, 2022
Treasury stock, common, shares 149,972 149,793
Common Shares [Member]    
Common stock shares par value € 0.1 € 0.1
Common stock shares authorized 96,250,954 94,137,145
Common stock shares issued 96,250,954 94,137,145
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating income $ 2,288 $ 1,529 $ 4,482 $ 4,074
Operating expenses        
Research and development expenses (17,616) (18,611) (33,653) (30,834)
Sales and marketing expenses (516) (1,037) (950) (1,500)
General and administrative expenses (9,231) (5,704) (16,120) (12,334)
Total Operating expenses (27,364) (25,352) (50,723) (44,669)
Loss from operations (25,076) (23,823) (46,242) (40,595)
Financial income(expenses) 846 784 1,450 936
Loss before taxes (24,230) (23,039) (44,791) (39,659)
Income tax (13) 0 (13) (87)
Net loss (24,243) (23,039) (44,804) (39,746)
Foreign currency translation differences, net of taxes (221) (11,394) 3,445 (13,327)
Actuarial gains (losses) on employee benefits, net of taxes (10) 200 (92) 224
Total comprehensive loss $ (24,475) $ (34,234) $ (41,452) $ (52,849)
Basic net loss per share attributable to shareholders $ (0.26) $ (0.35) $ (0.48) $ (0.66)
Weighted average number of shares outstanding used in computing per share amounts: 94,324,889 66,047,949 94,150,141 60,490,075
Diluted net loss per share attributable to shareholders $ (0.26) $ (0.35) $ (0.48) $ (0.66)
Weighted average number of shares outstanding used in computing per share amounts: 94,324,889 66,047,949 94,150,141 60,490,075
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Statement of Cash Flows [Abstract]    
Net loss for the period $ (44,804) $ (39,746)
Cash flows used in operating activities:    
Depreciation, amortization and accrued contingencies 369 1,249
Retirement pension obligations 11 14
Expenses related to share-based payments 3,446 2,441
Other elements 23 (3)
Changes in operating assets and liabilities:    
Decrease (increase) in other current assets (6,481) 23,436
(Decrease) increase in trade payables 3,419 5,894
(Decrease) increase in other current and non-current liabilities (2,913) (3,040)
Change in operating lease liabilities and right of use assets 535 (1,979)
Net cash flow provided by (used in) operating activities (46,394) (11,733)
Cash flows provided by (used in) investing activities:    
Acquisitions of property, plant, and equipment, net from proceeds (275) (369)
Proceeds from property, plant, and equipment dispositions 0 3
Acquisitions of non-current financial assets (27) (279)
Proceeds from non-current financial assets dispositions 4 426
Net cash flows provided by (used in) investing activities (299) (218)
Cash flows provided by (used in) financing activities:    
Decrease in conditional advances 0 (328)
Treasury shares 27 279
Capital increases, net of transaction costs 7,766 195,270
Other cash flows related to financing activities 0 0
Net cash flows provided by (used in) financing activities 7,793 195,221
Effect of exchange rate changes on cash and cash equivalents 3,668 (12,600)
Net increase (decrease) in cash and cash equivalents (35,232) 170,670
Net Cash and cash equivalents at the beginning of the period 209,194 77,301
Net cash and cash equivalents at the end of the period $ 173,961 $ 247,971
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Shares [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive income (loss) [Member]
Accumulated Currency Translation Effect [Member]
Beginning balance at Dec. 31, 2021 $ 99,274 $ 6,538 $ 358,115 $ (1,232) $ (258,528) $ 519 $ (6,137)
Beginning balance (Shares) at Dec. 31, 2021   55,095,762          
Net (loss) (16,706)       (16,706)    
Other comprehensive income (loss) (1,909)         24 (1,933)
Issuance of ordinary shares 1 $ 1 0        
Issuance of ordinary shares (Shares)   775          
Treasury shares 40     40      
Share-based payments 1,363   1,363        
Other change in equity         15   (15)
Ending balance at Mar. 31, 2022 82,062 $ 6,539 359,478 (1,193) (275,219) 543 (8,086)
Ending balance (Shares) at Mar. 31, 2022   55,096,537          
Beginning balance at Dec. 31, 2021 99,274 $ 6,538 358,115 (1,232) (258,528) 519 (6,137)
Beginning balance (Shares) at Dec. 31, 2021   55,095,762          
Net (loss) (39,746)            
Ending balance at Jun. 30, 2022 244,416 $ 10,708 456,447 (953) (203,050) 743 (19,480)
Ending balance (Shares) at Jun. 30, 2022   94,022,679          
Beginning balance at Mar. 31, 2022 82,062 $ 6,539 359,478 (1,193) (275,219) 543 (8,086)
Beginning balance (Shares) at Mar. 31, 2022   55,096,537          
Net (loss) (23,039)       (23,039)    
Other comprehensive income (loss) (11,194)         200 (11,394)
Issuance of ordinary shares 107,176 $ 4,170 103,007        
Issuance of ordinary shares (Shares)   38,926,142          
Issuance of warrants 88,094   88,094        
Treasury shares 240     240      
Share-based payments 1,078   1,078        
Allocation of accumulated net losses     (95,209)   95,209    
Ending balance at Jun. 30, 2022 244,416 $ 10,708 456,447 (953) (203,050) 743 (19,480)
Ending balance (Shares) at Jun. 30, 2022   94,022,679          
Beginning balance at Dec. 31, 2022 194,453 $ 10,720 458,221 (1,109) (259,578) 781 (14,581)
Beginning balance (Shares) at Dec. 31, 2022   94,137,145          
Net (loss) (20,561)       (20,561)    
Other comprehensive income (loss) 3,584         (82) 3,666
Issuance of ordinary shares 0 $ 1 (1)        
Issuance of ordinary shares (Shares)   10,174          
Treasury shares (14)     (14)      
Share-based payments 1,632   1,632        
Ending balance at Mar. 31, 2023 179,094 $ 10,721 459,852 (1,123) (280,138) 698 (10,915)
Ending balance (Shares) at Mar. 31, 2023   94,147,319          
Beginning balance at Dec. 31, 2022 194,453 $ 10,720 458,221 (1,109) (259,578) 781 (14,581)
Beginning balance (Shares) at Dec. 31, 2022   94,137,145          
Net (loss) (44,804)            
Ending balance at Jun. 30, 2023 164,240 $ 10,952 375,759 (1,082) (210,940) 687 (11,136)
Ending balance (Shares) at Jun. 30, 2023   96,250,954          
Beginning balance at Mar. 31, 2023 179,094 $ 10,721 459,852 (1,123) (280,138) 698 (10,915)
Beginning balance (Shares) at Mar. 31, 2023   94,147,319          
Net (loss) (24,243)       (24,243)    
Other comprehensive income (loss) (232)         (10) (221)
Issuance of ordinary shares 7,766 $ 231 7,535        
Issuance of ordinary shares (Shares)   2,103,635          
Treasury shares 42     42      
Share-based payments 1,814   1,814        
Allocation of accumulated net losses     (93,441)   93,441    
Ending balance at Jun. 30, 2023 $ 164,240 $ 10,952 $ 375,759 $ (1,082) $ (210,940) $ 687 $ (11,136)
Ending balance (Shares) at Jun. 30, 2023   96,250,954          
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
The Company
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
The Company
Note 1: The Company
Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”, or the “group”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin
. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT
, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin
.
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form
10-K
filed with the SEC on March 2, 2023 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2022 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2022.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2023, or any other future period.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an
on-going
basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of
right-of-use
assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies, and (8) estimate of employee benefits obligations.
Accounting Pronouncements adopted in 2023
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU
2016-13—Financial
Instruments—Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU
2019-10
which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Adoption of this new standard did not have a material impact on the consolidated financial statements.
In October 2021, the FASB issued ASU
2021-08,
which amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. This amendment is effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption of this new standard has no impact on the consolidated financial statements.
 
Accounting Pronouncements issued not yet adopted
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Significant Events and Transactions
6 Months Ended
Jun. 30, 2023
Significant Events And Transactions of the Period Disclsure [Abstract]  
Significant Events and Transactions
Note 2: Significant Events and Transactions
Clinical programs
United States Regulatory History and Current Status
In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following receipt of the Complete Response Letter. The FDA agreed with its position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of one peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and a modified patch, FDA requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages
4-11.
The Company named that assessment EQUAL, which stands for Equivalence in Uptake of ALlergen. The FDA also recommended conducting a
6-month,
well-controlled safety and adhesion trial to assess a modified Viaskin Peanut patch in the intended patient population. The Company later named this study STAMP, which stands for Safety, Tolerability, and Adhesion of Modified Patches.
Based on the January 2021 FDA feedback, the Company defined three parallel workstreams:
 
  1.
Identify a modified Viaskin patch (which the Company calls “mVP”).
 
  2.
Generate the
6-month
safety and adhesion clinical data FDA requested via STAMP, which the Company expected to be the longest component of the mVP clinical plan. The Company prioritized the STAMP protocol submission so the Company could begin the study as soon as possible.
 
  3.
Demonstrate the equivalence in allergen uptake between the current and modified patches in the intended patient population via EQUAL. The complexity of EQUAL hinged on the lack of established clinical and regulatory criteria to characterize allergen uptake via an epicutaneous patch. To support those exchanges, the Company outlined its proposed approach to demonstrate allergen uptake equivalence between the two patches, and allotted time to generate informative data through two additional Phase 1 clinical trials in healthy adult volunteers:
 
  a.
PREQUAL, a Phase 1 study with adult healthy volunteers to optimize the allergen sample collection methodologies and validate the assays we intend to use in EQUAL
.
The data collection phase of the trial is complete, and the data analysis phase is ongoing.
 
  b.
‘EQUAL in adults’—a second Phase I study with adult healthy volunteers to compare the allergen uptake of cVP and mVP;
In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches. The Company completed CHAMP in the second quarter of 2021. All modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the then-current Viaskin Peanut patch, and the Company then selected two modified patches that performed best out of the five modified patches studied for further development. The Company then selected the circular patch for further development, which is larger in size relative to the current patch and circular in shape.
In May 2021, the Company submitted its proposed STAMP protocol to the FDA, and on October 14, 2021, the Company received an Advice/Information Request letter from the FDA. In this letter, the FDA requested a stepwise approach to the modified Viaskin patch development program and provided partial feedback on the STAMP protocol. Specifically, the FDA requested that the Company conduct allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL), and submit the allergen uptake comparison data for FDA review and feedback prior to starting the STAMP study. The FDA’s explanation was that the results from the allergen uptake studies might affect the design of the STAMP study.
After careful review of the FDA’s information requests, in December 2021, the Company decided not to pursue the sequential approach to the development plans for Viaskin Peanut as requested by the FDA in the October 2021 feedback. The Company estimated that the FDA’s newly proposed sequential approach would require at least five rounds of exchanges that necessitate FDA alignment prior to initiating STAMP, the
6-month
safety and adhesion study. As such, in December 2021, the Company announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. The Company considers this approach the most straightforward to potentially demonstrate effectiveness, safety, and improved in vivo adhesion of the modified Viaskin Peanut system. The FDA confirmed the Company’s change in strategy is agreeable via oral and written
exchanges.
 
In 2022, the Company announced the new Phase 3 pivotal study for modified Viaskin Peanut (mVP) patch would be in younger
(4-7
years old) and more sensitive children with peanut allergy.
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institution
al
Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced it received feedback from the U.S. FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol.
On March 2, 2023, the Company announced the completion of EVOLVE, a
12-week
caregiver and patient user experience study of the mVP patch in 50 peanut allergic children ages
4–11-years
old. The objective of EVOLVE was to evaluate the Instructions for Use (IFU) and ease of use for the mVP patch. The study concluded that the updated IFU supported correct patch application, which included no lifting of the patch edges or detachment directly after application. Furthermore, EVOLVE concluded that the majority of parents/caregivers reported a positive ease of use experience with the mVP patch. In EVOLVE, DBV also tested the functionality of an electronic patient diary (eDiary) to collect information on activities of daily living and patch adhesion scores. EVOLVE verified that the eDiary tool can be used by caregivers in VITESSE to capture the adhesion data in support of a potential BLA.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE study. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025.
On April 19, 2023, the Company outlined
the
regulatory path for Viaskin Peanut in children
1-3
years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the
pre-specified
criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.
Viaskin Peanut for children ages
4-11—European
Union Regulatory History and Current Status
On August 2, 2021, the Company announced it received from the European Medicines Agency (“EMA”) of the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. It is a letter that is meant to include any remaining questions or objections at that stage in the process. The EMA indicated many of their objections and major objections from the Day 120 list of questions had been answered. One major objection remained at Day 180. The Major Objection questioned the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.
On December 20, 2021, the Company announced it had withdrawn the Marketing Authorization Application (“MAA”) for Viaskin Peanut and formally notified the EMA of our decision. The initial filing was supported by data from a single, placebo-controlled Phase 3 pivotal trial known as PEPITES
(V712-301).
The decision to withdraw was based on the view of EMA Committee for Medicinal Products for Human Use (CHMP) that the data available to date from a single pivotal clinical trial were not sufficient to preclude a Major Objection at Day 180 in the review cycle. The Company believes data from a second Viaskin Peanut pivotal clinical trial will support a more robust path for licensure of Viaskin Peanut in the EU. The Company intends to resubmit the MAA when that data set is available.
Viaskin Peanut for children ages
1-3
In June 2020, the Company announced that in Part A, patients in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigation of the 250 µg dose in this age group, which is the dose being studied in Part B of the study. Enrollment for Part B of EPITOPE was completed in the first quarter
of 2021.
 
In June 2022, the Company announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms respectively. Enrollment was balance for age and baseline disease characteristics between the active and placebo treatment arms.
On April 19, 2023,
the Company announced it will begin a new safety study after it received confirmation from the FDA that the EPITOPE study meets the
 
pre-specified
 
criteria for success for the primary endpoint, with no additional efficacy study requested. This safety study will increase the safety data collected from EPITOPE in support of a BLA. It will also generate patch adhesion data and will include updated instructions for use.
On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut
exposure
by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages
1-3
years old with a confirmed peanut allergy.
Viaskin Peanut for Children ages
4-7
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced we had received feedback from the FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE trial. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025.
Financing
In June 2023, the Company issued and completed sales of new ordinary shares (the “Ordinary Shares”) in
the
form of American Depositary Shares (“ADSs”), for a total gross amount of $7.8 million, under the
At-The-Market
(“ATM”) program established in May 2022. In this context, 2,052,450 new Ordinary Shares in
the
form of ADS have been issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics (the “ATM Issuance”), at a unit subscription price of 1.90 dollar per ADS (i.e., a subscription price per Ordinary Share of 3.52 euro based on the USD/EUR exchange rate of 1.0809 dollar for 1 euro, as published by the European Central Bank on June 14, 2023) and each ADS giving the right to receive
one-half
of one ordinary share of the Company.
Legal Proceedings
From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings.
 
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Cash and Cash Equivalents
6 Months Ended
Jun. 30, 2023
Cash and Cash Equivalents [Abstract]  
Cash and Cash Equivalents
Note 3: Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Cash
     24,111        30,104  
Cash equivalents
     149,850        179,090  
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of financial position
  
 
173,961
 
  
 
209,194
 
    
 
 
    
 
 
 
Bank overdrafts
     —          —    
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of cash flows
  
 
173,961
 
  
 
209,194
 
Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Assets
6 Months Ended
Jun. 30, 2023
Other Current Assets [Abstract]  
Other Current Assets
Note 4 Other Current Assets
Other current assets consisted of the following:
 
 
  
June 30,
2023
 
  
December 31,
2022
 
Research tax credit
     9,662        5,792  
Other tax claims
     5,851        3,903  
Prepaid expenses
     4,494        2,680  
Other receivables
     1,571        1,504  
    
 
 
    
 
 
 
Total
  
 
21,578
 
  
 
13,880
 
    
 
 
    
 
 
 
Research tax credit
The variance in Research Tax Credit is presented as follows:
 
    
Amount in
thousands of US
Dollars
 
Opening research tax credit receivable as of January 1, 2023
  
 
5,792
 
+ Operating revenue
     3,741  
- Payment received
     —    
- Adjustment and currency translation effect
     130  
    
 
 
 
Closing research tax credit receivable as of June 30, 2023
  
 
9,662
 
    
 
 
 
Of which -
Non-current
portion
     —    
Of which - Current portion
     9,662  
Before currency translation effect, the balance in research tax credit as of June 30, 2023, consisted of $5.8 million research tax credit for the 2022 fiscal year filed with the tax authorities and yet to be reimbursed, and $3.7 million estimated research tax credit for the first six months of the 2023 fiscal year.
The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies.
 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Lease contracts
6 Months Ended
Jun. 30, 2023
Lessee Disclosure [Abstract]  
Lease contracts
Note 5 Lease contracts
Future minimum lease payments under the Company’s operating leases’ right of use as of June 30, 2023 and December 31, 2022, are as follows:
 
    
June 30, 2023
   
December 31, 2022
 
    
Real estate
   
Other
assets
   
Total
   
Real estate
   
Other
assets
   
Total
 
Current portion
     1,886       74       1,961       1,972       79       2,051  
Year 2
     291       43       334       1,168       74       1,243  
Year 3
     —         —         —         65       6       71  
Thereafter
     —         —         —         —         —         —    
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total minimum lease payments
  
 
2,177
 
 
 
118
 
 
 
2,295
 
 
 
3,204
 
 
 
160
 
 
 
3,364
 
Less: Effects of discounting
     (153     (10     (163     (325     (17     (343
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Present value of operating lease
  
 
2,024
 
 
 
107
 
 
 
2,131
 
 
 
2,879
 
 
 
143
 
 
 
3,021
 
Less: current portion
     (1,873     (72     (1,944     (1,823     (71     (1,894
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Long-term operating lease
  
 
151
 
 
 
36
 
 
 
187
 
 
 
1,055
 
 
 
72
 
 
 
1,127
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average remaining lease term (years)
     0.95       —                 1.40       —            
Weighted average discount rate
     2.90     2.50             3.00     2.45        
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was:
 
    
June 30,
 
    
2023
    
2022
 
Operating lease expense / (income)
     1,543        950  
Net termination impact
     (920      (1,657
Supplemental cash flow information related to operating leases is as follows for the period June 30, 2023 and 2022:
 
    
June 30,
 
    
2023
    
2022
 
Cash paid for amounts included in the measurement of lease liabilities
                 
Operating cash outflows related to operating leases
     963        1,079  
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Trade Payables and Other Current Liabilities
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Trade Payables and Other Current Liabilities
Note 6: Trade Payables and Other Current Liabilities
6.1 Trade Payables
Trade payables increased by $4.6 million as of June 30, 2023, compared to December 31, 2022.
No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each period presented.
 
6.2 Other Liabilities
The following tables summarize the other liabilities as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
    
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total     
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total  
Employee related liabilities
     4,374        —          4,374        5,872        45        5,917  
Deferred income
     2,264        3,987        6,251        2,137        4,690        6,828  
Tax liabilities
     187        —          187        69        —          69  
Other debts
     433        —          433        1,131        —          1,131  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,258
 
  
 
3,987
 
  
 
11,245
 
  
 
9,210
 
  
 
4,735
 
  
 
13,945
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The Employee related liabilities include short-term debt to employees including social welfare and tax agency obligations.
Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' equity
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Shareholders' equity
Note 7: Shareholders’ equity
The share capital as of June 30, 2023 is set at the sum of €9,625,095.40 ($10,952 thousands converted at historical rates). It is divided into 96,250,954 fully authorized, subscribed and
paid-up
ordinary shares with a par value of €0.10.
Pursuant to the authorization granted by the General Meeting of the Shareholders held on April 12, 2023 (the “SH General Meeting”), the accumulated net losses of DBV Technologies S.A. after appropriation of the net result for the year ended December 31, 2022, have been allocated to additional
paid-in
capital.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Payments
6 Months Ended
Jun. 30, 2023
Share-based Payment Arrangement [Abstract]  
Share-Based Payments
Note 8: Share-Based Payments
The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and
non-employee
warrants (
Bons de Souscription d’Actions
or “BSA”).
During the six months ended June 30, 2023, the Company granted 59,200 stock options and 35,800 restricted stock units to employees. There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report. 
Change in Number of BSA/SO/RSU:
 
    
Number of outstanding
 
    
BSA
    
SO
    
RSUs
 
Balance as of December 31, 2022
  
 
251,693
 
  
 
5,306,569
 
  
 
1,589,081
 
Granted during the period
     —          59,200        35,800  
Forfeited during the period
     —          (75,200      (54,444
Exercised/released during the period
     —          —          (61,359
Expired during the period
     —          —          —    
    
 
 
    
 
 
    
 
 
 
Balance as of June 30, 2023
  
 
251,693
 
  
 
5,290,569
 
  
 
1,509,078
 
    
 
 
    
 
 
    
 
 
 
 
Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
 
           
Three Months
Ended June 30,
   
Six Months
Ended June 30,
 
           
2023
   
2022
   
2023
   
2022
 
Research & development
     SO        (465     (290     (894     (665
       RSU        (271     (185     (529     (393
Sales & marketing
     SO        (27     (38     (54     (33
       RSU        (8     (17     (17     (16
General & administrative
     SO        (925     (478     (1,722     (1,176
       RSU        (118     (70     (231     (157
             
 
 
   
 
 
   
 
 
   
 
 
 
Total share-based compensation (expense)
           
 
(1,814
 
 
(1,078
 
 
(3,446
 
 
(2,441
             
 
 
   
 
 
   
 
 
   
 
 
 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies
6 Months Ended
Jun. 30, 2023
Loss Contingency [Abstract]  
Contingencies
Note 9: Contingencies
The following tables summarize the contingencies as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Current contingencies
     5,076        3,944  
Non-current
contingencies
     15,731        16,680  
    
 
 
    
 
 
 
Total contingencies
  
 
20,807
 
  
 
20,625
 
    
 
 
    
 
 
 
The changes in contingencies are as follows:
 
    
Pension
retirement
obligations
    
Collaboration
agreement -
Loss at
completion
    
Other
contingencies
    
Total
 
At January 1, 2023
  
 
790
 
  
 
19,835
 
  
 
—  
 
  
 
20,625
 
Increases in liabilities
     11        —          780        791  
Used liabilities
     —          —          —          —    
Reversals of unused liabilities
     —          (1,083      —          (1,083
Net interest related to employee benefits, and unwinding of discount
     —          —          —          —    
Actuarial gains and losses on defined-benefit plans
     93        —          —          93  
Currency translation effect
     15        366        —          381  
    
 
 
    
 
 
    
 
 
    
 
 
 
At June 30, 2023
  
 
909
 
  
 
19,118
 
  
 
780
 
  
 
20,807
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Of which Current
  
 
—  
 
  
 
4,296
 
  
 
780
 
  
 
5,076
 
Of which
Non-current
  
 
909
 
  
 
14,822
 
  
 
—  
 
  
 
15,731
 
The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report.
In 2022 and during the first six months of 2023, the Company updated its measurement of progress of the Phase 2 clinical trial (“PII”) conducted as part of the collaboration and license agreement with Nestlé Health Sciences and updated the cumulative income recognized. The Company recognized a reversal of $1.1 million of the loss for completion recorded in the amount of the excess between the Company’s current best estimates of costs yet to be incurred and income yet to be recognized for the completion of the PII.
The other contingencies mainly consisted of a provision for refurbishment amounting to the best estimate of costs to be incurred in case the Montrouge office lease agreement is not renewed at its July 2024 term.
 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Income
6 Months Ended
Jun. 30, 2023
Other Income and Expenses [Abstract]  
Operating Income
Note 10: Operating income
The following table summarizes the operating income during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research tax credit
     1,975        1,491        3,741        3,060  
Other operating income
     312        37        741        1,014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
2,288
 
  
 
1,529
 
  
 
4,482
 
  
 
4,074
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The increase in operating income was primarily due to the increase in the research and development costs eligible to research tax credit in France.
The Company recognizes as other operating income accrued revenues based on its updated measurement of progress of the Phase 2 clinical trial conducted as part of the collaboration agreement with Nestlé. Moreover, the loss for completion recorded in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase 2 clinical trial was updated accordingly as of June 30, 2023 (see note 9 related to contingencies).
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Allocation of Personnel Expenses
6 Months Ended
Jun. 30, 2023
Operating Expenses [Abstract]  
Allocation of Personnel Expenses
Note 11: Allocation of Personnel Expenses
The Company had an average of 88 employees during the six months ended June 30, 2023, in comparison with an average of 87 employees during the six months ended June 30, 2022.
The following table summarizes the allocation of personnel expenses by function during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research and Development expenses
     4,014        3,097        8,020        6,172  
Sales and Marketing expenses
     208        344        373        589  
General and Administrative expenses
     2,858        2,767        5,958        5,362  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total personnel expenses
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The following table summarizes the allocation of personnel expenses by nature during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Wages and salaries
     4,078        3,509        8,516        7,497  
Social security contributions
     1,185        1,256        1,884        1,507  
Expenses for pension commitments
     246        211        504        509  
Employer contribution to bonus shares
     (244      154               170  
Share-based payments
     1,814        1,078        3,446        2,441  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The increase in personnel expenses was mainly due to recruitment of US employees partially offset by the departure of
non-US
employees, and the increase of charges related to share-base payments.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments
Note 12: Commitments
There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the Annual Report.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Relationships with Related Parties
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Relationships with Related Parties
Note 13: Relationships with Related Parties
The Company’s related parties exclusively consisted of the members of the Board of Directors and the members of the Executive Committee. As of June 30, 2023, the total amount of remuneration granted to the members of the Board of Directors and Executive Committee has not significantly changed since December 31, 2022.
There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Loss Per Share
Note 14: Loss Per Share
Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three- and
six-month
periods ended June 30, 2023 and 2022, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three and six months ended June 30, 2023 and 2022 indicated in number of potential shares:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Non-employee
warrants
     251,693        256,693        251,693        256,693  
Stock options
     5,290,569        3,442,358        5,290,569        3,442,358  
Restricted stock units
     1,509,078        1,145,223        1,509,078        1,145,223  
Prefunded warrants
     28,276,331        28,276,331        28,276,331        28,276,331  
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Events After the Close of the Period
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Events After the Close of the Period
Note 15: Events after the Close of the Period
The Company evaluated subsequent events that occurred after June 30, 2023, through the date the condensed consolidated financial statements were issued after their approval by the Board of Directors on July 28, 2023, and determined that there are no significant events that require adjustments or disclosure in such condensed consolidated financial statements.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
The Company (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form
10-K
filed with the SEC on March 2, 2023 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2022 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2022.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2023, or any other future period.
Use of estimates
Use of estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an
on-going
basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of
right-of-use
assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies, and (8) estimate of employee benefits obligations.
Accounting Pronouncements adopted in 2023
Accounting Pronouncements adopted in 2023
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU
2016-13—Financial
Instruments—Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU
2019-10
which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Adoption of this new standard did not have a material impact on the consolidated financial statements.
In October 2021, the FASB issued ASU
2021-08,
which amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. This amendment is effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption of this new standard has no impact on the consolidated financial statements.
Accounting Pronouncements issued not yet adopted
Accounting Pronouncements issued not yet adopted
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Cash and Cash Equivalents (Tables)
6 Months Ended
Jun. 30, 2023
Cash and Cash Equivalents [Abstract]  
Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Cash
     24,111        30,104  
Cash equivalents
     149,850        179,090  
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of financial position
  
 
173,961
 
  
 
209,194
 
    
 
 
    
 
 
 
Bank overdrafts
     —          —    
    
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of cash flows
  
 
173,961
 
  
 
209,194
 
Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Assets (Tables)
6 Months Ended
Jun. 30, 2023
Other Current Assets [Abstract]  
Summary of Other Current Asset
Other current assets consisted of the following:
 
 
  
June 30,
2023
 
  
December 31,
2022
 
Research tax credit
     9,662        5,792  
Other tax claims
     5,851        3,903  
Prepaid expenses
     4,494        2,680  
Other receivables
     1,571        1,504  
    
 
 
    
 
 
 
Total
  
 
21,578
 
  
 
13,880
 
    
 
 
    
 
 
 
Summary of Research Tax Credit
The variance in Research Tax Credit is presented as follows:
 
    
Amount in
thousands of US
Dollars
 
Opening research tax credit receivable as of January 1, 2023
  
 
5,792
 
+ Operating revenue
     3,741  
- Payment received
     —    
- Adjustment and currency translation effect
     130  
    
 
 
 
Closing research tax credit receivable as of June 30, 2023
  
 
9,662
 
    
 
 
 
Of which -
Non-current
portion
     —    
Of which - Current portion
     9,662  
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Lease contracts (Tables)
6 Months Ended
Jun. 30, 2023
Lessee Disclosure [Abstract]  
Summary of Operating Leases Future Minimum Payments Receivable
Future minimum lease payments under the Company’s operating leases’ right of use as of June 30, 2023 and December 31, 2022, are as follows:
 
    
June 30, 2023
   
December 31, 2022
 
    
Real estate
   
Other
assets
   
Total
   
Real estate
   
Other
assets
   
Total
 
Current portion
     1,886       74       1,961       1,972       79       2,051  
Year 2
     291       43       334       1,168       74       1,243  
Year 3
     —         —         —         65       6       71  
Thereafter
     —         —         —         —         —         —    
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total minimum lease payments
  
 
2,177
 
 
 
118
 
 
 
2,295
 
 
 
3,204
 
 
 
160
 
 
 
3,364
 
Less: Effects of discounting
     (153     (10     (163     (325     (17     (343
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Present value of operating lease
  
 
2,024
 
 
 
107
 
 
 
2,131
 
 
 
2,879
 
 
 
143
 
 
 
3,021
 
Less: current portion
     (1,873     (72     (1,944     (1,823     (71     (1,894
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Long-term operating lease
  
 
151
 
 
 
36
 
 
 
187
 
 
 
1,055
 
 
 
72
 
 
 
1,127
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average remaining lease term (years)
     0.95       —                 1.40       —            
Weighted average discount rate
     2.90     2.50             3.00     2.45        
Summary of Rent expenses Rent expense presented in the consolidated statement of operations and comprehensive loss was:
 
    
June 30,
 
    
2023
    
2022
 
Operating lease expense / (income)
     1,543        950  
Net termination impact
     (920      (1,657
Summary of Supplemental cash flow information related to our operating leases
Supplemental cash flow information related to operating leases is as follows for the period June 30, 2023 and 2022:
 
    
June 30,
 
    
2023
    
2022
 
Cash paid for amounts included in the measurement of lease liabilities
                 
Operating cash outflows related to operating leases
     963        1,079  
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Trade Payables and Other Current Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Other Liabilities, Current [Abstract]  
Summary of Other Liabilities
The following tables summarize the other liabilities as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
    
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total     
Other
 current

liabilities
    
Other
 non-current

liabilities
     Total  
Employee related liabilities
     4,374        —          4,374        5,872        45        5,917  
Deferred income
     2,264        3,987        6,251        2,137        4,690        6,828  
Tax liabilities
     187        —          187        69        —          69  
Other debts
     433        —          433        1,131        —          1,131  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,258
 
  
 
3,987
 
  
 
11,245
 
  
 
9,210
 
  
 
4,735
 
  
 
13,945
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Payments (Tables)
6 Months Ended
Jun. 30, 2023
Summary of RSU Activity Change in Number of BSA/SO/RSU:
 
    
Number of outstanding
 
    
BSA
    
SO
    
RSUs
 
Balance as of December 31, 2022
  
 
251,693
 
  
 
5,306,569
 
  
 
1,589,081
 
Granted during the period
     —          59,200        35,800  
Forfeited during the period
     —          (75,200      (54,444
Exercised/released during the period
     —          —          (61,359
Expired during the period
     —          —          —    
    
 
 
    
 
 
    
 
 
 
Balance as of June 30, 2023
  
 
251,693
 
  
 
5,290,569
 
  
 
1,509,078
 
    
 
 
    
 
 
    
 
 
 
Summary of Share-Based Payments Expenses
Share-based payments expense reflected in the condensed consolidated statements of operations is as follows:
 
           
Three Months
Ended June 30,
   
Six Months
Ended June 30,
 
           
2023
   
2022
   
2023
   
2022
 
Research & development
     SO        (465     (290     (894     (665
       RSU        (271     (185     (529     (393
Sales & marketing
     SO        (27     (38     (54     (33
       RSU        (8     (17     (17     (16
General & administrative
     SO        (925     (478     (1,722     (1,176
       RSU        (118     (70     (231     (157
             
 
 
   
 
 
   
 
 
   
 
 
 
Total share-based compensation (expense)
           
 
(1,814
 
 
(1,078
 
 
(3,446
 
 
(2,441
             
 
 
   
 
 
   
 
 
   
 
 
 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies (Tables)
6 Months Ended
Jun. 30, 2023
Loss Contingency [Abstract]  
Summary of Current Contingencies and Non-current Contingencies
The following tables summarize the contingencies as of June 30, 2023 and December 31, 2022:
 
    
June 30,
    
December 31,
 
    
2023
    
2022
 
Current contingencies
     5,076        3,944  
Non-current
contingencies
     15,731        16,680  
    
 
 
    
 
 
 
Total contingencies
  
 
20,807
 
  
 
20,625
 
    
 
 
    
 
 
 
Summary of Movement in Provisions
The changes in contingencies are as follows:
 
    
Pension
retirement
obligations
    
Collaboration
agreement -
Loss at
completion
    
Other
contingencies
    
Total
 
At January 1, 2023
  
 
790
 
  
 
19,835
 
  
 
—  
 
  
 
20,625
 
Increases in liabilities
     11        —          780        791  
Used liabilities
     —          —          —          —    
Reversals of unused liabilities
     —          (1,083      —          (1,083
Net interest related to employee benefits, and unwinding of discount
     —          —          —          —    
Actuarial gains and losses on defined-benefit plans
     93        —          —          93  
Currency translation effect
     15        366        —          381  
    
 
 
    
 
 
    
 
 
    
 
 
 
At June 30, 2023
  
 
909
 
  
 
19,118
 
  
 
780
 
  
 
20,807
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Of which Current
  
 
—  
 
  
 
4,296
 
  
 
780
 
  
 
5,076
 
Of which
Non-current
  
 
909
 
  
 
14,822
 
  
 
—  
 
  
 
15,731
 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Income (Tables)
6 Months Ended
Jun. 30, 2023
Other Income and Expenses [Abstract]  
Schedule of operating income
The following table summarizes the operating income during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research tax credit
     1,975        1,491        3,741        3,060  
Other operating income
     312        37        741        1,014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
2,288
 
  
 
1,529
 
  
 
4,482
 
  
 
4,074
 
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Allocation of Personnel Expenses (Tables)
6 Months Ended
Jun. 30, 2023
Operating Expenses [Abstract]  
Summary of Allocation of Personnel Expenses By Function
The following table summarizes the allocation of personnel expenses by function during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Research and Development expenses
     4,014        3,097        8,020        6,172  
Sales and Marketing expenses
     208        344        373        589  
General and Administrative expenses
     2,858        2,767        5,958        5,362  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total personnel expenses
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Summary of Allocation of Personnel Expenses By Nature
The following table summarizes the allocation of personnel expenses by nature during the three and six months ended June 30, 2023 and 2022:
 
    
Three Months
Ended June 30,
    
Six Months
Ended June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Wages and salaries
     4,078        3,509        8,516        7,497  
Social security contributions
     1,185        1,256        1,884        1,507  
Expenses for pension commitments
     246        211        504        509  
Employer contribution to bonus shares
     (244      154               170  
Share-based payments
     1,814        1,078        3,446        2,441  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,079
 
  
 
6,208
 
  
 
14,351
 
  
 
12,123
 
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share, Basic [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three and six months ended June 30, 2023 and 2022 indicated in number of potential shares:
 
    
Three Months Ended
June 30,
    
Six Months Ended
June 30,
 
    
2023
    
2022
    
2023
    
2022
 
Non-employee
warrants
     251,693        256,693        251,693        256,693  
Stock options
     5,290,569        3,442,358        5,290,569        3,442,358  
Restricted stock units
     1,509,078        1,145,223        1,509,078        1,145,223  
Prefunded warrants
     28,276,331        28,276,331        28,276,331        28,276,331  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Significant Events and Transactions of the Periods - Additional Information (Detail)
$ / shares in Units, $ in Millions
1 Months Ended
Jan. 31, 2020
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
€ / shares
American Depositary Shares [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Stock Issued During Period, Shares, New Issues | shares   2,052,450  
Shares Issued, Price Per Share | (per share)   $ 1.9 € 3.52
Stockholders' Equity Note, Stock Split, Conversion Ratio   1.0809  
Proceeds From Issuance Of Common Stock | $   $ 7.8  
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Clinical Program Trial Period 6 months    
Minimum [Member] | ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Age Of Child 4 years    
Maximum [Member] | ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Age Of Child 11 years    
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value [Abstract]    
Cash $ 24,111 $ 30,104
Cash equivalents 149,850 179,090
Total cash and cash equivalents as reported in the statements of financial position 173,961 209,194
Bank overdrafts 0 0
Total cash and cash equivalents as reported in the statements of cash flows $ 173,961 $ 209,194
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Assets - Summary of Other Current Asset (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Other Assets [Abstract]    
Research tax credit $ 9,662 $ 5,792
Other tax claims 5,851 3,903
Prepaid expenses 4,494 2,680
Other receivables 1,571 1,504
Total $ 21,578 $ 13,880
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Assets - Summary Of Research Tax Credit (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Tax Credit Carryforward [Line Items]  
Opening balance $ 5,792
+ Operating revenue 3,741
- Payment received 0
- Adjustment and currency translation effect 130
Closing balance 9,662
Of which - Non-current portion 0
Of which - Current portion $ 9,662
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Assets - Additional Information (Detail) - USD ($)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Research Tax Credit Carryforward [Member]    
Other Current Assets [Line Items]    
Tax credit carryforward amount before currency translation $ 3.7 $ 5.8
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current portion $ 1,961 $ 2,051
Year 2 334 1,243
Year 3 0 71
Thereafter 0 0
Total minimum lease payments 2,295 3,364
Less: Effects of discounting (163) (343)
Present value of operating lease 2,131 3,021
Less: current portion (1,944) (1,894)
Long-term operating lease 187 1,127
Real Estate [Member]    
Current portion 1,886 1,972
Year 2 291 1,168
Year 3 0 65
Thereafter 0 0
Total minimum lease payments 2,177 3,204
Less: Effects of discounting (153) (325)
Present value of operating lease 2,024 2,879
Less: current portion (1,873) (1,823)
Long-term operating lease $ 151 $ 1,055
Weighted average remaining lease term (years) 11 months 12 days 1 year 4 months 24 days
Weighted average discount rate 2.90% 3.00%
Other Asset [Member]    
Current portion $ 74 $ 79
Year 2 43 74
Year 3   6
Thereafter 0 0
Total minimum lease payments 118 160
Less: Effects of discounting (10) (17)
Present value of operating lease 107 143
Less: current portion (72) (71)
Long-term operating lease $ 36 $ 72
Weighted average discount rate 2.50% 2.45%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Lease contracts - Summary of Rent expenses (Detail) - Rent Expenses [Member] - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating lease expense / (income) $ 1,543 $ 950
Net termination impact $ (920) $ (1,657)
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flow, Operating Activities, Lessee [Abstract]    
Operating cash outflows related to operating leases $ 963 $ 1,079
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Other current liabilities $ 7,258 $ 9,210
Other non-current liabilities 3,987 4,735
Total 11,245 13,945
Employee Related Liabilities [Member]    
Other current liabilities 4,374 5,872
Other non-current liabilities 0 45
Total 4,374 5,917
Deferred Incomes [Member]    
Other current liabilities 2,264 2,137
Other non-current liabilities 3,987 4,690
Total 6,251 6,828
Tax Liabilities [Member]    
Other current liabilities 187 69
Other non-current liabilities 0 0
Total 187 69
Other Debts [Member]    
Other current liabilities 433 1,131
Other non-current liabilities 0 0
Total $ 433 $ 1,131
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Trade Payables and Other Current Liabilities - Additional Information (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Increase decrease in trade payables current $ 3,419 $ 5,894
Increase in Current Trade Payables [Member]    
Increase decrease in trade payables current $ 4,600  
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' equity - Additional Information (Detail)
€ / shares in Units, $ in Thousands
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2023
EUR (€)
€ / shares
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Class of Stock [Line Items]              
Share capital | $ $ 164,240   $ 179,094 $ 194,453 $ 244,416 $ 82,062 $ 99,274
Share Capital [Member]              
Class of Stock [Line Items]              
Share capital authorized | shares 96,250,954 96,250,954          
Nominal value | € / shares   € 0.1          
Share capital $ 10,952 € 9,625,095.4          
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Payments - Summary of RSU Activity (Detail)
6 Months Ended
Jun. 30, 2023
shares
B S A Warrants [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of warrants outstanding, Beginning Balance 251,693
Number of warrants outstanding, Ending Balance 251,693
Restricted Stock Units [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of RSU outstanding, Beginning Balance 1,589,081
Number of RSU outstanding, Granted during the period 35,800
Number of RSU outstanding, Forfeited during the period (54,444)
Number of RSU outstanding, Released during the period (61,359)
Number of RSU outstanding, Ending Balance 1,509,078
Share-based Payment Arrangement, Option [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of stock options outstanding, Beginning Balance 5,306,569
Number of stock options outstanding, Granted during the period 59,200
Number of stock options outstanding, Forfeited during the period (75,200)
Number of stock options outstanding, Ending Balance 5,290,569
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Payments - Summary of Share-Based Payments Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments $ (1,814) $ (1,078) $ (3,446) $ (2,441)
Research and Development expenses [Member] | Stock Options [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments (465) (290) (894) (665)
Research and Development expenses [Member] | Restricted Stock Units [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments (271) (185) (529) (393)
Sales and Marketing expenses [Member] | Stock Options [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments (27) (38) (54) (33)
Sales and Marketing expenses [Member] | Restricted Stock Units [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments (8) (17) (17) (16)
General and Administrative expenses [Member] | Stock Options [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments (925) (478) (1,722) (1,176)
General and Administrative expenses [Member] | Restricted Stock Units [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based payments $ (118) $ (70) $ (231) $ (157)
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Payments - Additional Information (Detail)
6 Months Ended
Jun. 30, 2023
shares
Share options [Member]  
Share-Based Payments [Line iteam]  
Number of stock options outstanding, Granted during the period 59,200
Restricted Stock Units [Member]  
Share-Based Payments [Line iteam]  
Number of RSU outstanding, Granted during the period 35,800
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Liability, Defined Benefit Plan [Abstract]    
Current contingencies $ 5,076 $ 3,944
Non-current contingencies 15,731 16,680
Total contingencies $ 20,807 $ 20,625
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies - Summary of Movement in Contingencies (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Contingencies, Beginning balance $ 20,625  
Increases in liabilities 791  
Used liabilities 0  
Reversals of unused liabilities (1,083)  
Net interest related to employee benefits, and unwinding of discount 0  
Actuarial gains and losses on defined-benefit plans 93  
Currency translation effect 381  
Contingencies, Ending balance 20,807  
Of which Current 5,076 $ 3,944
Of which Non-current 15,731 $ 16,680
Pension retirement obligations [Member]    
Contingencies, Beginning balance 790  
Increases in liabilities 11  
Actuarial gains and losses on defined-benefit plans 93  
Currency translation effect 15  
Contingencies, Ending balance 909  
Of which Non-current 909  
Collaboration agreement -Loss at completion [Member]    
Contingencies, Beginning balance 19,835  
Reversals of unused liabilities (1,083)  
Currency translation effect 366  
Contingencies, Ending balance 19,118  
Of which Current 4,296  
Of which Non-current 14,822  
Other provisions incl. restructuring [Member]    
Increases in liabilities 780  
Currency translation effect 0  
Contingencies, Ending balance 780  
Of which Current $ 780  
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies - Additional Information (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Loss contingency reversal amount $ (1,083)
Collaboration And License Agreement [Member]  
Loss contingency reversal amount $ 1,100
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Income - Summary of Operating Income (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Other Income and Expenses [Abstract]        
Research tax credit $ 1,975 $ 1,491 $ 3,741 $ 3,060
Other operating income 312 37 741 1,014
Total $ 2,288 $ 1,529 $ 4,482 $ 4,074
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Research and Development expenses $ 17,616 $ 18,611 $ 33,653 $ 30,834
Sales and Marketing expenses 516 1,037 950 1,500
General and Administrative expenses 9,231 5,704 16,120 12,334
Total Operating expenses 27,364 25,352 50,723 44,669
Expenses by Function [Member]        
Research and Development expenses 4,014 3,097 8,020 6,172
Sales and Marketing expenses 208 344 373 589
General and Administrative expenses 2,858 2,767 5,958 5,362
Total Operating expenses $ 7,079 $ 6,208 $ 14,351 $ 12,123
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-based payments $ (1,814) $ (1,078) $ (3,446) $ (2,441)
Total Operating expenses 27,364 25,352 50,723 44,669
Expenses by Nature [Member]        
Wages and salaries 4,078 3,509 8,516 7,497
Social security contributions 1,185 1,256 1,884 1,507
Expenses for pension commitments 246 211 504 509
Employer contribution to bonus shares (244) 154 0 170
Share-based payments 1,814 1,078 3,446 2,441
Total Operating expenses $ 7,079 $ 6,208 $ 14,351 $ 12,123
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments - Additional Information (Detail)
6 Months Ended
Jun. 30, 2023
USD ($)
Disclosure Of Commitments [Line Items]  
Increase (decrease) in other commitments during the period $ 0
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Relationships with Related Parties - Additional Information (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Related Party Transactions [Abstract]  
Increase decrease in related party transactions and changes in nature of the transactions $ 0
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Non-employee warrants [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 251,693 256,693 251,693 256,693
Stock options [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,290,569 3,442,358 5,290,569 3,442,358
Restricted stock units [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,509,078 1,145,223 1,509,078 1,145,223
Prefunded warrants [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 28,276,331 28,276,331 28,276,331 28,276,331
XML 64 d515836d10q_htm.xml IDEA: XBRL DOCUMENT 0001613780 2023-06-30 0001613780 2022-12-31 0001613780 2022-04-01 2022-06-30 0001613780 2023-01-01 2023-06-30 0001613780 2022-01-01 2022-06-30 0001613780 2023-04-01 2023-06-30 0001613780 2023-07-31 0001613780 2022-01-01 2022-03-31 0001613780 2023-01-01 2023-03-31 0001613780 2021-12-31 0001613780 2022-03-31 0001613780 2022-06-30 0001613780 2023-03-31 0001613780 us-gaap:CommonStockMember 2022-12-31 0001613780 us-gaap:RealEstateMember 2022-12-31 0001613780 dbvt:OtherAssetMember 2022-12-31 0001613780 dbvt:TaxLiabilitiesMember 2022-12-31 0001613780 dbvt:OtherDebtsMember 2022-12-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2022-12-31 0001613780 dbvt:DeferredRevenueMember 2022-12-31 0001613780 us-gaap:CommonStockMember 2023-06-30 0001613780 us-gaap:RealEstateMember 2023-06-30 0001613780 dbvt:OtherAssetMember 2023-06-30 0001613780 dbvt:TaxLiabilitiesMember 2023-06-30 0001613780 dbvt:OtherDebtsMember 2023-06-30 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2023-06-30 0001613780 dbvt:DeferredRevenueMember 2023-06-30 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2023-06-30 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2023-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2023-06-30 0001613780 dbvt:AmericanDepositarySharesMember 2023-06-30 0001613780 dbvt:ShareCapitalMember 2023-06-30 0001613780 dbvt:ExpensesByFunctionMember 2022-01-01 2022-06-30 0001613780 dbvt:ExpensesByNatureMember 2022-01-01 2022-06-30 0001613780 dbvt:NonemployeewarrantsMember 2022-01-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001613780 dbvt:PrefundedWarrantsMember 2022-01-01 2022-06-30 0001613780 dbvt:RentExpensesMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001613780 dbvt:ExpensesByFunctionMember 2022-04-01 2022-06-30 0001613780 dbvt:ExpensesByNatureMember 2022-04-01 2022-06-30 0001613780 dbvt:NonemployeewarrantsMember 2022-04-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001613780 dbvt:PrefundedWarrantsMember 2022-04-01 2022-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0001613780 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001613780 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001613780 dbvt:ExpensesByFunctionMember 2023-01-01 2023-06-30 0001613780 dbvt:ExpensesByNatureMember 2023-01-01 2023-06-30 0001613780 dbvt:NonemployeewarrantsMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 dbvt:PrefundedWarrantsMember 2023-01-01 2023-06-30 0001613780 dbvt:RentExpensesMember 2023-01-01 2023-06-30 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2023-01-01 2023-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2023-01-01 2023-06-30 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001613780 dei:AdrMember 2023-01-01 2023-06-30 0001613780 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001613780 dbvt:CollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001613780 dbvt:IncreaseInCurrentTradePayablesMember 2023-01-01 2023-06-30 0001613780 us-gaap:ResearchMember 2023-01-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001613780 dbvt:ExpensesByFunctionMember 2023-04-01 2023-06-30 0001613780 dbvt:ExpensesByNatureMember 2023-04-01 2023-06-30 0001613780 dbvt:NonemployeewarrantsMember 2023-04-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001613780 dbvt:PrefundedWarrantsMember 2023-04-01 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0001613780 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001613780 us-gaap:TreasuryStockMember 2023-04-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001613780 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001613780 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001613780 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001613780 us-gaap:TreasuryStockMember 2023-01-01 2023-03-31 0001613780 srt:MinimumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 srt:MaximumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:AmericanDepositarySharesMember 2023-06-01 2023-06-30 0001613780 us-gaap:ResearchMember 2022-01-01 2022-12-31 0001613780 us-gaap:CommonStockMember 2022-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001613780 us-gaap:TreasuryStockMember 2022-06-30 0001613780 us-gaap:RetainedEarningsMember 2022-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2022-12-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2022-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001613780 dbvt:BSAWarrantsMember 2022-12-31 0001613780 dbvt:BSAWarrantsMember 2023-06-30 0001613780 us-gaap:EmployeeStockOptionMember 2022-12-31 0001613780 us-gaap:EmployeeStockOptionMember 2023-06-30 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001613780 us-gaap:TreasuryStockMember 2023-06-30 0001613780 us-gaap:RetainedEarningsMember 2023-06-30 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001613780 us-gaap:CommonStockMember 2021-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001613780 us-gaap:TreasuryStockMember 2021-12-31 0001613780 us-gaap:RetainedEarningsMember 2021-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001613780 us-gaap:CommonStockMember 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001613780 us-gaap:TreasuryStockMember 2022-03-31 0001613780 us-gaap:RetainedEarningsMember 2022-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001613780 us-gaap:TreasuryStockMember 2022-12-31 0001613780 us-gaap:RetainedEarningsMember 2022-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001613780 us-gaap:CommonStockMember 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001613780 us-gaap:TreasuryStockMember 2023-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 iso4217:USD shares utr:Year utr:Month pure iso4217:EUR iso4217:EUR shares iso4217:USD shares false Q2 0001613780 --12-31 00-0000000 10-Q true 2023-06-30 2023 false 001-36697 DBV TECHNOLOGIES S.A. I0 177-181 avenue Pierre Brossolette 92120 Montrouge FR 33 1 55 42 78 78 American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share DBVT NASDAQ Ordinary shares, nominal value €0.10 per share NASDAQ true Yes Yes Non-accelerated Filer true false false 96250954 173961000 209194000 21578000 13880000 195539000 223074000 14135000 15096000 1832000 2513000 68000 10000 5944000 5824000 21979000 23444000 217518000 246518000 19094000 14473000 1944000 1894000 5076000 3944000 7258000 9210000 33373000 29521000 187000 1127000 15731000 16680000 3987000 4735000 19905000 22543000 53277000 52064000 0.1 0.1 96250954 96250954 94137145 94137145 10952000 10720000 375759000 458221000 149972 149793 1082000 1109000 -210940000 -259578000 687000 781000 -11136000 -14581000 164240000 194453000 217518000 246518000 2288000 1529000 4482000 4074000 17616000 18611000 33653000 30834000 516000 1037000 950000 1500000 9231000 5704000 16120000 12334000 27364000 25352000 50723000 44669000 -25076000 -23823000 -46242000 -40595000 846000 784000 1450000 936000 -24230000 -23039000 -44791000 -39659000 13000 0 13000 87000 -24243000 -23039000 -44804000 -39746000 -221000 -11394000 3445000 -13327000 -10000 200000 -92000 224000 -24475000 -34234000 -41452000 -52849000 -0.26 -0.26 -0.35 -0.35 -0.48 -0.48 -0.66 -0.66 94324889 94324889 66047949 66047949 94150141 94150141 60490075 60490075 -44804000 -39746000 369000 1249000 11000 14000 3446000 2441000 -23000 3000 6481000 -23436000 3419000 5894000 -2913000 -3040000 -535000 1979000 -46394000 -11733000 275000 369000 0 3000 27000 279000 4000 426000 -299000 -218000 0 -328000 27000 279000 7766000 195270000 0 0 7793000 195221000 3668000 -12600000 -35232000 170670000 209194000 77301000 173961000 247971000 55095762 6538000 358115000 -1232000 -258528000 519000 -6137000 99274000 -16706000 -16706000 24000 -1933000 -1909000 775 1000 0 1000 40000 40000 1363000 1363000 15000 -15000 55096537 6539000 359478000 -1193000 -275219000 543000 -8086000 82062000 -23039000 -23039000 200000 -11394000 -11194000 38926142 4170000 103007000 107176000 88094000 88094000 240000 240000 1078000 1078000 -95209000 95209000 94022679 10708000 456447000 -953000 -203050000 743000 -19480000 244416000 94137145 10720000 458221000 -1109000 -259578000 781000 -14581000 194453000 -20561000 -20561000 -82000 3666000 3584000 10174 1000 -1000 0 -14000 -14000 1632000 1632000 94147319 10721000 459852000 -1123000 -280138000 698000 -10915000 179094000 -24243000 -24243000 -10000 -221000 -232000 2103635 231000 7535000 7766000 42000 42000 1814000 1814000 -93441000 93441000 96250954 10952000 375759000 -1082000 -210940000 687000 -11136000 164240000 <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 1: The Company </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”, or the “group”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">™</div>. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">™</div>, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">™</div>. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed with the SEC on March 2, 2023 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2022 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2023, or any other future period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Use of estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies, and (8) estimate of employee benefits obligations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Accounting Pronouncements adopted in 2023 </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13—Financial</div> Instruments—Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10</div> which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Adoption of this new standard did not have a material impact on the consolidated financial statements. </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> which amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. This amendment is effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption of this new standard has no impact on the consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 13.28px;;font-weight:bold;display:inline;">Accounting Pronouncements issued not yet adopted</div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption. <br/></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed with the SEC on March 2, 2023 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2022 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2023, or any other future period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Use of estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies, and (8) estimate of employee benefits obligations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Accounting Pronouncements adopted in 2023 </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13—Financial</div> Instruments—Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10</div> which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Adoption of this new standard did not have a material impact on the consolidated financial statements. </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> which amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. This amendment is effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption of this new standard has no impact on the consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 13.28px;;font-weight:bold;display:inline;">Accounting Pronouncements issued not yet adopted</div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption. <br/></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 2: Significant Events and Transactions </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical programs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">United States Regulatory History and Current Status </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following receipt of the Complete Response Letter. The FDA agreed with its position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of one peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and a modified patch, FDA requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-11.</div> The Company named that assessment EQUAL, which stands for Equivalence in Uptake of ALlergen. The FDA also recommended conducting a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month,</div> well-controlled safety and adhesion trial to assess a modified Viaskin Peanut patch in the intended patient population. The Company later named this study STAMP, which stands for Safety, Tolerability, and Adhesion of Modified Patches. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the January 2021 FDA feedback, the Company defined three parallel workstreams: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">1.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identify a modified Viaskin patch (which the Company calls “mVP”). </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">2.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Generate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> safety and adhesion clinical data FDA requested via STAMP, which the Company expected to be the longest component of the mVP clinical plan. The Company prioritized the STAMP protocol submission so the Company could begin the study as soon as possible. </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">3.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Demonstrate the equivalence in allergen uptake between the current and modified patches in the intended patient population via EQUAL. The complexity of EQUAL hinged on the lack of established clinical and regulatory criteria to characterize allergen uptake via an epicutaneous patch. To support those exchanges, the Company outlined its proposed approach to demonstrate allergen uptake equivalence between the two patches, and allotted time to generate informative data through two additional Phase 1 clinical trials in healthy adult volunteers: </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">a.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">PREQUAL, a Phase 1 study with adult healthy volunteers to optimize the allergen sample collection methodologies and validate the assays we intend to use in EQUAL<div style="display:inline;">.</div> The data collection phase of the trial is complete, and the data analysis phase is ongoing. </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">b.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">‘EQUAL in adults’—a second Phase I study with adult healthy volunteers to compare the allergen uptake of cVP and mVP; </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches. The Company completed CHAMP in the second quarter of 2021. All modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the then-current Viaskin Peanut patch, and the Company then selected two modified patches that performed best out of the five modified patches studied for further development. The Company then selected the circular patch for further development, which is larger in size relative to the current patch and circular in shape. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2021, the Company submitted its proposed STAMP protocol to the FDA, and on October 14, 2021, the Company received an Advice/Information Request letter from the FDA. In this letter, the FDA requested a stepwise approach to the modified Viaskin patch development program and provided partial feedback on the STAMP protocol. Specifically, the FDA requested that the Company conduct allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL), and submit the allergen uptake comparison data for FDA review and feedback prior to starting the STAMP study. The FDA’s explanation was that the results from the allergen uptake studies might affect the design of the STAMP study. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful review of the FDA’s information requests, in December 2021, the Company decided not to pursue the sequential approach to the development plans for Viaskin Peanut as requested by the FDA in the October 2021 feedback. The Company estimated that the FDA’s newly proposed sequential approach would require at least five rounds of exchanges that necessitate FDA alignment prior to initiating STAMP, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> safety and adhesion study. As such, in December 2021, the Company announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. The Company considers this approach the most straightforward to potentially demonstrate effectiveness, safety, and improved in vivo adhesion of the modified Viaskin Peanut system. The FDA confirmed the Company’s change in strategy is agreeable via oral and written <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exchanges. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In 2022, the Company announced the new Phase 3 pivotal study for modified Viaskin Peanut (mVP) patch would be in younger <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(4-7</div> years old) and more sensitive children with peanut allergy. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-7</div> years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institution<div style="display:inline;">al</div> Review Board (IRB)/Ethics Committee (EC) approval. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 21, 2022, the Company announced it received feedback from the U.S. FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> activities for prompt study launch once the partial clinical hold was lifted. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 2, 2023, the Company announced the completion of EVOLVE, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> caregiver and patient user experience study of the mVP patch in 50 peanut allergic children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4–11-years</div> old. The objective of EVOLVE was to evaluate the Instructions for Use (IFU) and ease of use for the mVP patch. The study concluded that the updated IFU supported correct patch application, which included no lifting of the patch edges or detachment directly after application. Furthermore, EVOLVE concluded that the majority of parents/caregivers reported a positive ease of use experience with the mVP patch. In EVOLVE, DBV also tested the functionality of an electronic patient diary (eDiary) to collect information on activities of daily living and patch adhesion scores. EVOLVE verified that the eDiary tool can be used by caregivers in VITESSE to capture the adhesion data in support of a potential BLA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 7, 2023, the Company announced that the first patient was screened in the VITESSE study. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 19, 2023, the Company outlined <div style="display:inline;">the </div>regulatory path for Viaskin Peanut in children <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div> years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use. </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Viaskin Peanut for children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-11—European</div> Union Regulatory History and Current Status </div></div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-style:italic;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px; background: none;;display:inline;"> </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August 2, 2021, the Company announced it received from the European Medicines Agency (“EMA”) of the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. It is a letter that is meant to include any remaining questions or objections at that stage in the process. The EMA indicated many of their objections and major objections from the Day 120 list of questions had been answered. One major objection remained at Day 180. The Major Objection questioned the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 20, 2021, the Company announced it had withdrawn the Marketing Authorization Application (“MAA”) for Viaskin Peanut and formally notified the EMA of our decision. The initial filing was supported by data from a single, placebo-controlled Phase 3 pivotal trial known as PEPITES <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(V712-301).</div> The decision to withdraw was based on the view of EMA Committee for Medicinal Products for Human Use (CHMP) that the data available to date from a single pivotal clinical trial were not sufficient to preclude a Major Objection at Day 180 in the review cycle. The Company believes data from a second Viaskin Peanut pivotal clinical trial will support a more robust path for licensure of Viaskin Peanut in the EU. The Company intends to resubmit the MAA when that data set is available. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Viaskin Peanut for children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div> </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the Company announced that in Part A, patients in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigation of the 250 µg dose in this age group, which is the dose being studied in Part B of the study. Enrollment for Part B of EPITOPE was completed in the first quarter <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of 2021. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2022, the Company announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms respectively. Enrollment was balance for age and baseline disease characteristics between the active and placebo treatment arms. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On April 19, 2023, </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;"></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">the Company announced it will begin a new safety study after it received confirmation from the FDA that the EPITOPE study meets the<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; top: 0px;;display:inline;">pre-specified</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>criteria for success for the primary endpoint, with no additional efficacy study requested. This safety study will increase the safety data collected from EPITOPE in support of a BLA. It will also generate patch adhesion data and will include updated instructions for use.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut <div style="display:inline;">exposure </div>by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div> years old with a confirmed peanut allergy. </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Viaskin Peanut for Children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-7</div> </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-7</div> years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On September 21, 2022, the Company announced we had received feedback from the FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> activities for prompt study launch once the partial clinical hold was lifted. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On March 7, 2023, the Company announced that the first patient was screened in the VITESSE trial. Screening of the last patient is anticipated in the first half in 2024 and topline results in the first half in 2025. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2023, the Company issued and completed sales of new ordinary shares (the “Ordinary Shares”) in <div style="display:inline;">the </div>form of American Depositary Shares (“ADSs”), for a total gross amount of $7.8 million, under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> (“ATM”) program established in May 2022. In this context, 2,052,450 new Ordinary Shares in <div style="display:inline;">the </div>form of ADS have been issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics (the “ATM Issuance”), at a unit subscription price of 1.90 dollar per ADS (i.e., a subscription price per Ordinary Share of 3.52 euro based on the USD/EUR exchange rate of 1.0809 dollar for 1 euro, as published by the European Central Bank on June 14, 2023) and each ADS giving the right to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one ordinary share of the Company. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Legal Proceedings </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> P4Y P11Y P6M 7800000 2052450 1.9 3.52 1.0809 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3: Cash and Cash Equivalents </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the cash and cash equivalents as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,111</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,104</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149,850</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179,090</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash and cash equivalents as reported in the statements of financial position</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">173,961</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209,194</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank overdrafts</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash and cash equivalents as reported in the statements of cash flows</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">173,961</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209,194</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the cash and cash equivalents as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,111</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,104</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149,850</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179,090</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash and cash equivalents as reported in the statements of financial position</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">173,961</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209,194</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank overdrafts</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash and cash equivalents as reported in the statements of cash flows</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">173,961</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209,194</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements. </div> 24111000 30104000 149850000 179090000 173961000 209194000 0 0 173961000 209194000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4 Other Current Assets </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets consisted of the following: <br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"></td> <td style="width: 4%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 4%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research tax credit</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,662</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,792</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other tax claims</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,851</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,903</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,494</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other receivables</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,504</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,578</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,880</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credit </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variance in Research Tax Credit is presented as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:82%"></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount in<br/> thousands of US<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Opening research tax credit receivable as of January 1, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,792</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">+ Operating revenue</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">- Payment received</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">- Adjustment and currency translation effect</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Closing research tax credit receivable as of June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,662</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which - Current portion</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,662</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before currency translation effect, the balance in research tax credit as of June 30, 2023, consisted of $5.8 million research tax credit for the 2022 fiscal year filed with the tax authorities and yet to be reimbursed, and $3.7 million estimated research tax credit for the first six months of the 2023 fiscal year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets consisted of the following: <br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"></td> <td style="width: 4%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 4%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research tax credit</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,662</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,792</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other tax claims</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,851</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,903</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,494</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other receivables</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,504</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,578</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,880</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 9662000 5792000 5851000 3903000 4494000 2680000 1571000 1504000 21578000 13880000 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variance in Research Tax Credit is presented as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:82%"></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount in<br/> thousands of US<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Opening research tax credit receivable as of January 1, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,792</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">+ Operating revenue</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">- Payment received</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">- Adjustment and currency translation effect</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Closing research tax credit receivable as of June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,662</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which - Current portion</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,662</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 5792000 3741000 0 130000 9662000 0 9662000 5800000 3700000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5 Lease contracts </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under the Company’s operating leases’ right of use as of June 30, 2023 and December 31, 2022, are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:64%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Real estate</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> assets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Real estate</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> assets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,961</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,972</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,051</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year 2</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">334</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,168</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total minimum lease payments</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,177</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">118</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,295</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,204</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">160</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,364</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Effects of discounting</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(153</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(343</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Present value of operating lease</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,024</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">107</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,131</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,879</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">143</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,021</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,873</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,944</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,823</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,894</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term operating lease</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">151</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">187</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,055</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,127</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term (years)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.95</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.50</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.45</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the consolidated statement of operations and comprehensive loss was: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:83%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease expense / (income)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,543</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">950</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net termination impact</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(920</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,657</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information related to operating leases is as follows for the period June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:87%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Operating cash outflows related to operating leases</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">963</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,079</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under the Company’s operating leases’ right of use as of June 30, 2023 and December 31, 2022, are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:64%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Real estate</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> assets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Real estate</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> assets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,961</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,972</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,051</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year 2</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">334</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,168</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total minimum lease payments</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,177</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">118</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,295</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,204</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">160</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,364</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Effects of discounting</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(153</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(343</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Present value of operating lease</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,024</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">107</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,131</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,879</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">143</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,021</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,873</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,944</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,823</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,894</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term operating lease</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">151</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">187</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,055</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,127</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term (years)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.95</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.50</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.45</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr></table> 1886000 74000 1961000 1972000 79000 2051000 291000 43000 334000 1168000 74000 1243000 0 0 65000 6000 71000 0 0 0 0 0 0 2177000 118000 2295000 3204000 160000 3364000 153000 10000 163000 325000 17000 343000 2024000 107000 2131000 2879000 143000 3021000 1873000 72000 1944000 1823000 71000 1894000 151000 36000 187000 1055000 72000 1127000 P0Y11M12D P1Y4M24D 0.029 0.025 0.03 0.0245 Rent expense presented in the consolidated statement of operations and comprehensive loss was: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:83%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease expense / (income)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,543</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">950</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net termination impact</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(920</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,657</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table> 1543000 950000 -920000 -1657000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information related to operating leases is as follows for the period June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:87%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Operating cash outflows related to operating leases</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">963</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,079</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 963000 1079000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6: Trade Payables and Other Current Liabilities </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">6.1 Trade Payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade payables increased by $4.6 million as of June 30, 2023, compared to December 31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each period presented. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="display:inline;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">6.2 Other Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the other liabilities as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:50%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> current</div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> non-current</div></div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">Total</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> current</div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> non-current</div></div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">Total</td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee related liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,872</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,917</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,987</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,251</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,690</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other debts</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,258</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,987</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,245</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,210</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,735</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,945</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee related liabilities include short-term debt to employees including social welfare and tax agency obligations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science. </div> 4600000 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the other liabilities as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:50%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> current</div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> non-current</div></div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">Total</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> current</div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> non-current</div></div></div><br/> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">liabilities </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">Total</td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee related liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,872</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,917</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,987</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,251</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,690</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other debts</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,258</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,987</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,245</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,210</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,735</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,945</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 4374000 0 4374000 5872000 45000 5917000 2264000 3987000 6251000 2137000 4690000 6828000 187000 0 187000 69000 0 69000 433000 0 433000 1131000 0 1131000 7258000 3987000 11245000 9210000 4735000 13945000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 7: Shareholders’ equity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share capital as of June 30, 2023 is set at the sum of €9,625,095.40 ($10,952 thousands converted at historical rates). It is divided into 96,250,954 fully authorized, subscribed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-up</div> ordinary shares with a par value of €0.10. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the authorization granted by the General Meeting of the Shareholders held on April 12, 2023 (the “SH General Meeting”), the accumulated net losses of DBV Technologies S.A. after appropriation of the net result for the year ended December 31, 2022, have been allocated to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div> 9625095.4 10952000 96250954 0.1 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 8: Share-Based Payments </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> warrants (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bons de Souscription d’Actions</div></div> or “BSA”). </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June 30, 2023, the Company granted 59,200 stock options and 35,800 restricted stock units to employees. There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in Number of BSA/SO/RSU: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of outstanding</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BSA</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SO</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSUs</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">251,693</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,306,569</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,589,081</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,200</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,800</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75,200</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54,444</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised/released during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61,359</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">251,693</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,290,569</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,509,078</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payments expense reflected in the condensed consolidated statements of operations is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research &amp; development</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(465</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(894</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(665</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(271</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(393</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales &amp; marketing</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General &amp; administrative</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(925</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(478</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,722</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,176</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(231</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total share-based compensation (expense)</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,814</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,078</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,446</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,441</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 59200 35800 Change in Number of BSA/SO/RSU: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of outstanding</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BSA</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SO</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSUs</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">251,693</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,306,569</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,589,081</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,200</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,800</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75,200</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54,444</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised/released during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61,359</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired during the period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">251,693</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,290,569</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,509,078</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 251693 5306569 1589081 59200 35800 75200 54444 61359 251693 5290569 1509078 <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payments expense reflected in the condensed consolidated statements of operations is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research &amp; development</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(465</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(894</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(665</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(271</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(393</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales &amp; marketing</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General &amp; administrative</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">SO</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(925</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(478</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,722</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,176</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">RSU</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(231</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total share-based compensation (expense)</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,814</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,078</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,446</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,441</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> -465000 -290000 -894000 -665000 -271000 -185000 -529000 -393000 -27000 -38000 -54000 -33000 -8000 -17000 -17000 -16000 -925000 -478000 -1722000 -1176000 -118000 -70000 -231000 -157000 -1814000 -1078000 -3446000 -2441000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9: Contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the contingencies as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current contingencies</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,076</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> contingencies</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,731</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total contingencies</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,807</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in contingencies are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:63%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension<br/> retirement<br/> obligations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Collaboration<br/> agreement -<br/> Loss at<br/> completion</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> contingencies</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">At January 1, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">790</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,835</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases in liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Used liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reversals of unused liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,083</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,083</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net interest related to employee benefits, and unwinding of discount</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Actuarial gains and losses on defined-benefit plans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation effect</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">At June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">909</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,118</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">780</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,807</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which Current</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">4,296</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">780</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">5,076</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">909</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">14,822</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">15,731</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2022 and during the first six months of 2023, the Company updated its measurement of progress of the Phase 2 clinical trial (“PII”) conducted as part of the collaboration and license agreement with Nestlé Health Sciences and updated the cumulative income recognized. The Company recognized a reversal of $1.1 million of the loss for completion recorded in the amount of the excess between the Company’s current best estimates of costs yet to be incurred and income yet to be recognized for the completion of the PII. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other contingencies mainly consisted of a provision for refurbishment amounting to the best estimate of costs to be incurred in case the Montrouge office lease agreement is not renewed at its July 2024 term. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the contingencies as of June 30, 2023 and December 31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current contingencies</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,076</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,944</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> contingencies</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,731</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total contingencies</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,807</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 5076000 3944000 15731000 16680000 20807000 20625000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in contingencies are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:63%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension<br/> retirement<br/> obligations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Collaboration<br/> agreement -<br/> Loss at<br/> completion</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> contingencies</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">At January 1, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">790</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,835</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases in liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Used liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reversals of unused liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,083</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,083</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net interest related to employee benefits, and unwinding of discount</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Actuarial gains and losses on defined-benefit plans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation effect</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">At June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">909</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,118</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">780</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,807</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which Current</div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">4,296</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">780</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">5,076</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Of which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">909</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">14,822</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—  </div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">15,731</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></td></tr></table> 790000 19835000 20625000 11000 780000 791000 0 -1083000 -1083000 0 93000 93000 15000 366000 0 381000 909000 19118000 780000 20807000 4296000 780000 5076000 909000 14822000 15731000 1100000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 10: Operating income </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the operating income during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research tax credit</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,975</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,491</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other operating income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,014</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,288</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,529</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,482</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,074</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in operating income was primarily due to the increase in the research and development costs eligible to research tax credit in France. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes as other operating income accrued revenues based on its updated measurement of progress of the Phase 2 clinical trial conducted as part of the collaboration agreement with Nestlé. Moreover, the loss for completion recorded in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase 2 clinical trial was updated accordingly as of June 30, 2023 (see note 9 related to contingencies). </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the operating income during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research tax credit</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,975</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,491</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other operating income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,014</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,288</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,529</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,482</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,074</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 1975000 1491000 3741000 3060000 312000 37000 741000 1014000 2288000 1529000 4482000 4074000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 11: Allocation of Personnel Expenses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had an average of 88 employees during the six months ended June 30, 2023, in comparison with an average of 87 employees during the six months ended June 30, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of personnel expenses by function during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and Development expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,014</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,097</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,020</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and Marketing expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">208</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">344</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and Administrative expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,858</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,767</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,958</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,362</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,079</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,208</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,351</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of personnel expenses by nature during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Wages and salaries</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,516</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Social security contributions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,884</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,507</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expenses for pension commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">246</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">211</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">504</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employer contribution to bonus shares</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based payments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,814</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,446</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,441</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,079</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,208</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,351</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in personnel expenses was mainly due to recruitment of US employees partially offset by the departure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-US</div> employees, and the increase of charges related to share-base payments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of personnel expenses by function during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and Development expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,014</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,097</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,020</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and Marketing expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">208</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">344</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and Administrative expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,858</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,767</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,958</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,362</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,079</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,208</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,351</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 4014000 3097000 8020000 6172000 208000 344000 373000 589000 2858000 2767000 5958000 5362000 7079000 6208000 14351000 12123000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of personnel expenses by nature during the three and six months ended June 30, 2023 and 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:1%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Wages and salaries</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,516</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Social security contributions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,884</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,507</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expenses for pension commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">246</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">211</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">504</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employer contribution to bonus shares</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based payments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,814</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,446</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,441</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,079</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,208</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14,351</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,123</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 4078000 3509000 8516000 7497000 1185000 1256000 1884000 1507000 246000 211000 504000 509000 -244000 154000 0 170000 1814000 1078000 3446000 2441000 7079000 6208000 14351000 12123000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 12: Commitments </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no significant changes in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the Annual Report. </div> 0 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 13: Relationships with Related Parties </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s related parties exclusively consisted of the members of the Board of Directors and the members of the Executive Committee. As of June 30, 2023, the total amount of remuneration granted to the members of the Board of Directors and Executive Committee has not significantly changed since December 31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no new significant related-party transactions during the period nor any changes in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report. </div> 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 14: Loss Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three- and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> periods ended June 30, 2023 and 2022, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three and six months ended June 30, 2023 and 2022 indicated in number of potential shares: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:56%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,290,569</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,442,358</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,290,569</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,442,358</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,509,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,145,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,509,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,145,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prefunded warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three and six months ended June 30, 2023 and 2022 indicated in number of potential shares: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:56%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256,693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,290,569</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,442,358</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,290,569</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,442,358</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,509,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,145,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,509,078</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,145,223</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prefunded warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,276,331</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 251693 256693 251693 256693 5290569 3442358 5290569 3442358 1509078 1145223 1509078 1145223 28276331 28276331 28276331 28276331 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 15: Events after the Close of the Period </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events that occurred after June 30, 2023, through the date the condensed consolidated financial statements were issued after their approval by the Board of Directors on July 28, 2023, and determined that there are no significant events that require adjustments or disclosure in such condensed consolidated financial statements. </div> EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( 'V$_U8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !]A/]6.?YL-^\ K @ $0 &1O8U!R;W!S+V-O&ULS9++ M:L,P$$5_I6AOCQ]]@'"T2>BJA4(#+=T):9*(6):0IMCY^\IJXE#:#^A2,U=G MSL!TRG/E KX$YS&0P7@SV7Z(7/D5.Q!Y#A#5 :V,94H,J;ESP4I*S[ '+]51 M[A&:JKH'BR2U) DSL/ +D8E.*ZX"2G+AC-=JP?O/T&>85H ]6APH0EW6P,0\ MT9^FOH,K8(81!AN_"Z@78J[^BQ'-N<2SO4\/[\])K7+&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !]A/]6LY%?69P& !)@ & 'AL+W=O X2>NM3=(XZ] 5^\!(M"U4$CV*RN7? M[U"2Q:2@CETA*H):M_.*+R]'CR@>/PCY(UUSKLAC'"7I26>MU.9=KY?Z:QZS M]%!L> )GED+&3,&N7/72C>0LR(/BJ$<=9]B+69AT)L?YL6LY.1:9BL*$7TN2 M9G',Y-,IC\3#2^K Y]M;]8OCO,%#KD\ZX0P*^9%FD;L3#1UX:&F@] M7T1I_C]Y**[M]SO$SU(EXC(82A"'2?'+'LN*>!8P=FH":!E ?PIPZ^[@E0%> M;K0H66[KC"DV.9;B@4A]-:CIC;QN\FAP$R:Z&1=*PMD0XM1D)NZY)-?08J1+ MTC63/#WN*1#6IWM^*7):B- :D2'Y+!*U3LEY$O#@97P/"E25BFY+=4I1P3^R MY)!XS@&A#O4LY9GM"H\@W+6%ORB.5U62E^MY-7IGPL^@ZRHR3XJ!HSO@]T]P M%9DK'J?_VJJLD.S;)?7H?)=NF,]/.C#\4B[O>6?R]HT[=-[;_+Z2V OW_X7FR4TJJ&E065I@)9I"GZ"W--%Q%8V3WC\DD6IK2IF M:%A#4\/*U'"_=KKF,A2!'HP$5SM)_/BS#U642^ M<2;)!1RT9BYOL8W<&+2JA->?PB'PD?_(GZV,6EW(C:P&T=BF!JDQ2-&RS3(I?TX[6([=(=?MNK3KN5:C M:&13HX9V7!0GJAY;^KWA&R%5F*S(0C%EST$[%+]9J7*&1S7U:;C&QN3[KML MV]!6Y[AB7;NV@4&NX2 7QY=M_Q5Q#)R^4,+_<4 6^;L-NV^GTE ML"GKH5 ;Y&KZA?I^ M@G"9>GMMP \U\$/W@I_SF,N5?H)\ 6UQHSN$*PUBL(CNQ4.W[)', X"_WN=[+@?B9A%%A]XTJUW0GR/6?^ MFDB>.TCR^1S()-TUBY;ZUCJK" GOQ3HD_Q!X0!(1PWY$[ED$S_.W;\;>L/_> M.70=LN&RN,A:FVW G/?L8QV.6_"Z&.2S54_QG8BLE8@+G)U^O;7Z:H/8/$-L M'HY7VVY!SA_]-4M6O';>?(?0Y71Q-K5^D\,#FSHT,.;A]'2U[7_E9 V: E\) MIDKC;:"99]#,&[:0 E]UKNJUU%[6@$$V#R>N7TF!N-+5BR26-L]B;=">9VC/ MPT'M%T8[+H2,]C90SS.HY^%<=BG(RU1=^S%^AU#=I (>]JO^>L\6V>CIK'SM M44I\/3=0K+>ICE;KFZ;YJIZ>N;Q8'/69Z=FPE$1\":'.X0BRCRS6&Q4[2FSR M)3MW0BD1YYMKS@(N]05P?BF$VN[H&U2KOB;_ U!+ P04 " !]A/]6 @O) M@E$& T&P & 'AL+W=OZS:BN-,%O*)+E=[]>?Y*2V8\E."O1+ M8L0"GEYB;!5JB7\8 M?5"=:V!=N17BI[WYF)]/ HN(%C33U@0Q7_?TDA:%M61P_-H9G33_:16[UT_6 MW]?.&V=NB:*7HOB7Y7I]/EE,0$Y7I"KT-_'P@>X7EX*GIN@T!R8*R4*EA-M;FZT^3+1T@J(%7C/ M..$9(P6X%HK5RS\#/VZNP)^O_P*O >/@^UI4BO!*GP <3 $*$/:H7XZK7]',J,-:'>VKS\U:- N"F@5!M3T\M""5E,9O0)2B M6IWZ_-D:"/T&;-Z=J@W)Z/G$)):B\IY.EF]>P3AXZ_/NA8SM^8H;7_&8]>4E M46M@H@8R>T%_5>R>%#;H/J^WIN+:E"T.]TN8X#2&9_/[KC^N& I2F(:-V![2 ML$$:CB+]JM=4FGSHQL8'7!R'&+[G!7\C8GKM)XVXR&I-K M:?A.ZLT^W]C:-@6<:I__B1NB$.*H%R&/5!2DL3] BP;Q8A1Q MS:,SL9I5BNXB9-BRJ(NR%L"Z0S3C=Z"@AKR\T5NXN!88]<"[0BB"V(\];;"G MH]@_2IT_COOIZ8K @=R$04MSP1$%A)OM?SA#=Z:Z *(T#'LH M?5(+-)"?L,/'\(@R> E$>S' MVR<7QEVY?8 MO4%\%)<7C-RRPC0N_H2!HRSYW'KW4M;V?6Z)$HXSY7=)<@HV MY)&8//2[ZZ&_-$B=_>T1"\-DH$; EB;A.$_>K(74,TUE>50U@SZ^=)/1([48 M:CI@RY9PE)V:#90);F%2TP0/H(S=8A D<1^E*X73P3QL20Z.L]Q^&@V0)VIDJ.A;D,93% 73- KK&2T-IQ G4QA& M.T5 *FT:!_8?S;=3'%.J,C,1,4\T^%1QVIPAU8^O:$;+6Y-R3T=#4S-&J0VM M3PV+1^^ZN^P, \,D_?WA$TO04(5H61R-L_A%GM=':V8C;PC+9XR#C&R8V=A> ML"Y!XR1*HG[O[Y$+S9@R1(^HI7)T@,JEX83*!E:+[.<4P#"=I@FJ%]]>)RD& M8C_X-EAB]?Q@36V(,Z&\LSIRZ7\&@X43-9^8">_ ,K1= AJ?>2^RK"JK[7R> MTQ7+F!^E.]/.3#^5AD$?IT\P2KMG6/M'?2VOXW%>[R(5VXY1E";GU_9,_IX" MQLT]]9[\N?0=.TSD$4H6 [L,MQ2/QRF^"WI+1=DCT))P97ZSY]!TM3+;Q(O: M97(3<8C[3;E7SN3($/:6\O$QX['RE'TO7)?)81PB9X/XY,P,$0UP*.Z^)YS7]^L[Y/SS?KSSBL-^S[I;R+O&%>F$UT9Q> D,0L@MZ]H MMC=:;.JW'+=":U'6EVMJ1F%I!E"W_!U!+ P04 " !] MA/]6+;3[?YH" S!P & 'AL+W=O279-T M;FAA;V+)NO_?O[N+S].=D/>J -#DH>25FCF%UO6%ZZJL@)*JD:BAPI.UD"75 MN)4;5]42:&Y%)7<#STO!OPG<%.[:V) MR60EQ+W9?,YGCF> @$.FC0/%RQ;FP+DQ0HS?G:?3/]((]]=/[C9A$E\0EJL S-74U\IFGN%G'<\ 9]YSQFSEIHPLAV1_(AT#C?_XBDR2(O4DW5&Y8I0B'-4J]T1@] M9#NBVXT6M9UR*Z%Q9MIE@5\UD"8 S]="Z*>-&9S]=S+]"U!+ P04 " !] MA/]6SXT_?KKV:KE"7W15Z:J]'6VMWE>&R66U6DYD+O5 F_ MK'55I!8>J\W8["J5KFJC(A]S2L-QD6;E:#JIWWVHIA.]MWE6J@\5,?NB2*MO MURK7=U?>A@J=QZV65%:HTF2Y)I=97HS?L M7>6%T6@R._:&/*: M?+Z=D9"0GR7I=V:\@<)K9" M[&?#]N& _1B"TT:(/T3HF@\Z_&U?7A!!7Q%.N4#F<_-TPMJ#JU.'*>=Q/!D?SH/6!;& )X]!LRY( MRI@_!LT1$(UD"WI$4[8T96TEODM3W>_<\D"%+(="Y2K\I=FE2W4U@M5B5'50 MH^F//["0_HRIZ#F=S9[3V?R9G#U*1- F(AC4VT?PF%;+;5UW5NH &]O.E:7! MO#0N@S-%O&91R$)/@A@L#AGS1(C A @#XV M\:_JNY(,N[,(.L01$*,B\G@CJ"2@'FO,54 I3CIJ24>#I']1)2R_O*:=KF#3 MRXQURQ$VFR'N$3)A+KQTWB"H(*+2(X^@6,BX3Q^#<=&7]+CE'P_R_Z0ML']: M#8J[,^"1"#T^-Q@L$(%72V<(+* 1][6.P*0,PP2GG;2TDT':=2.QKG1!=-MO M8)03C N-?)5C,!'[7&8(3(9<^KL,!J-!$N"4&3VU7W20]-NL3,ME!OEN-M27 M#\G^"6V=:&<:L?2)(Z H]@6.@)CL+&\$E8BPA_-9R\F^G^B%@E..(C:]QX5] M]/$X?Y(+ZK/%<((*OY? <%)&"?,I(SB1A$&/N!D_L>:#K-_5^76$4;H<*27" MY]H%49_F$_S,,5 <]1 \M89LN#?\ XZU.:06I2?0;,H.0PR'91/!06_HU_$Y MAA-))/LT?&H0V6#;,X53*IQ!2SBB594JE]\([%"ER>NJ15;9>JW<:V5>D1+" M F>H?J%+A#+WMRT,Q9A(.NNZBQ-2!GY8,&]"\#X-G-HU-MROO5G:?5JY&>[AF.U\^.C3WKI.P,X 14QXX<$)R$0M]ACN "'LN^ MJG=JY=AP+W>=FFQ9Y]E1)K"Q$[--H?"GUE;98F_310Y%43=OMSI?J0J/3#-. M?#Y#>L$[FQ\*$X$?%Q0F8S\L*"SLJQZG!H\-=WA?ZOLK!>WM 3J=C2+EOEA M:& MU'$P1.^ML= N_YO[ZYGLK*6T+[N",_"6.A]:>;^I+WJ]]]?L\H8A[V?L;!Z5]_)+K2UNJB_;E4*(G4 ^'VMM7UX< .T_SB8_@-02P,$ M% @ ?83_5KU#VMEO!@ /AL !@ !X;"]W;W)KT+N^Y^":WC"GTL,L+>379*E5>S&8R MV;(=E>]XR0KX9L/%CBJX%7Y;S^ZL)GAP_^)S=;97^8+:\+.D=NV7J:WDCX&[6>$FS'2MD MQ@LDV.9J7@M\CH:W!F[XPL3&K@4U6Z#3>*@'?9K!.+5>\2"$I+$5P M)7F>I53!S:V"?Y M)1'?H!656_01,B[1%'V]_8#.WKQ%;U!6H"];OI>T2.7E M3 $:[7.6U$]^7SV9C#PY1)]XH;82_0P(TM/U,V#14"%'*N^)T^%O^^(=\KUS M1#SB6_"LGK^<..#X361]X\\?\=>$L!?!OZ_74@G8OO_88E;Y#.P^=4U?R)(F M[&H"12N9.+#)\L&@A5I-$2!>T M)H$=YJ*!N7#"_/E!HV,2]"\W;59Q)+=4 ML*E6HA25]-'T7!O@Q3"T06?O5Y"'1B0(L!UTW(".G:#_@.(5"'1W%%H\?*K? M S8TF?IV6-AKE/56[M_I?)]+6^GP>C( M.'ZB@A.8XB1#9UE17;TU@=')JQZ3[(70!5)%R!H0/,Q2&"SZ=6$Q(W[@C_1A M3%H*Q$GA[,A!(Z_9 70RI3ITJ#KW-YU:K^GM8'[?<=B-5_$(Q6-6Y7'3A4= M0VT"CYJ8PW8L>#$]WG>VII60/TP$B7&_J&QFOA=X(Y1:Y<9NZ:X*Z[2NE8(?,I@W MT?H1G=6"_]:J^%8B\R'&(/3C_JABL\,X\L=Z7JO3.'SNM&)GDA4')I\SNV#G M1/#B[O=*WD[#TLH_=NO_=?)]G\G,J+W>CA ;R*AZ/$=E3@MU;C8K YM2B]@Y M*F!/; 3?:<.$L9'CRW F))HL&TM5MVAYY11.RE@]ZAP4P-K8#KXH#23):_I M6YD,YP*O3\,R7XQP: <'[)X<^EGI=L!-5E 8(VGN:AN6J8%$?>!6HY'XDW:X M($Z][L7?A?S)Z-=/ZB+L]PN;"1D15-+.!,0]$YQTOI<-P:.CW HO)U"=C26S'"N(>*[YHK'OQ6!UY[."&,\"@X*TV8_7>3@G$ M/26L:)DI"-UQAI.52$#7@OFSD+3ZT3'ATMZJR%#PHRCL'\\L5CB>DVAD8B/M M6$#8[KHG3]8^D.Y)EZ,!\< BUT4^=[( M/O-;8?>?*>PN/@R^>YH)'ORH"L>4..R?^2UV)(CBJ$]EUGD3L6/BSKR@D= W M]X6J?LEO/FU> EV;5Q^]S]_CBU7U*J=U4[U9^D0%)$K"B70#+KUW$8175"]K MJAO%2_.^8\V5XCMSN64T94(;P/<;SM7Q1C^@>66V_ ]02P,$% @ ?83_ M5O)W//O%Y05 M400.(=)Y]TM\R<%S*.*( !^ UO5C67VI[XNB<7[?K+?UFXO[IGEX?755+^Z+ M35Z_*A^*K?J?V[+:Y(WZL;J[JA^J(E_N&VW65]QU_:M-OMI>W%SO?_>ANKDN M=\UZM2T^5$Z]VVSRZMN[8ET^OKE@%]]_\ZY/OG?:E?"[++^T//R_? M7+CM$17K8M&TB%Q]^5K,BO6Z):GC^.T O3CF;!N>?O^=GNQ?O'HQG_.ZF)7K M_ZZ6S?V;B_#"61:W^6[=_%(^9L7A!>T/<%&NZ_V_SN,AUKUP%KNZ*3>'QNH( M-JOMT]?\]\.).&G Q$ #?FC M09\J($X-!!: ^$/-)"'!E+/( <:>(<&GMX@ M&FC@'QKX6@/5NW2#X- @T!K(H0SAH4&X[]VG[MCWY3QO\IOKJGQTJC9:T=IO M]@6Q;ZVZ<+5M:_=C4ZG_7:EVS/1T.'SB<3V63KXEF,WNS6;G9E(>#JYW_O2\V MGXOJ_P1G;N>\72Y7[5LJ7SL?\M7R4KV86?ZP4L=D@\9G7I.ZIM2[ZILZJ>7B MBPV4G#FZQ6*WV:WW'30O;E>+56.CI>-I_V[NBTI5P$9=_^[;"]/70G7DHMP4 MSHMU6=R@0Q7JIZ/15 RG?%W6J[76WOU&5MG6\7A9,WZHPM7CF"_=WA+F=493XQ_3VSO>1_O8DB M'LCKJZ^GA6A&^9X(^T%S,TAX(6->/RPVPRX9%[P?E1!1W L]KB5-S3B/1?V8 MC&#Y3 3'J-[I%L?3+2:>[A=/[\27H\Z[%=Z.W:_KAWQ1O+E0Q5D7U=?BXN:O M?V&^^P_J.O$$\TY/@N=&7N!K9W6.S!HC80D2EB)A&0C6*S)Y+#)I+;)_J7G< MT[6(JB%I=/LE\P/7U]Z\UA03S\8<"8N1L&3.@6F=[QNCI18Q-QFN-L9;#WEJ-R%A M*1*6@6"]?@^._1X\M]^/,Q&J *S4J1./P*B$(-#F>W-DPA@)2Y"P% G+0+!> M887'P@JMA76\I]71V?"R9)AQH&$W-4EQ^P0IMDJ[1YG3L"$%\E $TPQ M$7?)U+1=&S*H,!YX7)=1*1'H28V64;30#?V!D]XI0F9WA-I)/S56Y\^^%3WY M#A#V!DA30=D'-".,EHD#JAMJ>9/+L#6H122F;4%^$TW< UQ@L3)SU?RD ?+\RXR\@S9H1$ M%'>%Z[GZ<&$&!N:,D*"Q2(;NP'C1:41F]XB6*>'Y\P^5B/Z^PQ1VY%U?..JNSX31=WUF''G71X31 M=WUF(''71] L=WV=MV-V<6>?$I[O *2?FC%3U@W=^"'SQE!: J6E4%J&HO5W M(74*D-L5H'U*R F9Q(6KOU%G]B13IX106@RE)2//2 K-FJ%H_2+I[!^WV[]G M;5[@I(I3LR"]=JRY)]<.DA9#:0F4EA+GE[O:;#6C.T&<=$*_)$ZV+]K=Y,2- M#-P4B&I.SP)][L_-W7^2!=JKFI,TX;KZU-_^&B9W'U0?0FD9BM:OADX?VR<\3.&$YM ]3WQMC3 M3*X2J.X<\P(2:,H42LM0M'Z-=!:3VRWFV$TRG-B(Z>H:8F9/-KE2QN2,H3D3 M*"V%TC(4K5\JG7GE=O/Z=KTN%T]/ ZG1)S]Y8FBK;J';NZ"!:PS4ND)IM73R=3N5VF/F.YA)M^D5PNX:9*I99+"!RY M7$+$$%74^.WT1#]P%2R\V$ M:=PBR42@7JG>65!5":4E4%H*I64H6K_:.O,I[.;3OF(B3#6I!D;/UY_;LB>9 M.I&#TF(H+1EY1E)HU@Q%ZQ?)R>/F=B'ZK!430>Z U*V5/?/DRL$^9(Y]RAS[ MF#FQA3/D^AA%=('O#ZSIBTYPV\P(2:,H42LM0M'Z-=!I3V#7F6.,M3$G'?/TA MBYD]V>1*&9,SAN9,H+042LM0M'ZI=,Y23'66IYL/!5DUILAC062NO K26>J: M8D[@I!>%GE$2Y/Y/KDM+*HR'+M,?14J)0#\*]:DBE=2-AIZU%)VT%,^6EN<[ M "HM!24MF0R$OF-V#LT;0VD)E)9":1F*UO][59VTE'^&M)0CI:4<)RT)'"DM MB3A*6E)AI+0D DUI228=EI:RDY;R3Y66=OK4-[H<+2VA>6,H+8'24B@M0]'Z MU=9)2_DCTE(2BD[*T-6';7N2J=,]*"V&TA(H+872,A2M7TJ=VI1VM6E?RB9G M)=*T:LR7YE8K:3XHKJ[O^G1O3N!$X 6>OFV!B%,S--WY)5085WGUPTN)0#\, M] LJ8&'"(\N2/2]H=XLBU;+H#D"IM)DVQ&/F\?5)<%TG0O#&4ED!I*926 MH6C]4NMDI;3+RK./_M%%1LA%ZN;O$'?NYH_ D3=_1!QU\T>%D3=_1*!Y\T1.^ M7A=S:-H82DN@M!1*RU"T?I5UGM2S>](1B]J>:2_U)SYG]BQ31QHH+1YQ_ DT M8PJE92A:OT(ZM^G9W>;8)6V/>&H\-#8_V)--+I0Q.6-HS@1*2Z&T#$7KETKG M+CV[NWSN0UQV[.0A"[J#TR.$8R2DU)?/H%D3(BN1-(4FS5"T?O5T!M:;9&#' MB%>/V*9)F6\JCC#?1!AIOHDXRGQ38:3Y)@)-\TTF'3;?WLE'Y]AUY(^8;SMZ M\CO7U'X#YAN:-X;2$B@MA=(R%.VIU*Y./G6R_9S3]WEUM]K6SKJX57CW5:"R M54\?'?KT0U,^[#^(\G/9-.5F_^U]D2^+J@U0_W];ELWW']K/MCQ^@.O-'U!+ M P04 " !]A/]6NAYNUX<& #%#P & 'AL+W=OY+(0? MVU(:?,FL*T3 J]M,?.FD2*-2H2?SZ?1X4@AE!I?G<>W679[;*FAEY*TC7Q6% M<+LKJ>WV8C ;M OOU"8/O#"Y/"_%1JYDN"MO'=XF'4JJ"FF\LH:?2[-A2]?"F"N#QW=DN.I8'&#S'4 MJ WGE.&BK(+#5P6]E#_0D[GVP:$;_CD4<(UW=!B/)^34ER*1%P.,@)?N7@XNG_TP.YZ>/>'M M4>?MT5/HWZK%D\J'7:,_;) T.Z4>-+TVB76E=2+(E)1!KJ=SJE!!1P%B6FP] MV8QNG#")'-++JP_T7B:YL=IN.(&K\7),/S[[X60^GYY]_748UV=G9&NT1JRQ MW7PY,!NN.AO)E-0I1Z2*HC(62TZ4 -IA>N_!2B4+"C(6+Q3:6'94 M:A&8]0A&-' _*.$_(5]P].AD?O:?_ROA5??!!%IAS.?6&37L&]X\FC$ M-.8^4P8I1EB$((,$U86H'WK%$@8UPO(VMUKO1G9KH.BKM5>I$H[+(9Q$]425 M*L9D^5S<2UI+:0B=4.)[++/ ++B4:PJ*"3EMI$$B ,I?9!F5]^-2.@772@T# MT&6/[DPTL&)7?5?_N_%J3+\NE[==^=@#]JFLLU ;CV(I0A#.CVFI$;+:&)6A M@"9 ($C7EK%QPD<@#*KQ(A*X1TAARU$=RL^#E.P3(+4":<9L.)9F MG[GO*=*#V$*.LO]9"8<@D,UW$K,5R.>V0MNM)?%>R7* _5B9>C.*%0AU:WS# M5LQGTF2'2X,6CE5)=)6V'G0)X3+,7IQY6AI3 :CQ!B9Y$Z/9=/0[74L7L%U# ML][4X^X(*YFU@<$I53[1UE>($M8@PEW2-_A84AYMMJY->K79)QQL8 L58@J< M+3@>+^NN4,5!8V-Z9;>87C=LA+^G>DTDA+!(I!^QR<;U8515/O:_-0@9LUB' MCQHFE7.1*/H*VUPE.7?[L"T#LPGG$ZJ%,* NEAR2D8GT'J<>"I8RH;A1HD=1 M"7G&(:*;_3;P$K\VC7UZ,!VM&D\;ZM894;%:*6:+3SR,VDK".!I2?@&;QNPT M-)Q5R$2&H@-T)X4C"6W$^A* Q1K[PF)6;\F1N'GL(HM"+U0\Z8V?=SX:D\A@ M$4F"!ZSNBKK)'G);UZK?4SLG/U>*^Y*!JJ\,#DEXG"[+FBZXI3]6Z:96#+D( M)+(,D37:+:[7*1TS\EG51V[<%R1R22]%J G( M*U@7-U)&!G_RT+)@4V.PKW5-_E1 _VB%P6M[">3FK1%K+7M'B$2YI"H0&:#\ M0Z_DO=!5].6;G@DTC-E8CG'-6VL-!'>J7N\7 MNX0EE=GSHZW#&];8!&-9+C M4_K(9B/NG?[QT%F#YZ0M16K+[G@T7^#,1#B;2KS,CB/ET$U7P1X*-D>3"I=Z MNK+XZW;)F^7JJG>^\16@EZN["#>:+>(DS,_VD%C_>32;LMFW2#^/(-R8-98! M]A!D/AM-3X9/A--(,TGL<-%KHWL;*]S;]7WG?RSWGJL; $Q_Z6QI>59Q?NJ\ M80*/6!W "&,1(=T'KBJYS1HOQG3H"#_I7:T*Z3;Q LF4!9_K6U:W MVMU1E_75;"]>7W#?"(#^IV;%^"+>-%;6T#KGWQ,G]L7-M#=W"__!5!+ P04 " !]A/]60IKC+S0. %*0 & 'AL M+W=O@#M4M)/-Y=[EER+>O\^GXS)/";A:ERZ?"V6A[9LE(R MY4UY=C09C5XV]?\V>SZNUK4[M,%VI6"5OGN:PV[U1FUF_VQGOQ@V]Z MN7+TP=';UZ5Y/]5:=N]6;OY9Y(U4+6F?MFUI]4L.=B, M][DN_']Y%_S0V?!R],"&2=@P8;W]0:SE!^GDV]>568N*5D,:O6!3>3>4TP4% MY%7NA$%DZD_ZOQO)1H;M5%K\8I\3DE?B) M(\5[B,2*3)25658RM^)'H9U*Q9633EGQ32WK3#I3;<0G;?D_R7A?5Q4$\JK: MBL^%^"*+&L1!(!@/.#CO35[*8@-V2!22.Q7K2CNGB"YLB;,A?5&9G-=^_# 5 MSHC?:F6]7E#G5@.?0A>\X/NF5&(J&A1&3ZL@ :L20VLP_[) M\Y$ J%^.SY9B7Y;X^DZ#/U6V$>.C\6@THD6FB/L/X#(J'U;4!;0HEJ0\3BA5 M147'QOA8F2NQEALX2:Q@7?@>JP',6VUJFVV&A!-3P0,4:WACH2L??O:,!3:2 M#1VO%H1:O$[!FO"<6ROECU%W6$:!)!TZWF?3!QRQ W6$WX&S&Q.SDH()A7M M)4%UZ>0-.T1FF:J6D+_?]]A![V ^0+&Y89G?IQ,$1V^OE;06Z'N^ZUZU-].; YP28 MCCG0H3LCJRCA8*R4S MMP+@4K15XM9D-2*G*L!1#L7L&X<#:C0BK*O3C>=.OR4*:+>2BJ:$LN1VLJBQ M'(R"4"/B66P2R M0N3O%TR(R2G2*+.?IA4Y>%#XBPTD^*J\(4>%FBFPM9-?,X..A&@&/W M6.A(;04WUHT7TY67CI,6A)5'*YRR/B\[JG-!C:K'ZN#=^1O8S_DR1E8/Q33+ MGI+?38N4L$\"&B5#F9&4%Z@Z(0 <>DZ/E2H.'ZN6@Z9<1@MHB_"#"^UN(D@1.^Q22SJ"@LKF':+P:ND\M1WXY821'RZ2D!; M56#V!Z0,A&=\;<�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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 163 206 1 false 37 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.dbv-technologies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Statements of Financial Position Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition Condensed Consolidated Statements of Financial Position Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Statements of Financial Position (Parenthetical) Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical Condensed Consolidated Statements of Financial Position (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity Condensed Consolidated Statements of Changes in Shareholders' Equity Statements 6 false false R7.htm 1007 - Disclosure - The Company Sheet http://www.dbv-technologies.com/role/TheCompany The Company Notes 7 false false R8.htm 1008 - Disclosure - Significant Events and Transactions Sheet http://www.dbv-technologies.com/role/SignificantEventsAndTransactions Significant Events and Transactions Notes 8 false false R9.htm 1009 - Disclosure - Cash and Cash Equivalents Sheet http://www.dbv-technologies.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 1010 - Disclosure - Other Current Assets Sheet http://www.dbv-technologies.com/role/OtherCurrentAssets Other Current Assets Notes 10 false false R11.htm 1011 - Disclosure - Lease contracts Sheet http://www.dbv-technologies.com/role/LeaseContracts Lease contracts Notes 11 false false R12.htm 1012 - Disclosure - Trade Payables and Other Current Liabilities Sheet http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilities Trade Payables and Other Current Liabilities Notes 12 false false R13.htm 1013 - Disclosure - Shareholders' equity Sheet http://www.dbv-technologies.com/role/ShareholdersEquity Shareholders' equity Notes 13 false false R14.htm 1014 - Disclosure - Share-Based Payments Sheet http://www.dbv-technologies.com/role/ShareBasedPayments Share-Based Payments Notes 14 false false R15.htm 1015 - Disclosure - Contingencies Sheet http://www.dbv-technologies.com/role/Contingencies Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Operating Income Sheet http://www.dbv-technologies.com/role/OperatingIncome Operating Income Notes 16 false false R17.htm 1017 - Disclosure - Allocation of Personnel Expenses Sheet http://www.dbv-technologies.com/role/AllocationOfPersonnelExpenses Allocation of Personnel Expenses Notes 17 false false R18.htm 1018 - Disclosure - Commitments Sheet http://www.dbv-technologies.com/role/Commitments Commitments Notes 18 false false R19.htm 1019 - Disclosure - Relationships with Related Parties Sheet http://www.dbv-technologies.com/role/RelationshipsWithRelatedParties Relationships with Related Parties Notes 19 false false R20.htm 1020 - Disclosure - Loss Per Share Sheet http://www.dbv-technologies.com/role/LossPerShare Loss Per Share Notes 20 false false R21.htm 1021 - Disclosure - Events After the Close of the Period Sheet http://www.dbv-technologies.com/role/EventsAfterTheCloseOfThePeriod Events After the Close of the Period Notes 21 false false R22.htm 1022 - Disclosure - The Company (Policies) Sheet http://www.dbv-technologies.com/role/TheCompanyPolicies The Company (Policies) Policies 22 false false R23.htm 1023 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://www.dbv-technologies.com/role/CashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://www.dbv-technologies.com/role/CashAndCashEquivalents 23 false false R24.htm 1024 - Disclosure - Other Current Assets (Tables) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.dbv-technologies.com/role/OtherCurrentAssets 24 false false R25.htm 1025 - Disclosure - Lease contracts (Tables) Sheet http://www.dbv-technologies.com/role/LeaseContractsTables Lease contracts (Tables) Tables http://www.dbv-technologies.com/role/LeaseContracts 25 false false R26.htm 1026 - Disclosure - Trade Payables and Other Current Liabilities (Tables) Sheet http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesTables Trade Payables and Other Current Liabilities (Tables) Tables http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilities 26 false false R27.htm 1027 - Disclosure - Share-Based Payments (Tables) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.dbv-technologies.com/role/ShareBasedPayments 27 false false R28.htm 1028 - Disclosure - Contingencies (Tables) Sheet http://www.dbv-technologies.com/role/ContingenciesTables Contingencies (Tables) Tables http://www.dbv-technologies.com/role/Contingencies 28 false false R29.htm 1029 - Disclosure - Operating Income (Tables) Sheet http://www.dbv-technologies.com/role/OperatingIncomeTables Operating Income (Tables) Tables http://www.dbv-technologies.com/role/OperatingIncome 29 false false R30.htm 1030 - Disclosure - Allocation of Personnel Expenses (Tables) Sheet http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesTables Allocation of Personnel Expenses (Tables) Tables http://www.dbv-technologies.com/role/AllocationOfPersonnelExpenses 30 false false R31.htm 1031 - Disclosure - Loss Per Share (Tables) Sheet http://www.dbv-technologies.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.dbv-technologies.com/role/LossPerShare 31 false false R32.htm 1032 - Disclosure - Significant Events and Transactions of the Periods - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail Significant Events and Transactions of the Periods - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) Sheet http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) Details 33 false false R34.htm 1034 - Disclosure - Other Current Assets - Summary of Other Current Asset (Detail) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail Other Current Assets - Summary of Other Current Asset (Detail) Details 34 false false R35.htm 1035 - Disclosure - Other Current Assets - Summary Of Research Tax Credit (Detail) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail Other Current Assets - Summary Of Research Tax Credit (Detail) Details 35 false false R36.htm 1036 - Disclosure - Other Current Assets - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail Other Current Assets - Additional Information (Detail) Details 36 false false R37.htm 1037 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail) Sheet http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail) Details 37 false false R38.htm 1038 - Disclosure - Lease contracts - Summary of Rent expenses (Detail) Sheet http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail Lease contracts - Summary of Rent expenses (Detail) Details 38 false false R39.htm 1039 - Disclosure - Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail) Sheet http://www.dbv-technologies.com/role/LeaseContractsSummaryOfSupplementalCashFlowInformationRelatedToOurOperatingLeasesDetail Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail) Details 39 false false R40.htm 1040 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail) Sheet http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail) Details 40 false false R41.htm 1041 - Disclosure - Trade Payables and Other Current Liabilities - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail Trade Payables and Other Current Liabilities - Additional Information (Detail) Details 41 false false R42.htm 1042 - Disclosure - Shareholders' equity - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail Shareholders' equity - Additional Information (Detail) Details 42 false false R43.htm 1043 - Disclosure - Share-Based Payments - Summary of RSU Activity (Detail) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail Share-Based Payments - Summary of RSU Activity (Detail) Details 43 false false R44.htm 1044 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expense (Detail) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail Share-Based Payments - Summary of Share-Based Payments Expense (Detail) Details 44 false false R45.htm 1045 - Disclosure - Share-Based Payments - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail Share-Based Payments - Additional Information (Detail) Details 45 false false R46.htm 1046 - Disclosure - Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) Sheet http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) Details 46 false false R47.htm 1047 - Disclosure - Contingencies - Summary of Movement in Contingencies (Detail) Sheet http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail Contingencies - Summary of Movement in Contingencies (Detail) Details 47 false false R48.htm 1048 - Disclosure - Contingencies - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail Contingencies - Additional Information (Detail) Details 48 false false R49.htm 1049 - Disclosure - Operating Income - Summary of Operating Income (Detail) Sheet http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail Operating Income - Summary of Operating Income (Detail) Details 49 false false R50.htm 1050 - Disclosure - Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) Sheet http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) Details 50 false false R51.htm 1051 - Disclosure - Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) Sheet http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) Details 51 false false R52.htm 1052 - Disclosure - Commitments - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail Commitments - Additional Information (Detail) Details 52 false false R53.htm 1053 - Disclosure - Relationships with Related Parties - Additional Information (Detail) Sheet http://www.dbv-technologies.com/role/RelationshipsWithRelatedPartiesAdditionalInformationDetail Relationships with Related Parties - Additional Information (Detail) Details 53 false false R54.htm 1054 - Disclosure - Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail) Details 54 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 10 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d515836d10q.htm 2343, 2479, 2615, 2785, 2921, 3039, 3175, 3277, 3413, 3549 d515836d10q.htm d515836dex311.htm d515836dex312.htm d515836dex321.htm dbvt-20230630.xsd dbvt-20230630_cal.xml dbvt-20230630_def.xml dbvt-20230630_lab.xml dbvt-20230630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d515836d10q.htm": { "axisCustom": 3, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 508, "http://xbrl.sec.gov/dei/2022": 32 }, "contextCount": 163, "dts": { "calculationLink": { "local": [ "dbvt-20230630_cal.xml" ] }, "definitionLink": { "local": [ "dbvt-20230630_def.xml" ] }, "inline": { "local": [ "d515836d10q.htm" ] }, "labelLink": { "local": [ "dbvt-20230630_lab.xml" ] }, "presentationLink": { "local": [ "dbvt-20230630_pre.xml" ] }, "schema": { "local": [ "dbvt-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 362, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 43, "keyStandard": 163, "memberCustom": 18, "memberStandard": 17, "nsprefix": "dbvt", "nsuri": "http://www.dbv-technologies.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.dbv-technologies.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://www.dbv-technologies.com/role/OtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Lease contracts", "menuCat": "Notes", "order": "11", "role": "http://www.dbv-technologies.com/role/LeaseContracts", "shortName": "Lease contracts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Trade Payables and Other Current Liabilities", "menuCat": "Notes", "order": "12", "role": "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilities", "shortName": "Trade Payables and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Shareholders' equity", "menuCat": "Notes", "order": "13", "role": "http://www.dbv-technologies.com/role/ShareholdersEquity", "shortName": "Shareholders' equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Share-Based Payments", "menuCat": "Notes", "order": "14", "role": "http://www.dbv-technologies.com/role/ShareBasedPayments", "shortName": "Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.dbv-technologies.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Operating Income", "menuCat": "Notes", "order": "16", "role": "http://www.dbv-technologies.com/role/OperatingIncome", "shortName": "Operating Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:AllocationOfPersonnelExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Allocation of Personnel Expenses", "menuCat": "Notes", "order": "17", "role": "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpenses", "shortName": "Allocation of Personnel Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:AllocationOfPersonnelExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Commitments", "menuCat": "Notes", "order": "18", "role": "http://www.dbv-technologies.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Relationships with Related Parties", "menuCat": "Notes", "order": "19", "role": "http://www.dbv-technologies.com/role/RelationshipsWithRelatedParties", "shortName": "Relationships with Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Statements of Financial Position", "menuCat": "Statements", "order": "2", "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "shortName": "Condensed Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Loss Per Share", "menuCat": "Notes", "order": "20", "role": "http://www.dbv-technologies.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Events After the Close of the Period", "menuCat": "Notes", "order": "21", "role": "http://www.dbv-technologies.com/role/EventsAfterTheCloseOfThePeriod", "shortName": "Events After the Close of the Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - The Company (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.dbv-technologies.com/role/TheCompanyPolicies", "shortName": "The Company (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Cash and Cash Equivalents (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.dbv-technologies.com/role/CashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Other Current Assets (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables", "shortName": "Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Lease contracts (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.dbv-technologies.com/role/LeaseContractsTables", "shortName": "Lease contracts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Trade Payables and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesTables", "shortName": "Trade Payables and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Share-Based Payments (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables", "shortName": "Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Contingencies (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.dbv-technologies.com/role/ContingenciesTables", "shortName": "Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:ScheduleOfOperatingIncome", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Operating Income (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.dbv-technologies.com/role/OperatingIncomeTables", "shortName": "Operating Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:ScheduleOfOperatingIncome", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Statements of Financial Position (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "shortName": "Condensed Consolidated Statements of Financial Position (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "dbvt:AllocationOfPersonnelExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Allocation of Personnel Expenses (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesTables", "shortName": "Allocation of Personnel Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "dbvt:AllocationOfPersonnelExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Loss Per Share (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.dbv-technologies.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P06_01_2023To06_30_2023_AmericanDepositarySharesMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Significant Events and Transactions of the Periods - Additional Information (Detail)", "menuCat": "Details", "order": "32", "role": "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail", "shortName": "Significant Events and Transactions of the Periods - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P06_01_2023To06_30_2023_AmericanDepositarySharesMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail)", "menuCat": "Details", "order": "33", "role": "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail", "shortName": "Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Other Current Assets - Summary of Other Current Asset (Detail)", "menuCat": "Details", "order": "34", "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail", "shortName": "Other Current Assets - Summary of Other Current Asset (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCreditReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Other Current Assets - Summary Of Research Tax Credit (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail", "shortName": "Other Current Assets - Summary Of Research Tax Credit (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCreditReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis", "decimals": "-5", "first": true, "lang": null, "name": "dbvt:TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Other Current Assets - Additional Information (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail", "shortName": "Other Current Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis", "decimals": "-5", "first": true, "lang": null, "name": "dbvt:TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail", "shortName": "Lease contracts - Summary of Operating Leases Future Minimum Payments Receivable (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_RentExpensesMemberdbvtRentExpensesAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Lease contracts - Summary of Rent expenses (Detail)", "menuCat": "Details", "order": "38", "role": "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail", "shortName": "Lease contracts - Summary of Rent expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_RentExpensesMemberdbvtRentExpensesAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail)", "menuCat": "Details", "order": "39", "role": "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfSupplementalCashFlowInformationRelatedToOurOperatingLeasesDetail", "shortName": "Lease contracts - Summary of Supplemental cash flow information related to our operating leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail)", "menuCat": "Details", "order": "40", "role": "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail", "shortName": "Trade Payables and Other Current Liabilities - Summary of Other Liabilities by Nature (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsPayableTrade", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Trade Payables and Other Current Liabilities - Additional Information (Detail)", "menuCat": "Details", "order": "41", "role": "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail", "shortName": "Trade Payables and Other Current Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_IncreaseInCurrentTradePayablesMemberdbvtEventAxis", "decimals": "-5", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsPayableTrade", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Shareholders' equity - Additional Information (Detail)", "menuCat": "Details", "order": "42", "role": "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail", "shortName": "Shareholders' equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023_ShareCapitalMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "2", "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_EUR_per_Share", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2022_BSAWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Share-Based Payments - Summary of RSU Activity (Detail)", "menuCat": "Details", "order": "43", "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "shortName": "Share-Based Payments - Summary of RSU Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2022_BSAWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expense (Detail)", "menuCat": "Details", "order": "44", "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail", "shortName": "Share-Based Payments - Summary of Share-Based Payments Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Share-Based Payments - Additional Information (Detail)", "menuCat": "Details", "order": "45", "role": "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "shortName": "Share-Based Payments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail)", "menuCat": "Details", "order": "46", "role": "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail", "shortName": "Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Contingencies - Summary of Movement in Contingencies (Detail)", "menuCat": "Details", "order": "47", "role": "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail", "shortName": "Contingencies - Summary of Movement in Contingencies (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "lang": null, "name": "us-gaap:LossContingencyAccrualProvision", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Contingencies - Additional Information (Detail)", "menuCat": "Details", "order": "48", "role": "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail", "shortName": "Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:LossContingencyDisclosures", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023_CollaborationAndLicenseAgreementMemberdbvtAgreementAxis", "decimals": "-5", "lang": null, "name": "us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfOperatingIncome", "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCreditIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Operating Income - Summary of Operating Income (Detail)", "menuCat": "Details", "order": "49", "role": "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail", "shortName": "Operating Income - Summary of Operating Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfOperatingIncome", "us-gaap:OtherOperatingIncomeAndExpenseTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:ResearchTaxCreditIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "5", "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "lang": null, "name": "dbvt:AdjustmentForDepreciationAmortizationAndAccruedContingencies", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail)", "menuCat": "Details", "order": "50", "role": "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "shortName": "Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "dbvt:AllocationOfPersonnelExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023_ExpensesByFunctionMembersrtProductOrServiceAxis", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail)", "menuCat": "Details", "order": "51", "role": "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "shortName": "Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dbvt:ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock", "dbvt:AllocationOfPersonnelExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023_ExpensesByNatureMembersrtProductOrServiceAxis", "decimals": "-3", "lang": null, "name": "dbvt:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "dbvt:IncreaseDecreaseInOtherCommitmentsDuringThePeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Commitments - Additional Information (Detail)", "menuCat": "Details", "order": "52", "role": "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail", "shortName": "Commitments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "dbvt:IncreaseDecreaseInOtherCommitmentsDuringThePeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:IncreaseDecreaseInRelatedPartyTransactionsAndChangesInNatureOfTheTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Relationships with Related Parties - Additional Information (Detail)", "menuCat": "Details", "order": "53", "role": "http://www.dbv-technologies.com/role/RelationshipsWithRelatedPartiesAdditionalInformationDetail", "shortName": "Relationships with Related Parties - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "dbvt:IncreaseDecreaseInRelatedPartyTransactionsAndChangesInNatureOfTheTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023_NonemployeewarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail)", "menuCat": "Details", "order": "54", "role": "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail", "shortName": "Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P04_01_2023To06_30_2023_NonemployeewarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - The Company", "menuCat": "Notes", "order": "7", "role": "http://www.dbv-technologies.com/role/TheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:SignificantEventsAndTransactionsOfThePeriodDisclsureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Significant Events and Transactions", "menuCat": "Notes", "order": "8", "role": "http://www.dbv-technologies.com/role/SignificantEventsAndTransactions", "shortName": "Significant Events and Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dbvt:SignificantEventsAndTransactionsOfThePeriodDisclsureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Cash and Cash Equivalents", "menuCat": "Notes", "order": "9", "role": "http://www.dbv-technologies.com/role/CashAndCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d515836d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 37, "tag": { "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_AccumulatedForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 25.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated foreign currency translation adjustment net of tax.", "label": "Accumulated Foreign Currency Translation Adjustment Net Of Tax", "terseLabel": "Accumulated currency translation effect" } } }, "localname": "AccumulatedForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "dbvt_AdjustmentForDepreciationAmortizationAndAccruedContingencies": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for depreciation, amortization and accrued contingencies.", "label": "Adjustment for Depreciation Amortization And Accrued Contingencies", "terseLabel": "Depreciation, amortization and accrued contingencies" } } }, "localname": "AdjustmentForDepreciationAmortizationAndAccruedContingencies", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dbvt_AdjustmentForRetirementPensionObligations": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for retirement pension obligations.", "label": "Adjustment For Retirement Pension Obligations", "terseLabel": "Retirement pension obligations" } } }, "localname": "AdjustmentForRetirementPensionObligations", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dbvt_AdjustmentsToAdditionalPaidInCapitalAllocationOfAccumulatedGainLossNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid in Capital Allocation Of Accumulated Gain Loss Net.", "label": "Adjustments To Additional Paid in Capital Allocation Of Accumulated Gain Loss Net", "terseLabel": "Allocation of accumulated net losses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAllocationOfAccumulatedGainLossNet", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "dbvt_AgeOfChild": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Age of child.", "label": "Age Of Child", "terseLabel": "Age Of Child" } } }, "localname": "AgeOfChild", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dbvt_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_AllocationOfPersonnelExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allocation of Personnel Expenses Text block", "label": "Allocation of Personnel Expenses [Text Block]", "terseLabel": "Allocation of Personnel Expenses" } } }, "localname": "AllocationOfPersonnelExpensesTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpenses" ], "xbrltype": "textBlockItemType" }, "dbvt_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American depositary shares.", "label": "American Depositary Shares [Member]", "terseLabel": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_BSAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA Warrants [member]", "label": "B S A Warrants [Member]" } } }, "localname": "BSAWarrantsMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "domainItemType" }, "dbvt_CashEquivalentTermDeposits": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalent term deposits.", "label": "Cash Equivalent Term Deposits", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentTermDeposits", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ClassOfWarrantOrRightExercisePriceRangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercise price range.", "label": "Class Of Warrant Or Right Exercise Price Range [Axis]" } } }, "localname": "ClassOfWarrantOrRightExercisePriceRangeAxis", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_ClassOfWarrantOrRightExercisePriceRangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercise price range.", "label": "Class Of Warrant Or Right Exercise Price Range [Domain]" } } }, "localname": "ClassOfWarrantOrRightExercisePriceRangeDomain", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_ClinicalProgramTrialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical program trial period.", "label": "Clinical Program Trial Period", "terseLabel": "Clinical Program Trial Period" } } }, "localname": "ClinicalProgramTrialPeriod", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dbvt_CollaborationAgreementLossAtCompletionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement loss at completion.", "label": "Collaboration Agreement Loss At Completion [Member]", "terseLabel": "Collaboration agreement -Loss at completion [Member]" } } }, "localname": "CollaborationAgreementLossAtCompletionMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "domainItemType" }, "dbvt_CollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreement.", "label": "Collaboration And License Agreement [Member]" } } }, "localname": "CollaborationAndLicenseAgreementMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_DeferredRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred revenue.", "label": "Deferred Revenue [Member]", "terseLabel": "Deferred Incomes [Member]" } } }, "localname": "DeferredRevenueMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "domainItemType" }, "dbvt_DisclosureOfCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Commitments Line Items.", "label": "Disclosure Of Commitments [Line Items]" } } }, "localname": "DisclosureOfCommitmentsLineItems", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_EmployeeRelatedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee related liabilities.", "label": "Employee Related Liabilities [Member]", "terseLabel": "Employee Related Liabilities [Member]" } } }, "localname": "EmployeeRelatedLiabilitiesMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "domainItemType" }, "dbvt_EmployerContributionToBonusShares": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employer contribution to bonus shares", "label": "Employer contribution to bonus shares", "terseLabel": "Employer contribution to bonus shares" } } }, "localname": "EmployerContributionToBonusShares", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_EventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event.", "label": "Event [Axis]" } } }, "localname": "EventAxis", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_EventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event.", "label": "Event [Domain]" } } }, "localname": "EventDomain", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_ExpensesByFunctionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses by Function", "label": "Expenses by Function [Member]", "terseLabel": "Expenses by Function [Member]" } } }, "localname": "ExpensesByFunctionMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail" ], "xbrltype": "domainItemType" }, "dbvt_ExpensesByNatureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses by nature", "label": "Expenses by Nature [Member]", "terseLabel": "Expenses by Nature [Member]" } } }, "localname": "ExpensesByNatureMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "domainItemType" }, "dbvt_ExpensesForPensionCommitments": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses for pension commitments", "label": "Expenses for pension commitments" } } }, "localname": "ExpensesForPensionCommitments", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_FinanceIncomeExpenses": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial (Expenses).", "label": "Finance Income Expenses", "terseLabel": "Financial income(expenses)" } } }, "localname": "FinanceIncomeExpenses", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "dbvt_ForeignCurrencyExchangeRateChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign currency exchange rate changes.", "label": "Foreign Currency Exchange Rate Changes", "terseLabel": "Currency translation effect" } } }, "localname": "ForeignCurrencyExchangeRateChanges", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liability and right of use asset.", "label": "Increase Decrease In Operating Lease Liability And Right Of Use Asset", "negatedLabel": "Change in operating lease liabilities and right of use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dbvt_IncreaseDecreaseInOtherCommitmentsDuringThePeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in other commitments during the period.", "label": "Increase Decrease In Other Commitments During The Period", "terseLabel": "Increase (decrease) in other commitments during the period" } } }, "localname": "IncreaseDecreaseInOtherCommitmentsDuringThePeriod", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_IncreaseDecreaseInRelatedPartyTransactionsAndChangesInNatureOfTheTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in related party transactions and changes in nature of the transactions.", "label": "Increase Decrease In Related Party Transactions And Changes In Nature Of The Transactions", "terseLabel": "Increase decrease in related party transactions and changes in nature of the transactions" } } }, "localname": "IncreaseDecreaseInRelatedPartyTransactionsAndChangesInNatureOfTheTransactions", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/RelationshipsWithRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_IncreaseInCurrentTradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in current trade payables.", "label": "Increase in Current Trade Payables [Member]", "terseLabel": "Increase in Current Trade Payables [Member]" } } }, "localname": "IncreaseInCurrentTradePayablesMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_LesseeOperatingLeaseLiabilityPaymentsDueThereafter": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due thereafter.", "label": "Lessee Operating Lease Liability Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThereafter", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_LossContingencyAccrualNetInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss contingency accrual net interest.", "label": "Loss Contingency Accrual Net Interest", "terseLabel": "Net interest related to employee benefits, and unwinding of discount" } } }, "localname": "LossContingencyAccrualNetInterest", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_LossContingencyAccrualUsedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss contingency accrual used liabilities.", "label": "Loss Contingency Accrual Used Liabilities", "negatedTerseLabel": "Used liabilities" } } }, "localname": "LossContingencyAccrualUsedLiabilities", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_LossContingencyActuarialGainsAndLossesOnDefinedBenefitPlans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss contingency actuarial gains and losses on defined benefit plans.", "label": "Loss Contingency Actuarial Gains And Losses On Defined Benefit Plans", "terseLabel": "Actuarial gains and losses on defined-benefit plans" } } }, "localname": "LossContingencyActuarialGainsAndLossesOnDefinedBenefitPlans", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New accounting pronouncements not yet adopted, policy.", "label": "New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]", "verboseLabel": "Accounting Pronouncements issued not yet adopted" } } }, "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "xbrltype": "textBlockItemType" }, "dbvt_NonemployeewarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-employee\u00a0warrants .", "label": "Nonemployeewarrants [Member]", "terseLabel": "Non-employee\u00a0warrants [Member]" } } }, "localname": "NonemployeewarrantsMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dbvt_OtherAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Asset [Member]", "label": "Other Asset [Member]", "terseLabel": "Other Asset [Member]" } } }, "localname": "OtherAssetMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "domainItemType" }, "dbvt_OtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Current Assets [Abstract]" } } }, "localname": "OtherCurrentAssetsAbstract", "nsuri": "http://www.dbv-technologies.com/20230630", "xbrltype": "stringItemType" }, "dbvt_OtherCurrentAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other current assets.", "label": "Other Current Assets [Line Items]" } } }, "localname": "OtherCurrentAssetsLineItems", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_OtherCurrentAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other current assets.", "label": "Other Current Assets [Table]" } } }, "localname": "OtherCurrentAssetsTable", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_OtherDebtsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other debts.", "label": "Other Debts [Member]", "terseLabel": "Other Debts [Member]" } } }, "localname": "OtherDebtsMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "domainItemType" }, "dbvt_OtherProvisionsInclRestructuringMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other provisions incl. restructuring.", "label": "Other Provisions Incl Restructuring [Member]", "terseLabel": "Other provisions incl. restructuring [Member]" } } }, "localname": "OtherProvisionsInclRestructuringMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "domainItemType" }, "dbvt_OtherReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other receivables current.", "label": "Other Receivables Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesCurrent", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_OtherperatingIncome1": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail": { "order": 2.0, "parentTag": "dbvt_TotalRevenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Operating Income1.", "label": "OtherOperating Income1", "terseLabel": "Other operating income" } } }, "localname": "OtherperatingIncome1", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded warrants member", "label": "Prefunded warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "dbvt_ProceedsFromNonCurrentFinancialAssets": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from non-current financial assets.", "label": "Proceeds From Non Current Financial Assets", "terseLabel": "Proceeds from non-current financial assets dispositions" } } }, "localname": "ProceedsFromNonCurrentFinancialAssets", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dbvt_ProceedsFromRepaymentOfTreasuryStock": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from repayment of treasury stock", "label": "Proceeds from Repayment of Treasury Stock", "terseLabel": "Treasury shares" } } }, "localname": "ProceedsFromRepaymentOfTreasuryStock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dbvt_ProvisionForLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision for liabilities current.", "label": "Provision For Liabilities Current", "verboseLabel": "Current contingencies" } } }, "localname": "ProvisionForLiabilitiesCurrent", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "dbvt_ProvisionForLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision for liabilities noncurrent.", "label": "Provision For Liabilities Noncurrent", "verboseLabel": "Non-current contingencies" } } }, "localname": "ProvisionForLiabilitiesNoncurrent", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "dbvt_RentExpensesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rent Expenses [Axis]" } } }, "localname": "RentExpensesAxis", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail" ], "xbrltype": "stringItemType" }, "dbvt_RentExpensesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rent Expenses [Domain]" } } }, "localname": "RentExpensesDomain", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail" ], "xbrltype": "domainItemType" }, "dbvt_RentExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rent Expenses [Member]" } } }, "localname": "RentExpensesMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail" ], "xbrltype": "domainItemType" }, "dbvt_ResearchTaxCredit": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit.", "label": "Research Tax Credit", "terseLabel": "Research tax credit" } } }, "localname": "ResearchTaxCredit", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditAdjustmentAndCurrencyTranslationEffect": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit adjustment and currency translation effect.", "label": "Research Tax Credit Adjustment And Currency Translation Effect", "terseLabel": "- Adjustment and currency translation effect" } } }, "localname": "ResearchTaxCreditAdjustmentAndCurrencyTranslationEffect", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit current.", "label": "Research Tax Credit Current", "terseLabel": "Of which - Current portion" } } }, "localname": "ResearchTaxCreditCurrent", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditIncome": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail": { "order": 1.0, "parentTag": "dbvt_TotalRevenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research tax credit income.", "label": "Research Tax Credit Income", "terseLabel": "Research tax credit" } } }, "localname": "ResearchTaxCreditIncome", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit, non current.", "label": "Research Tax Credit Non current", "terseLabel": "Of which - Non-current portion" } } }, "localname": "ResearchTaxCreditNonCurrent", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit payment received.", "label": "Research Tax Credit Payment Received", "terseLabel": "- Payment received" } } }, "localname": "ResearchTaxCreditPaymentReceived", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ResearchTaxCreditReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit receivable.", "label": "Research Tax Credit Receivable", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance" } } }, "localname": "ResearchTaxCreditReceivable", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ReverseTaxCreditOperatingRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reverse tax credit operating revenue.", "label": "Reverse Tax Credit Operating Revenue", "terseLabel": "+ Operating revenue" } } }, "localname": "ReverseTaxCreditOperatingRevenue", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Allocation of Personnel Expenses By Function\u00a0[Table text block]", "label": "Schedule of Allocation of Personnel Expenses By Function [Table Text Block]", "terseLabel": "Summary of Allocation of Personnel Expenses By Function" } } }, "localname": "ScheduleOfAllocationOfPersonnelExpensesByFunctionTableTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesTables" ], "xbrltype": "textBlockItemType" }, "dbvt_ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Allocation of Personnel Expenses By Nature[Table text block]", "label": "Schedule of Allocation of Personnel Expenses By Nature [Table Text Block]", "terseLabel": "Summary of Allocation of Personnel Expenses By Nature" } } }, "localname": "ScheduleOfAllocationOfPersonnelExpensesByNatureTableTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesTables" ], "xbrltype": "textBlockItemType" }, "dbvt_ScheduleOfOperatingIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating income", "label": "Schedule of operating income", "terseLabel": "Schedule of operating income" } } }, "localname": "ScheduleOfOperatingIncome", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OperatingIncomeTables" ], "xbrltype": "textBlockItemType" }, "dbvt_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Supplemental cash flow information related to operating leases [Table Text block]", "label": "Schedule Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block]", "terseLabel": "Summary of Supplemental cash flow information related to our operating leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsTables" ], "xbrltype": "textBlockItemType" }, "dbvt_ShareCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital [Member]", "terseLabel": "Share Capital [Member]" } } }, "localname": "ShareCapitalMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_SignificantEventsAndTransactionsOfThePeriodDisclsureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant events and transactions of the period disclsure.", "label": "Significant Events And Transactions of the Period Disclsure [Abstract]" } } }, "localname": "SignificantEventsAndTransactionsOfThePeriodDisclsureAbstract", "nsuri": "http://www.dbv-technologies.com/20230630", "xbrltype": "stringItemType" }, "dbvt_SignificantEventsAndTransactionsOfThePeriodDisclsureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant events and transactions of the period disclsure.", "label": "Significant Events and Transactions of the Period Disclsure [Text Block]", "terseLabel": "Significant Events and Transactions" } } }, "localname": "SignificantEventsAndTransactionsOfThePeriodDisclsureTextBlock", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactions" ], "xbrltype": "textBlockItemType" }, "dbvt_SocialSecurityContributions": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Social security contributions", "label": "Social security contributions", "terseLabel": "Social security contributions" } } }, "localname": "SocialSecurityContributions", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_SubsidiaryAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary Axis.", "label": "Subsidiary [Axis]", "terseLabel": "Subsidiary Axis" } } }, "localname": "SubsidiaryAxis", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dbvt_SubsidiaryDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidiary .", "label": "Subsidiary [Domain]" } } }, "localname": "SubsidiaryDomain", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_TaxCreditCarryforwardAmountBeforeCurrencyTranslation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax credit carryforward amount before currency translation.", "label": "Tax Credit Carryforward Amount Before Currency Translation", "terseLabel": "Tax credit carryforward amount before currency translation" } } }, "localname": "TaxCreditCarryforwardAmountBeforeCurrencyTranslation", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_TaxLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax liabilities.", "label": "Tax Liabilities [Member]", "terseLabel": "Tax Liabilities [Member]" } } }, "localname": "TaxLiabilitiesMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "domainItemType" }, "dbvt_TotalRevenues": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Revenues", "label": "Total Revenues", "totalLabel": "Total" } } }, "localname": "TotalRevenues", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/OperatingIncomeSummaryOfOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "dbvt_ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ViaskinTM clinical program for children aged between four to eleven.", "label": "ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]", "terseLabel": "ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]" } } }, "localname": "ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dbvt_WagesAndSalaries": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Wages and salaries", "label": "Wages and salaries", "terseLabel": "Wages and salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "http://www.dbv-technologies.com/20230630", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "dei_AdrMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "ADR [Member]", "terseLabel": "American Depositary Share [Member]" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r203", "r205", "r206", "r207", "r299", "r379", "r403", "r423", "r424", "r434", "r445", "r451", "r486", "r526", "r527", "r528", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r203", "r205", "r206", "r207", "r299", "r379", "r403", "r423", "r424", "r434", "r445", "r451", "r486", "r526", "r527", "r528", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r189", "r380", "r435", "r449", "r481", "r482", "r487", "r533" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r189", "r380", "r435", "r449", "r481", "r482", "r487", "r533" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r203", "r205", "r206", "r207", "r259", "r299", "r327", "r328", "r329", "r378", "r379", "r403", "r423", "r424", "r434", "r445", "r451", "r478", "r486", "r527", "r528", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r203", "r205", "r206", "r207", "r259", "r299", "r327", "r328", "r329", "r378", "r379", "r403", "r423", "r424", "r434", "r445", "r451", "r478", "r486", "r527", "r528", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r190", "r191", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r436", "r450", "r487" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r190", "r191", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r436", "r450", "r487" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r475", "r522" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Trade Payables and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r0", "r17" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "verboseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r29", "r30", "r31", "r123", "r398", "r408", "r409" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r31", "r93", "r369", "r404", "r405", "r462", "r463", "r464", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive income (loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r27", "r31", "r93", "r134", "r135", "r354", "r355", "r356", "r357", "r359", "r462" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Currency Translation Effect [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r12", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r335", "r336", "r337", "r471", "r472", "r473", "r516" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r89", "r90", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based payments" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r64", "r69", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash flow provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r331" ], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based payments" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r104", "r119", "r142", "r180", "r183", "r187", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r344", "r346", "r352", "r448", "r484", "r485", "r524" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r115", "r126", "r142", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r344", "r346", "r352", "r448", "r484", "r485", "r524" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-Current assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BankOverdrafts": { "auth_ref": [ "r21", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.", "label": "Bank Overdrafts", "terseLabel": "Bank overdrafts" } } }, "localname": "BankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "The Company" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TheCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r410", "r411", "r448", "r461" ], "calculation": { "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r48", "r117", "r426" ], "calculation": { "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents as reported in the statements of financial position", "verboseLabel": "Total cash and cash equivalents as reported in the statements of cash flows" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalentsSummaryOfBreakdownOfCashAndCashEquivalentsDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r44", "r48", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Net cash and cash equivalents at the end of the period", "periodStartLabel": "Net Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r44", "r96" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r120", "r121", "r122", "r142", "r159", "r160", "r162", "r164", "r171", "r172", "r193", "r211", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r224", "r228", "r235", "r352", "r425", "r459", "r468", "r474" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r80", "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of warrants outstanding, Ending Balance", "periodStartLabel": "Number of warrants outstanding, Beginning Balance" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Domain]" } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r60", "r199", "r200", "r413", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r471", "r472", "r516" ], "lang": { "en-us": { "role": { "definitionGuidance": "Ordinary Shares [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Shares [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.dbv-technologies.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, \u20ac0.10 par value; 96,250,954 and 94,137,145 shares authorized, and issued as at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r33", "r130", "r132", "r138", "r394", "r400" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r304", "r332", "r333", "r334", "r338", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r139", "r149", "r150", "r151", "r152", "r153", "r157", "r159", "r162", "r163", "r164", "r168", "r350", "r351", "r395", "r401", "r429" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share attributable to shareholders" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r139", "r149", "r150", "r151", "r152", "r153", "r159", "r162", "r163", "r164", "r168", "r350", "r351", "r395", "r401", "r429" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share attributable to shareholders" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r518" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-Based Payments [Line iteam]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "presentationGuidance": "Stock options [Member]", "terseLabel": "Share options [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r69", "r113", "r133", "r134", "r135", "r144", "r145", "r146", "r148", "r154", "r156", "r170", "r194", "r236", "r335", "r336", "r337", "r340", "r341", "r349", "r353", "r354", "r355", "r356", "r357", "r359", "r369", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.dbv-technologies.com/role/CoverPage", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "verboseLabel": "Net termination impact" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative expenses", "verboseLabel": "General\u00a0and Administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "verboseLabel": "General\u00a0and Administrative expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r36", "r97", "r102", "r110", "r180", "r182", "r186", "r188", "r396", "r431" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r155", "r156", "r179", "r339", "r342", "r343", "r402" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r46" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "(Decrease) increase in trade payables", "verboseLabel": "Increase decrease in trade payables current" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r467" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Decrease (increase) in other\u00a0current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r46" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "(Decrease) increase in other current and non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r57", "r58" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 7.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Rent expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Operating Leases Future Minimum Payments Receivable" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r367" ], "calculation": { "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r367" ], "calculation": { "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Current portion" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r367" ], "calculation": { "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year 3" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r367" ], "calculation": { "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year 2" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Effects of discounting" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease contracts" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContracts" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r142", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r345", "r346", "r347", "r352", "r430", "r484", "r524", "r525" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r100", "r107", "r448", "r470", "r476", "r517" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r116", "r142", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r345", "r346", "r347", "r352", "r448", "r484", "r524", "r525" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r142", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r345", "r346", "r347", "r352", "r484", "r524", "r525" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-Current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r19", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r19", "r469" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency [Abstract]", "terseLabel": "Contingency [Abstract]" } } }, "localname": "LossContingencyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r201", "r460" ], "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "periodEndLabel": "Contingencies, Ending balance", "periodStartLabel": "Contingencies, Beginning balance", "totalLabel": "Total contingencies" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r201" ], "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail": { "order": 1.0, "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Current contingencies", "verboseLabel": "Of which Current" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "auth_ref": [ "r201" ], "calculation": { "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail": { "order": 2.0, "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Noncurrent", "terseLabel": "Non-current contingencies", "verboseLabel": "Of which Non-current" } } }, "localname": "LossContingencyAccrualCarryingValueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfCurrentContingenciesAndNonCurrentContingenciesDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "definitionGuidance": "Loss contingency reversal amount", "documentation": "Amount of increase (decrease) in loss contingency liability.", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "terseLabel": "Reversals of unused liabilities" } } }, "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualProvision": { "auth_ref": [ "r479" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.", "label": "Loss Contingency Accrual, Provision", "terseLabel": "Increases in liabilities" } } }, "localname": "LossContingencyAccrualProvision", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r201", "r202", "r204", "r206", "r207", "r208", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MajorPropertyClassAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class.", "label": "Major Property Class [Axis]", "terseLabel": "Major Property Class [Axis]" } } }, "localname": "MajorPropertyClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MajorPropertyClassDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date.", "label": "Major Property Class [Domain]", "terseLabel": "Major Property Class [Domain]" } } }, "localname": "MajorPropertyClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r140" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by (used in) financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r140" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash flows provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows provided by (used in) investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r44", "r45", "r47" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash flow provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r37", "r47", "r103", "r109", "r114", "r128", "r131", "r135", "r142", "r147", "r149", "r150", "r151", "r152", "r155", "r156", "r161", "r180", "r182", "r186", "r188", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r351", "r352", "r431", "r484" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net (loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Accounting Pronouncements adopted in 2023", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r191" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "Total Operating expenses", "terseLabel": "Total Operating expenses", "totalLabel": "Total Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r180", "r182", "r186", "r188", "r431" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense / (income)" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r362" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "verboseLabel": "Short-term operating leases" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r362" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease", "verboseLabel": "Long-term operating leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r363", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfSupplementalCashFlowInformationRelatedToOurOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r361" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets related to operating leases" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r366", "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r365", "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Receivable [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r125", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets", "totalLabel": "Total" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r118" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 8.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r26" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 11.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation differences, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r69", "r129", "r132", "r137", "r353", "r358", "r359", "r393", "r399", "r462", "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r29", "r32", "r85", "r127" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 12.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Actuarial gains (losses) on employee benefits, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Total" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Other Liabilities [Table Text Block]", "terseLabel": "Summary of Other Liabilities" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other elements" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other operating income and other operating expense items.", "label": "Other Operating Income and Expense [Text Block]", "verboseLabel": "Operating Income" } } }, "localname": "OtherOperatingIncomeAndExpenseTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OperatingIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Acquisitions of non-current financial assets" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r41" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property, plant, and equipment, net from proceeds" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability, Defined Benefit Plan [Abstract]", "terseLabel": "Liability, Defined Benefit Plan [Abstract]" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentRetirementBenefitsMember": { "auth_ref": [ "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Special and contractual termination benefits provided in connection with termination of employment and payable upon retirement, but not payable from defined benefit plan. Excludes benefits payable upon termination from defined benefit pension and other postretirement plan, and postemployment benefits payable before retirement.", "label": "Postemployment Retirement Benefits [Member]", "terseLabel": "Pension retirement obligations [Member]" } } }, "localname": "PostemploymentRetirementBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r124", "r195", "r196", "r427" ], "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r428", "r433", "r477" ], "calculation": { "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Other tax claims" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfOtherCurrentAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds From Issuance Of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r43" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Capital increases, net of transaction costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r465", "r466" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other cash flows related to financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from other long-term debt.", "label": "Proceeds from (Repayments of) Other Long-term Debt", "terseLabel": "Decrease in conditional advances" } } }, "localname": "ProceedsFromRepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r40" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from property, plant, and equipment dispositions" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r59", "r108", "r397", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r7", "r99", "r105" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r7", "r99", "r105" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r7", "r99", "r105" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateMember": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Property consisting of land, land improvement and buildings.", "label": "Real Estate [Member]", "terseLabel": "Real Estate [Member]" } } }, "localname": "RealEstateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r283", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r283", "r372", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r370", "r371", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Relationships with Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/RelationshipsWithRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r91", "r111", "r532" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development expenses", "verboseLabel": "Research and Development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]", "verboseLabel": "Restricted stock units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r76", "r106", "r407", "r409", "r448" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r113", "r144", "r145", "r146", "r148", "r154", "r156", "r194", "r335", "r336", "r337", "r340", "r341", "r349", "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r82", "r83", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r82", "r83", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r136", "r142", "r177", "r178", "r181", "r184", "r185", "r189", "r190", "r192", "r193", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r352", "r396", "r484" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Operating income" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "verboseLabel": "Summary of Current Contingencies and Non-current Contingencies" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareSummaryOfTheCommonStockEquivalentsWhichWereExcludedFromTheCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Summary of share-based payments expenses [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share-Based Payments Expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "auth_ref": [ "r61", "r62", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "terseLabel": "Summary of Movement in Provisions" } } }, "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Summary of Other Current Asset" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r35", "r55" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r301", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r67", "r68", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r120", "r121", "r122", "r171", "r220", "r221", "r222", "r224", "r228", "r233", "r235", "r434", "r459", "r468" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r9", "r10", "r11", "r66", "r67", "r68", "r70", "r71", "r72", "r73", "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of RSU Activity" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "negatedLabel": "Sales and marketing expenses", "verboseLabel": "Sales\u00a0and Marketing expenses" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "verboseLabel": "Sales\u00a0and Marketing expenses [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Disclosure [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r46" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Expenses related to share-based payments" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of RSU outstanding, Forfeited during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of RSU outstanding, Granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of RSU outstanding, Ending Balance", "periodStartLabel": "Number of RSU outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of RSU outstanding, Released during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of stock options outstanding, Forfeited during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of stock options outstanding, Granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of stock options outstanding, Ending Balance", "periodStartLabel": "Number of stock options outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfRsuActivityDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (Shares)", "periodStartLabel": "Beginning balance (Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r120", "r121", "r122", "r142", "r159", "r160", "r162", "r164", "r171", "r172", "r193", "r211", "r213", "r214", "r215", "r218", "r219", "r220", "r221", "r224", "r228", "r235", "r352", "r425", "r459", "r468", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r69", "r113", "r133", "r134", "r135", "r144", "r145", "r146", "r148", "r154", "r156", "r170", "r194", "r236", "r335", "r336", "r337", "r340", "r341", "r349", "r353", "r354", "r355", "r356", "r357", "r359", "r369", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.dbv-technologies.com/role/CoverPage", "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r170", "r380" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByFunctionDetail", "http://www.dbv-technologies.com/role/AllocationOfPersonnelExpensesSummaryOfAllocationOfPersonnelExpensesByNatureDetail", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.dbv-technologies.com/role/ContingenciesAdditionalInformationDetail", "http://www.dbv-technologies.com/role/ContingenciesSummaryOfMovementInContingenciesDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfOperatingLeasesFutureMinimumPaymentsReceivableDetail", "http://www.dbv-technologies.com/role/LeaseContractsSummaryOfRentExpensesDetail", "http://www.dbv-technologies.com/role/ShareBasedPaymentsTables", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetail", "http://www.dbv-technologies.com/role/TradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherLiabilitiesByNatureDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Shares, Dividend Reinvestment Plan", "terseLabel": "Issuance of ordinary shares (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r11", "r69", "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r11", "r69", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of ordinary shares" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other change in equity" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r10", "r11", "r69", "r76", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Treasury shares" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r14", "r15", "r56", "r448", "r470", "r476", "r517" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Share capital", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition", "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r141", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r236", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholders' equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Events After the Close of the Period" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/EventsAfterTheCloseOfThePeriod" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail", "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Summary of Tax Credit Carryforwards [Table Text Block]", "terseLabel": "Summary of Research Tax Credit" } } }, "localname": "SummaryOfTaxCreditCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/OtherCurrentAssetsSummaryOfResearchTaxCreditDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r1", "r66" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Nominal value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Share capital authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, common, shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r24", "r78" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r24", "r78", "r79" ], "calculation": { "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, 149,972 and 149,793 ordinary shares as of June 30, 2023 and December 31, 2022, respectively, at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/SignificantEventsAndTransactionsOfThePeriodsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r173", "r174", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/TheCompanyPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/ShareBasedPaymentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r158", "r164" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares outstanding used in computing per share amounts:" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r157", "r164" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding used in computing per share amounts:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.dbv-technologies.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/subtopic&trid=2127163", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/subtopic&trid=2127197", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r454": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 72 0001193125-23-199175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-199175-xbrl.zip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

3UJ'ZEZW(LQ[]Y=[L.!3W-WAR=)?N MOH$3A3N8]?JK';KV?2WC;?=2QS'BTB_:ZS>QL9#,R,2YH=&WE6%MOVDH0?D?B/XQ''9W=G8NW\S.;.MJ_M>HW;H:=/KM?*XU M'\Y'@_;@[U*]5M9;E6B(\Y68 %K=: M+20O65RL+-6X=KPULS7: _D M?*G"7:U)0K9FWDK(DG+<1M5538C'"T-.9B MS7VXYK)A5! 2D.KTFVW*A/2^CX)]-H3 MB$"']KBGQ%(83 E'PF(#RN+0LP1?PN".&X$2WSB,ETC!/6#2C- MKKF!YP=,*E .Z&_@8WE6[I5!KY]5B\!\8*;C*F[ND^D@O?;;ZMGH.S MI./SN1GS%DQROS2^L_D&.H:BI5JU6MO:Y7['G#^1528I*\EUF\(9T;CWF:FV]SDKZ:6%QTJH0:3M6 ME P0>$()[N=S@SO#8G+%$VWUM_73R')XJHF6*]".5R_TT]?--"W-O&F>%$/G MQ!8-C41V"O]%]B5/$-^>Q= 1'IS7:307"A5 ?\42?92"O#133*%1>H[)H;#S M9L+PA7[^NAD/0A>?T* (?28%MV'.?/\59P@>WBP>!1.>V._>Y'-S;EC2L9T5 MF@%FY4XYK6G/6;M,;O:53'@OF(^V0RQPA M;T0Q@,#A%=W/.T/IB7,:J/.9#9H)#\>!&P6W1I$;"ZTJ@:]P6@TZ?3[P^MWV_%L MTNDEXT_#_OSJ0M.KU9=:&TB>*?AJ@YBX ,UE*UY:>)Q]*0GI"Y,WV#='F#%A M/]E\^E*#FSB;H>+;S!;E4+V,";R?;$DO[6U*FQ3VK0B/#>DF9&2:[Y! R#IO M^O A8!Z&A;V!*7'C\0W-72AR2N,2^$T'&Y)QP3PL#-Y]X'DD=N MKV,RK%5K]1!CR PQJ A>^UD8)YA2"%",1$P >_="*C:R(F^#9!G8.&F@@C:! M^E8H*YO%? +V7O[5ZP5VDDXB\?19P3Q)HB>==Z)8)!R'_L7/E#X$Y[U+Z]?C M _X/X5'[0\-#R"653B$>#=S+L*@RZ<8C'!P$RY()&KD>]PE<12)DMHV"(1FE M85QP$5:X0ON727K.YY"W*<)3"$Y(%M@1.!V,H?!X/Y.[RT= =W]%\#2%4A_U M:,#[P-[$<:Q'<0S9$BW%M?;+<,^B,(O2-"K3:'[:,(DA880%LQ;>5E$$M.,? M.X2_QN@(';)=2; ;J;H3.2'<9W#^R/VG9\E\B(B=J(E)CH0J_)Q)VAGALH'Y M<(>@T]3"\4SN[:;NP'=L%.1%-?S[M18B<5'%K]Q7@FW#Y7[;;B%X2)%.5\DA M$?7CO]^7Z&&Y_C3#/U"5[N>KYT)F5LC?W\HF)QW!X)%6]G=(<*3G.-XX'H/- M8X0H3#R!MYQ+U]R!*">/B\H?V/IS8?U\Z/A.H#P[2@YZQ?\.)3M1J!CJ&(83 M2"7DZA T\3WW'+7/G!H48Z]!8881UF)1RWQ8#Q:IA9&. I-CMV%BO8>]\ZX/ MV3U[A'INNPHL\-;"]Y-B4/CY'#'!5FE!!:GA>,B7V+W+@U:00HL M#.D8,M9^N0@!-F%>]MS=(TL]_7/]2 D R$FO%)1:X=DHOTMO&0P.\$L+">%=T^P%VBI%Z MY:3FK/2'-XB#^$$SJG@J]"Z*D^%SZK]02P,$% @ @(3_5O+9?XZ_$ M([$ !$ !D8G9T+3(P,C,P-C,P+GAS9.T=VV[CN/6]0/^!]4NW#XYSV9G= M"39;.+=%BDP<))Z=+8IB(4NTS8Y,>2@IL5OTWWM(W2A1M"A9D0>U7Q)9Y+D? M'I*'%/G37U<+%[U@YA./7O1.CHY["%/;8!JB/YD&P/!\,7E]?CYPI MH;[GA@$0\(]L;S& \E\C@NCI[.@8?L+3V4G_;Z&[[I\>GYZA?QS_6"BPV P'#]8"^TO+QA<]F=;DI1]@>TX]UYL1')'C M&(_?GW'!7,SYN_78XAI/K= -+GI?0\LE4X*='@)-4/\<< 1UD JH',#KV9'' M9E#E^&3PV\?[9\%W@MXE]$NN]FK"W*3^V8 73RP?)]572OT8^\F'#Q\&HC2M M"HC(!M0DMI-%0IR%4%#P7J)_5+=B9(\WF#)-(BAI*"#)<,V;[E:,WX8 M6,QFGHN!JAWT\6KI6M0*/+:^A=\I31:HW,'+/&,LT F2%N79"U@!(,<=% ]X M,81!_'ZT9M$P"%LI^IH@=#$&4"+(G M$%4@8DJQ5M1''."G0;%V@B#TL3.B/XMG\ 4?((44O.G&4'&5,H@,H5E]VW+M MT-43&.2TM;WZJ(,I((<'Z&B(PQW]&>039O5'TUM"(>X1RWWT?"%%HN?:4V)&.+4#G8N-=&5Y<]O7>_5U*19?8WUWC6Q'L>*!-J#F(YY1+)H;"WI MMT;W/_!Q)?%MU_-#AN$'@* 89C]U^$QFE$RASZ;!S0OW-NA3QLRB/LR)>-R/ M-%M92Z/O'XOZEA"A")/H6&1<^VD''JMY=P[_>)-^L5RNG#@*E9=I=/ZAJ'/1 M#8CNFS](&/93TR,8I+(KD4@)AKZ/$RV7O"_7\,EQ4<,"%,6P* +>3^7>8\N' M($P#!JTY5FSAG4:I)T6E"C!D)W#[J4\(C Y^M-;6Q,4\Z,I.>D^L"7&!=1PK MVK2RQ@*G2N?(\:$$H0@A>4^7D.ZG>73C1N/1X,F9TD/FAG=XCX=W0A.7$ 0< M<,%%UAV6O-!^JG3HNIXMB(VFCQ )/4JQ>[-:\HER[*Z; MJVC4K4P ,RQ\FIWB00FB_50_3(D7))!BKOQ"HUIEKB?![*<6GW!$RI^3I?^9 M!'/Q@G=;+!NT5572:%N9Y>7PH%= A&),*$:UGT;@66IHUJ+GC^ MI..8>(CF/R)D^VF$+,GYZ+DD&[V5O-*6YMK&8 6_* MQL4U-"I79GG:G!SZ+L*TI^I7DW"RZK6E&K4K\[^R1-V>:SR?G9.U75JBT;0R M+2QD[_9GMN,S7-))M'6ZJQA#+Q+$M%[;G&?Q>NX$Z4T_- MIA3))F\ IS&OV=P_9]F2&@[?A@&H]B/( ML0@721[A"=L8.B(8C086+ZFNL:>23=EH3XX7X72Z>;"4JOKG]&-C%\A<1,/B*?"!B!386;PQ(?"0%S+DI7' C>+ ?KN. M8>8_/S"6"B[7#Q:/H[+'M(RSW%&^5W)2M98;2L;B#NYA8LK*$5X+ M>#1NH"3*:KK!83AHM-6\.HM6"T1C3#575K)!_6 TTS7$;!#FAT,[("^@/<5F MIA :DY5_4U!<:\P/W9X_H03YP68Z"ZA%\3#:T()5\!I[&GW&4!B$E=6(B1WL M6S""62 U!M%84G!'U3[??1>Q,3SCM8T_&9 C8659-<&"R<$^ $. M!SMJ[%@9AXUK:RQ6L3GH$'M-=@VIB>/H?6[UH!:(QEK5NXPTV>1D#])>6VWC MUJ+4(!MK7:YO0VH7&^%;("[W@'?U]SCE/**R]N4:)8PTI-1SGD'O/?A1ITUD9U-095TDX2ND-'W>A[TTJ+;0&OL:*2B:K^2O5@ MW.K]JVGDC#[Z6WCT.?#L+]*6M<]S8L\_8X9O5K8;.MBY9=Z"U\YX'DVOB1N" MYA]P("//+31V3%3C1DH"K+#S-M?K!]'7C, ?$@SF=O()%A'G$25,(LYE!)7Q MR1'%G")@5=GJ^__ABOP//XK]"4^1.&C]G)]"?='SR6+I\E/4Q;LYP].+'C\T MOI^<"?\[B'2T6KA)%8YYP_GIPH&+6H@))RCBP[DW'P0/2/AB,8\3@X3Y'AJT M(!!HO*Y >2-]6^*XUJ2N. ""W6]/$G#MNI(46D/+\@RD,]$'^=/201B/!8B6 MWMR@NZH@NO3A/AZ ;@#AO_H)7)^_ZI^<]L].CE:^$_-6@X%,JGH,)' U&2B_ M>\&0= + :;XSH::YDZ&,G)\P5PHSP&[@IP?L\S?&PI;?\K"1A3*0Y$=#XOD+ M(\RHRS#IKV;TI8LEC&BG]<53,YKR!15&1#. Z+$9V>RR"R.B277^T)!@=@F& M&<6DOG@RIJG>HR&"+,4S/FPW:\,N8SDHWI _\.!Q\GXK%@Q#B$0^V)KTYEM$ M3-F1L=QD2&IRI[GNQ<@=DNK\P=@9=!>V;!%9!9KZ#!0O6C'C(+G)):*>XFA$ M?DO"C=I?Z4TQ.@ZJ(,5OOTE_FKMJIK[MOY[)B/K1J]K6K\]#8@2@'R-0:<]@(7Q855\,/R[ 1=^"(1( M(.X@^X5YX3)AB0 K"=6)Y?*QXT7/%E_%E$H\M.UP$8J4#%##9!:O?=MK\35D M-*P>.O\*?9&,@\GQ:#JV5IWHH3%OK6E'8XFKW3O#5>N><"MN><'1:EIV]N+6 M(CIA=*?(!ADUI%L3#1 SOM7\&D?_[VA^0WRBU_60.D]D-@<_^N1C\;U2-PK8 MBL'V8D':E,#7KL45:R1J8PN(S^3?T3-UH%T"^T[A3-DN]+0=A_44Y>")B9Z> M<$"8*'WD%^5X=#1QR2S*>N] *9O9:4L#$)1LC!V?YU*?\#+:S0;!ESMOR-8B M$=N-\&:;1(LX=O;*6) ":TL*N MU'?_8A'*$^H/7473MGAM2W MA9):4L<8KX)+5XHJZ16;YT%2U+8;;W F*8, MU1?U ;]" .%96S *1&4*CW9TE=>#%_P=!T/'6_)E=<\E=G1:ZWH7&MB2SP;M M'";I3NCB&E^JYC]3%0A<&BV)'A?\2+"6:JY(ZW@!%M )SR<8><2!Z\8TULO9&/OQL4P M"NE4\.W9K*^: JDQXU<[\7>9?GM"OL"0&*PD:S7> M&)R=X'P.N)D=3O"=>1[NGE!1W=^)2!+U^F.Z++!;C*VG'GNUF#-<\#S0)8:? MN*31=^.?S3AKRV?O,>@6:Y99D_,9KD,\!FM@BU],U4E\:L)6:PO PO6$SW4Z MS53)UG=S^9##X8ITT5!5DOJ@XY!%M!RK#3JY4QJ%ECO2?AGA[?3?J?.4$:[/ M_C6>8@@V3MPU=BJ!AG:C4"_M$.I4AG+2]46X62Q=;XUQG%C?E3C5;#1 M\P^8^6H=A8?@$?#N2A]U&'QC!WG P1V%633V.\K &K#1FLA7'F?"BW@:SA@6 MA9R#8D74_]C9@ILFZ=KD*UP1 JY[H0MJ"GICY.,>^P'>F9:=B"\ON]3KH)C>64 M6XN&RM)/?D-=QPMOACOIS,4;>S"[B7-('77L!9*MB:)NL>LV^Z,E7[\U?;9F MXE#A9Q";=38"5:FV]BV#Q[\N><8V=&#!6EQ*0R8":T>B;62@+2GC_!^3T8^] M2X^&?K3UKQM9#=AH3>+8YV'.%G\X)IW UY&TFUEH6])DD^J.0DN>>(-D&D 0 MAX =.AH"%@EN,P;,<'4Z"%3)-E@I2@^F&TTE_^QRAT U"\W3S](7R&(?0H;^ M6DQ9TD^>=O9A=!5;;<4)E;1T/N9:_A",[YR*\EEW-&K6XM,PN10-] OWY#>61X&E('.SM9"]!2-Q%D$!V;\O/_ %!+ P04 M" " A/]6!M:YMO(+ !NG@ %0 &1B=G0M,C R,S V,S!?8V%L+GAM;.U= MZV_CN!'_7J#_@^M^=NPD]]@-;N_@O!8NDCAP>L=W;>^F?OQXOO>Q>]=_]J_??Q_G^=CJ# (\'G,>*X!10'_$-[ M8X[7,?-.*)MVSWJ]\^ZJ83MI>?'*R5;KE_-5V]/N[_=W3\X,^ZA#4C;>>HEA M\OJ=OG__OAO_%9IRN=L6 M,F#4PR,\:<737X3+.?[0YL2?>X+L^+,9PY,/;7>\"&-1]GXX[XG>?[VB@8L# MCEWX > @K@#R*81_!61\.+DE ;!/D/=(.1&="8X7F]0-HY,\9GD$'LL!WE//2.=1-=VQVKQ"?W7KT MI7S.-D8^E D824@'_KOY(R(+Y(D9GB+?1VPYG%PRC#Z[]"5(YLRVO,8A(EYA M!DN:]4#FA^$,LZN(,1BSSSG>("'SI_T8W6>& YFZP[!;@>*$##F;TR6+(9C& M?^>W41@Q?$\"XD?^(UK&BC7"#@81CSV\'[>E3GWXZA13PND))+Z1DLI[ZX^@ M7@\TR/O+GLI=XLR'*OA*\@,P(GR<123Y?$_=+C;X@:ST/2\]TX>31[!7:!!@ M[^9U+O;)M925K2Z7#TBHWG[L'H& 6"0.\IS(B[O<@0"V1(-?0PQ'@;L2CB"D MHM,QMO&HLT5.S!IEVU ):CB0$]M.$\3'L0$5\R%?/6)0/4L M1C3]X-/6W(G./.!P.'E&KZN9/#3&7CS_)Z->W>JHATF3V1.;0DKO3KM=Z/ML MFUC$G-5@\&,&]VU#-6W1Y4(+Q6@= C"O^D\8]0O(+J6"*LF/.-!#YV(N!(I, MF8L9W%?:K1=,IK,P_K%"$!+2@/QTI5W"W6A"0@4>2SRA#+\QA/G-*]@.0#C<3=AR ++B<$ ZPJ*@ MGA9@+IN6RND"I640K$F/1^([VO;P4>88Y" N(%?XP7VZ%P8CRF]"E0T M_>Q :%>[=O'1,)&/U0]U+9HG'*]_(/8>L<]X@T$%3JI.S0!)Q4$^0C_6A5#B ML/> U+[KDX#P4+"XP'J8M#V;@966C7S WM4%V A6?1 ICY]U$SL@T)\Z:XKS MI?U^3VEG/3;BDT])E"&U8!3GN:KQUV*CJ60@N7#W:K/18N]UUH\0"PK$0::I M7]-9/C,4<.3$R 5N_%N*H_OOB(?B4#7P]QQKPJ8Y8HXE!XF"U>;24?$YPHZ' M."<3XNSP(]9H?W@U>!1=8K;C<1XIG#5@'+#8^9DZ3!X]$,B!FG<42KXDE3R* M@"2Z>I;5U>Z.=[U.A_LZ:%NA;QWFW(F=PK4F9,0!XM+8ZO8'&RT?,2/4!2R9 MB-M=X^1_^-V+W-C<+M $&RV(VL)T+CAX9 M71#8<2^7O\+>.0C2M"2XTH/ALB A4=Z_B@SR30T+B4L;3:I678!F!V,WOH6- M\#Q-&TG3:.YH,'W&S+_&8]4A5&",N@,]!9?&+M %."TWIB-Q ^32 ]:<4.2( M+9]"ZGR6>07,^C84L (<6A:EV21ZE<4%%]!8PXIMXH5':BC6>_.K#0O5A_R M\TCXJX;L"8F'8X ;;C'4=VQSIHR(8B?#CC^IA9L=U;@O=&S(2RT5ML) V<#,<>F4K] MP$4':#*6!=@TCR!5E+TU0PQ?HCAZY(N8/TI>9$JW8%F'AN*G8TN"5WV9Q^(, M$%D=P.Y6JH8NCIS?I^&H*3B3 /?=,;?(:SQGV"&))'W*0O(?E"9!@)'&HCA$ MNWYK9[1K%AZSH9"6P+D$\MK<54U\H77XFC1[L&6;PVD0+# _U.&4.\@WAU,A M<4GT95^/DT%8:/T2^JTRA=215*2SC>M8H>;2P)""10E8M25.KX(:S[3O@!Z+ MY%C!;_R9*C2@[-90',V8DR#XOC8_X*;F)9$+^ 1.GW IM\K2J6;M:HVB;8LA3DE+G5VZO5$TKY94.Q27VZ>L&2#CZEDB M5:$,H#?'^:*QWF34Q@VV_-J\S:IV=XB1\'D =B-7E)MRW_[*%I _]^A2E/)9+]YG M>DF#B,?DR1>1OJ/=<)AR8?P0UZ:Z0]DO^JEPN>N> FYE:55)D_ZFEQ?0J4N# MM^68V46V*;7L0E9EX+Y>?#0!%$-&+"N\4DXDU&I@\JBVS&Y:W\"U6VJVJ04( MR$2?)=:^,B?YB5T/N:\IS;K5F_TF4:64W?,GRDU'TAGJ< S*Q[(W S8\6RTA\;9Z61&UW2 MOA$ 26@W+E/_[1:81AC6-1*$+U:4,YM1#Z3&M>6B]%VK#"T95<>PI_J%J=PS M$2%]38O:*IALT&80K,UI; LB!L+7W>AK>RZ25^O&P*&BZF4++)JKHI('ZVKH MYYYI(!: S!LM[,V/A.'F?S(F>SN,C6G9W?1N+9SST)B!^] M?1W/^OE]]>\N,><82QP+*_JNU4\OC8>HTH-G2-0#(/[\@KT%O@?H9LI(Z]Y# MUGLA*XAPQDFX-]N690:;,O(/C-CS"RU!$]Y&^BH4X(U;RU**"]$/P3+$:!)B)K.P]AFID9#NS>U!!6NZ@H8QS/+S_P%02P,$ M% @ @(3_5LSBL7VA+@ [LX" !4 !D8G9T+3(P,C,P-C,P7V1E9BYX M;6SM?5MSXSB6YOM$['_(S7EVV9*RF!REI^N;F[O M/_W;Q=/=I]LT+X(T!)^NLK"<@[3X=/!I5A3OOQX>_OCQXY=H$J=YEI0%^D#^ M2YC-#]'O?] /?GH:_7*$_A/]:S0X^-7 05S#6M7 SK'J#\_/S0_(K*IK'O^:D_ET6!@71 MH52N3]P2^+\.5L4.\)\.!L.#T>"7CSQ:RX7*1,7Z,\T&OAS2'S]C=<$L 4]@ M\HE(^FNQ? >_?<[C^7N"$9*_S2"8_/8Y>EL41.M')Z,C_*%_OLQ0?W@,IJ@@ M;N3WI]L-4*C"00'"69HEV30&E%-<\+!1\;"K"&D$TAQ$Z!^H\\01[G;/!?I? MW,'RA\E-G"*RXB!YS/(8Z[V]K.V_T#NHQP"B7V:@B,,@L8]PZW.VX3Z\X^D$ M3POC%!6:OT,P0Q7B!;C+\MPX7-GG;,.]G 7I%.2WZ?,,Z7F6)1&:!*__JXR+ MI7&LPF]U!$J:O$ 35/08+,GW7H*W!+0FC-].5P'C:1I/4!].B^L%;A?Q_0*# M- ]"0O_#Y&4&'@&,LR@?1Q'I^D%RFTXR."<=Y H40=QZO!G[;$?X#V@$P\L2 MXK$\SG-0Y,_E?![ Y0@@.'L)?BXA ")H(=4YPO&01EDKF7C':'< =3G MT< M(.H8M>:JZ2F=DM_SF[(H(?@6I_&\G*\&R!,(0;S HT0/J-%/VU'#$_K8 M]<<[GMURHR!9#7>$@$9W!)""R+2%1GNS']W%P5N!UC5 M>CA-?[T?91@32XH[1HWOJS70RD-V? MJAG!."SIEXR#--WQU!OOOG'&:P] 1Y'&;/4-G27QIV_3C=_U &E]PB0L@^2H MM]L1P#A)*IO&PP1M6_,L34&R6D'72A26NEC>E&FHC]6*"#ZHI'L.X#@ M^B-,R@A$-S";X])!$I9)I>^K."G1@?P>%,W&-7>S?8MGW0P2Y+.;)/MAWL#3 M:-GF&#846JR:S=!7&$S'/J_1O=MW24XK5@13D^9XK:L"+J>)BX@ M"/Z,LA\I'1N[)34G9D-?-6X2ZF[WL2"47K?AMV//.KCSDW'K(/<+'4%5]M9) M 2!>[)(L!PUK:UL LM8,;CBZ[ 8Z"_($Z(X@G\7O^?>XF)$_X$,?Q':3MK)) MFS-J,.QF%30LC-X89[=A;B_>8F'078RN8XB< M\MZ#=/F(CCNASG!AM&#%6E<-P4W;5!K=9RGK%Y-&/+TO6[YA-GUU;'3/H;E8 M,5HP;L/N;J@V/;UVG$#-#K=.(\:L*)J'8583_>PT] 1NV;CQV\3N5X:V3PD& M#;Y=OF1LJ=5?8BLA ABNY*C^V6QL[:X9I\5A%,\/JS*'09)\E@K.<1Q=^7UB MC]$O! ]IK8LXZ-_8-RY+#R(P"CD?(>E,=P4#?6256M5A]$HQDB+ <-TDPY2A[HPR1]?1HS[3-AL!6]["'KDUMQ]=I=(5V M-)(^OE&6RC[8,_6+H;!I&/5 PTV+E%RC3B@_>,F3@"\1)),,R@>%!LEJ=RG>\:"" B;@'/K M!-RF!<#W8_$"H X15!U%R 2["D6R;ZO((**!-;9OIT\6N#BT&7S]+TV N#+O9A>([]GD#>.>,4IA'W=^'+1< BQ M>3ZGW>5Z#N 4=8VO,/M1S-;V?,' 8=:@0/9S R8&Q&'&YI&=BC6.(C1Z\\NL M1/M#,26;1:GH^[;_$B+AD&#SJ%[-IG2=HZ,5]1'L=,\]K8NJ$"CG9WM)B@01 MAQS[A_;G&4@2E2FK61"+?7RT;T9= 0Z.^FV>UQD@B!^ ^A4+*4[QVCFB-"Z5 MC:[@7 ST/NW7,$,;Y8_BFKK/_?8Y!],Y/2U4OV.?ZNBWSP4L 9<[_4/^),C? MB#[*_& :!.^40) 4^>HO-9/5'U[7@434;0+WKRPEKE@?,6NJ4ZJ']?)E8,=B M++BJE7*]1=H&S^V <;C3-PCH<+I(N-HBH9^F>#X.CNEPVSRI"C=^IL,[LE9QNNZOB78$Y6NWA6#]'A[>+,D>GLEP\P6^4))/GGIH@V4 X M#-@\V3^#L(1(H,'P[24NN"?Z[6)4Y'VS;G%1+(B MF\(P]']1ADB[/F^61+9$#CZMGFYOAI]JR5*X'C% M*DI%W[<[6B$2CG.H_4MT'+$'WS.:(YH^N5FK .(08_.A/N)>_W<9P + 9*GD#+I5^G4X.#X]/AN5U71] MN!FC;3-JN_5S40Y\5]9:5W%8:5 T/#GYHG\\T!&Y>F;E+2=)MP3B;A:DHCK9 MGBKH;[.+2Q"8#OW69V&5D%.5C*WR%)&3O:M$Q2(^>"!,AXAWID65#H+ S>V# MFF85V%AC,!TAKN7PPDQ>/"XN PB7<3K](TA*UIFZ57VJ'2?W=5U8:X?-=(BY M#ILD)K_G@ @M(DI4CR \<7+5T94P)5BF@]5UB+M-BR"=QF\)J*"" M@CZ.@X,=LRSZ$2IZ=231I;H3,>WJY#9P.B;/.P793.)TYNXCO2 MQ$5B/(1=AY)'F*'9H%@^)@$2,(WPB> =6TCNA3.CJ!KM(]^1U%:;?6$]#/',K9&B M-1M24@4PC0?::Y\(F/+*C@7,2@2<&S>T=LH7'!#$P$Q$X.]F!L=_P9/Z(L9A M'3>9,B5J%:GT3F[NNM#2$ISQZ'QC4V/;*9%"AK9%=7!YF+P$'[PU3K,Y@O3N* MUXMH_EWHK88D!>-T-]F:/ 4TQJ/ZM:YJUN_!N]Q$8ALE)P:%)93 M(XHV23)(QL/\=9AZ@6@9+N&2H)2Y ^P6IF"<6O^U^1&@,9X-0(>:)_PN5 JB MZP"F.,:^,6E?(46'L6@+(J],P3KV0].DK@4ZXSD%M.;#6C[Z_%HV?X=@AO,L M+ !]9@\_3BC8IFBV1-7@]#I5?_[4A&H\WT''5$-2)ZNMHA2(8TNS)F=<+,93 M('0TGZ@[C/(KT1.2T\V)>9LR#Z.)5 KM3)."_.SR6M2*X'1CHJ!4=8OD-BSC M>14TES4<2YU7KXN2ET857'[YM:ABG.Y)6K/6!I;Q[ PF;F44?4EYG7$_V9)! M,I["P/( M4AM2KV?'9T=#7RXY#>WUUJ",9W6PX%GHS#1.W MJ6,[MW#,?/7:'ER&+D'1;LE&0BFK'!MEZFU%I3;)D M;,IM\BF2@:70F=<1X@@1D1=Y1' (G :F.*5YMV2N\RN*F.+RDL'W)5[,P'X[*8 M93#^>[L)L:Y%T3GVA.LZ*3+@B/-3^&-_J&X'T:\XZ5;3E0\[\>V3_6%X>G3D MZ&'7MO8'+*J=+M_^FH-J3U#4#JH"OC;*$=ANM]6MB6,#\,&6 M0,5Z"3ZN/][QQ'0!4J11D6<&IP9%Y=U&34B+#(H7!H3*=W^U_;B*D[(0KNZ< M&E6RY:'S.*&6)*G \<%8\!W@U%@@&B_0"CZMDO4_3"IQZ<;DH2SR(DAQSB4! M@2U;JC7A.,"H);%=8'IBB-@.M%"(3!'4(B\[# ;[M;0IX?'!++'VNZLF>Y64 MY-PZ1"D#[VQ'0J;D8'PP2^Q(V88>@L3MX^-R+2NRL\;B@YWA*]H9P2!!9])Q M-$=*Q9 *-. K804<26I2K3C-]*#+F"HR'U)C/H,$-3=%LGX+X)^@@59T3.96 MHMB<.HKJLJ8 RHOLET\@!T@E./?Z%5B )".I!>6D">M1B$Z3.>CRIH;+BRR9 MHC#<)Q!B;ZGUVT1U]A#LVCA^N+Q]I+>P""=I!S\P"%$WA62MKTZH..6D2AAT MSY)4&[[].E\ZTY$7J4%%Z%DY;]! I7#;)A"R^\%*J_[E'=7M>294X46:TO5\ MKV3I992F^^#],FV(8)A(.71 RE>I?7R_YMH^U.%%[M-5I(SPB$"+T%WS?LVL.[)[DL6%? M!'D<"IAIU4YM$-^OH:@/THM4I]OW43).F>77L-PF.>U\&;<+1I+-U!]/F\M9 MD$Y!?DM]\S9#J/?(S68T..O9,E4?.?*7C).]D>CT+2#JG^--&5ECGP!2;QX7 MX!G 11QBE[HXB] A.YO2#B#+ 6;[TZCWGXU.O)M.*X[90[(WG?C@,=0]F>W9 MR%8TK"5^!2A\<" BXE$O]*L2HK6!]B+2=>[!#_*+>$Y3J$\1.[UOT.--&9@! M5R->#G"%^6&Y(GA7!3.N5S);D@O/ 9ZI:%6#$?+^I^WEE< MA:2UPN6#4Y%H+=Z(UGH"L2R:L'5;1)E#[WS%M#"NI+,[? PB#M) & MC[9NJUK3]VNSV@&E%^Y-@NY*)BO-\4SJ5N8MU+WWRS#0#I@73D_Z$5QGQT=V MCO4:&62$G##E-AG!]3.DD"%ZL;.1[91!9D67F%LA)"^\?LQD)2&0+)W\#"60 M66F=PR!Y#0.7SPZV/3P<7CABM.P MPC%]Z*0\J35 0+MUK- AKR4X+]Q=%%X_:D.JN T*W>GU44=>%?%YX52S_7J9 ME$=V!:H$8"N0#3E2/0G1J+M,:9$J83+SU:S9!EY0L1FD* MQ^EMG0Y%(B3^/-6[:[&A=R17\2*.0!H]@3A= +HBX\B2]J8M<7O4DNMA!JCV MIBY%H)*W@'MS65MYU('H,5A26RPV.^Q7UJ?S0<^V#'V;X?G@R)?'+:C6%&V& M5.Z]S?I4I8NOKA,>X!-V!Y:8"[EUJ.[L&*&ZF0HKEMC'9"D<'UR[F%*J/G/ MJD7165I:E"V&Y(MP"< +["5J8^G[6YS!+4>S.:*6>,9^(I#3NCY#&9LA2H"'X@#,DR MA<'\!>(7Q,B\R^!14H/V4Z>^9CVPIZH$'TY40O-BAR"GK08H9J?[\C[GZ78Z M,7 BXP5(3?%T,8L3[EBM2Q!Q3IW>?/0U-AF@_3I<&5"$^OO)ICY&-&[I?0VA MV;G/D6U/:P:-WOWZJ9A^H/E\:"FB1/.!9O-,B^]"N"KQ(=RH^[/ "(LECQ4C M;S9350O-K"P\/L0&F>'&%UNX<9)D)O!6GBJ\#=<<[?3"(+T"[_B1Y0 NZ::/ MZXJB4(N(/W+J-23H^*SME1H<+\)R7E#;#Y/&M"U9N)CEZ'*6+J-:<->F%(.B\8T@/ZKG@+0?[RNTDISUO'M(N3:\]R.U-A M3#D(?YEFB\.P^AJE;?5?-6VKO[R.DZ22+ 8Y]P0C*D[!N#I?==.<3GGX$N\[U[W0V^N]TQ<&&+XE-LLP4]U2X58**:RF)G=*.K3X76;DZ.,P:\!B1,4O]6)J"YPO(4BJO<7&I:9C CA<-AQH!%H6=F M?%C*;5 D7>A[-@?L/)YPGQ6 _/7Y/8F+RRQ=H)^0C$\X'F; 8%.WJ=>SD]%H M]-_*FU='.YQNTOM[030S$K%H%N,\!T7^7,[GZ#".8\+HT\,OP<NK4J!7HIHY<9!R1H^Q-H@,^N6;".G9Z6=U M$DNT]=EX5)LFN;R>3$"H/D&J-;=Z%_%H\--,H1K #00-J;*,]K1ME[JZ2K4L M. V3-DD5"YF!2!@N%WA[#]9?7[^ 7CW8RR=$7&_U1L&IK43C/1#3 J$X>L7A M8.:^KBLK*E@,[NCZ=6UG=SE)P JO3JT2 M._L"I5L2=<[4]^\[X+P]<&&?%JFSCZ1FC=1YI(D2&2V(Y(#T(8%='W2ZOD?I MEU?9[4J_J1A61PZ%Q/S-@C4>_[;TG-'$YDT RY/\<'<@R,$E6L)A$#8N--9' M$/)[?E,6)025D\,J]71MLN[]MJ-[$NJSH_-^5ZX[@)9DL*G7NSAXBY.X6*Y4 M>H4?_OXH7GZ 9 &^(59F(F"Z36+X TN/IW5)V$@Y88^DSEA]2.G&$5] ,:<& M037T[DE@(8,R*#Z<##J\+GED:>/8/E.\B 2.W :/IPXX5I>.C MDD?\/88Y)51 62TN6D80W5-5LB@1X?-BEF^'&EW.6<9)D1ZI^TX1] M"_XS@X\P0]-)05.<2Z8[=@6*S:')2FNNDV#Q(;/7KHC2(<6K0G%9NAE6GO0D M.E;\,6):"Y#K'";6FS*,7C]/ D'1X\I-_:%/L[P"\1@6B\0'^=@B> -;;Z\07 N2@LH6U31!$CIR.W MHW&I!483J;9LV07YGFIJ%:EIS:DGL"DKX38B>WFQ+,S&!J9A"OSGG'_7V$QD MSN+L8E1E>4&K/P@F!7^?T[XENK X?5Y,WR[L4J!?9 MO#C"X]A5W=U379="W8^9NSTH+Q)X"3?N5U4'?$(Z> 0P;$.GO"EZ!G":$49+/R[6_T1.2]?H#O[<)\OWS)AH=#X_ZSEJ@Z:B 1>W1#UU!:Y);[4VY M#3HJ]&NY,^RH@-5AQX+=Z?)NQ9*84BX<'UR .E^&8RR6;"XF'!4J5:O?@5=X M?/#V,<.-+Y=TQDDR^C@]-XJS7J@YTQ>S'!71A[==5*8L,02;\I&E/6@G@]^0GS51!L4K MVT;[J)FAI?27&E$S A(XPUL6V*%X5J@P?'O[B M<,0D5(K&!VL'2TBIU8-?B6)S_6:T5//JA&W!\B'*R0YEKH^5)2*>.?5# MU5.X$(P]6\OU_#W)E@ \@00MA9&R[F7UZO1S3KU;]+AH!./M5&XS& MQ;+Y3,K%LOF+Q-JBW@A5F(>N0"L>F:1KX//!;M843GJLWRU,L;CV#=+0O9S$ M+8 ^F,_,D.6+[<4^:WUX#UTO<&Y:@=O0NL Z5Z(73ZFKS&T"^>V9M-IDB&[/9J6M3]?SA G%]N$0=)N&$-_HWZZ>GM@X0(B-(RIU M:SA.#GO";LL@HC4D'WR)5D)?@97PXY $GN25X 2$8+55:Z#&[>&5O>!$HX%. M;!3K[3#_/ L@V'BBT8]S>]/C6>7HSBR_-I_TG"6@?KF8R'-!,]%(C_/\6C40 M!^=[N6HYQWQ%/'M[[G\NW_(XB@.X? [6,&4!/KPZM4KL7']I/KTMH8Y-O!)& M'T[W#?EPDO>'2>.<)3U RBO7YEM+RYEZ=) 2)1PZV^'TP1#0'Z^N#P&]$]R' MS8!L2BZ#][@($O'Y8+=D+:K;(/YV@X9Q3I! \R&+\.[[WL+;BNW"===TFN5( M>W\C!N1#YN 7,'_/()H4J'R/ 7R Y' 3_1$D)WY"9"YN.RF&4P_COS06G%FC52I\DR#/$I1"3E&"\<"(>G__GPMUF4VQX%4U 44HM5L2@YJ%\L=R<<;[Z"*EH3.C;^> M#<]/COL==-I2T\YXF^;H"$L8)IX3+[,@?2#=+_^*FBCRVQ3--W$F&KU]B4#5 MZ]869ZZ/<);QOG7IA>G"&NB;#$Y C%9.I]UX1PJB_2]N,]SN;T_FJ],+*XXU MW'^ W'5/WA2!ZMUM K/][<8<7?I@L:IVNM\##+-X@$\XS=M#6>1%D$9Q.I5? M?7"KKG>[E@(O?>DWK?3@0^B8MD:J[MS =E]*7L0P_JU:F_]85/45YX45S]I\ M>Y^E"S+EVNN>;66@;+LU#7O;9;65Z8.MLW%G*<.?\Q30XHJ^VS>HYEPD0K#> M^8RKR*!_0+^&(HH%?4#B$[!1CL*V?I5;[X/GC2O62>$3V'SSZA MC1J,0[19(]=GOR-J\J?GWQ7>3A34HU#=/GEA/%L(-/L)=EQ#62*JIH7 MG56KANCZT6DU%EHPR #HQ1N"-CGT94MFGTSI;LM$K.7%\[@20Q*GME.PEM3I MNW"J V.3"05(7KSZU]4VO^F@\15FN15O)?[7:I7^P\>FB^J\>).P*\C*R:*$ MP*H+&/]KM4K_<3_217625Q)]<"G=_:E*D]^[@^GZI 7@(L8YYYC<)$F5A@Z_ M&Q=FTQ2[\5+57V9YD=\I>)L:_A+I9.<]WRA0Z4#$%E[^QH-: QC:Z9'3>WU; M9''N(-JIQ0L/SO7AV(RJU*\^#7Z/T&(I,XGP&K3?[F57=WN;DU[S?O3D;'AJ MY^9ZF] M@B2H17?]=H)QO-^*JNC%!R<^CIS2O8"P'D5H*9Q&>:NH0D$K\K; ^> M9Y,^ M7_9D=GGTS"WM&22HN2E:9KX%\$^ GVFMS&O2U5=6E0)V>G>A-K XVVU5>%XX MFGT%*8!!@J0=1W.D:+0+0% 70)5,I?H4LM.[T2Z,ML/HA3<9VLX!I*$9DOD* M+$"2O6/4JJ0JU*9PG3I%=*&T#4*)QYC#>T _?)6.'?UEGUN8" MIP'KMCJ-8:>$+LKUXB+SYW'B?;B?_&FNV&V]4MCW%;NH/UK5 MG<$K]GZO9;5#D&VE]?##KDE)5;EBKS3QC\M08U%7IR-+RZ1^.#*AN,\[T$H+ M/MQ]_CR]RA=SKB?=2V;W_2EN7!'28[^SX769'[1N7"N5^'#C:M:O@FC%[Q1V MYLF6J\.'2U:S,<@8V<#.B<7[[:=<*S[3JQR;=B[=VU+Z/>XF)''FK&%=!:_OV37:1$+WK+6:(7"=N6Z)&=# M@3U%@/82=GC,J^N9N#^"I3-RO]8YG%L<>^^(-[V-4G2^\N&I3.3Q M,$6C=$^T48Y"]%2H\N^G<]]YDA0CJO]9S58N4F1?T,\$R0 MI<2'2/+0K:C>ZV T& XL997S?O)35(TDC41/)KQ-$:7CDEF^PN3Z>*^H=XXA M3@R,0U:_9AFC9/DRF]IC33;3#EL99S@IQ)BFA>L/-$/%.7B$:*9YPM9CSFS: MM@FZ-[;C7>OMO*JM) [MK4PYW6CG#M'VC5!4=M)VRN=8;0[TJ=R"S2&SE1G' M-S)=S\&N697.T+W[TE]F*=ZQ@S1$?UZGT_J6+<@2=9MN_-[_:ZWKF :5UU=W M"J/Y]>QDV&K/PADQ-QD$\32]+"%$JEA>?X0S3.X3^N(E^1=WL9/7)%(Z?LJ1 MKSI&SV\!R0>'[+LLS^MNO!R'(2R#Y!*-VR7Z$WD0FT(I!)U+O1&*W6W8O"J= M'= 9<&CFC#6V,+^C'=9='+S%"=(F?[@I528@1FYSP+<:<>U0^>"HRY9X7&ST MJ=;C;:L^1>PV+8F9H<8#YH.?KL+D<)^EH8DIM&Z'SC/[,42[ ?3":78%51K2 ML5$08_AR;F>I$[_ZUI8:CMP&XR#Z=C\M8DBDQ=YW"@$1[ I4$3[*#I^BNB%+C):\*Q>7Z,DZB M06I)G4)0I37(<[1-RN;O"1!Z7K=N@ZP=1Y8LC6I[#>E(81F@="":<-ODT$;B MM!]AMHAQ]\QOTS AKOUE6)00;8#$A*G5)C@LN?Q9I*HE."\2XCQF.5J2\5T' MQEJCO@ I4KO@ 9EV#=">Z=3ZU9)137Q>I,-1.*+02RK412$(\/L)]/^[G>O8 M;1+5.'Y\T<(93P+6BW?7V##6,U1KMM7B9^!T%Y()OTQ5FV=1!C .DJ\( M<#Y.(_P[R!_2*ZQ0$%53#)ZNU"VAZDW2ONKV":=N]E$-K!:?76-WL'M0W*8% M@&@CT,Z:W:A(I=\/,UE+1!+W33%%7H.C=N8>/P]YEYOJ;8F>:K6*U M<*Y>L94H3*1=!@0#-Y*V].O:6&=2T3+CG(F=ZJ;5"6VMXA"G"ET+U<8LQZM= M0W*25U7:G:7&."5@/ES\^64/6&O';58,G27?#&CQU6)O6]ZF]S*2.L_2%"15 M3N#:25!8ZF)Y4Z;A7NZ.ST:#LU&_@0X/:,\3-!*DBR3>*?N*WSP:.KV^$&B1 M/5SX('SP&.1GKA?U)&XEBLVW.4U,D (:+U*:ZCJN8/!VADQKQQ4Q#VRY_4K@ M*,R>N#[,6R#&:]I%SIMW=M(I/L;SR1.0O3LZL M:OV<<7"58O'!G6X]\U9!5R1[H&K _G8=.G'[$*NOLIZHP_'!F:XIG&H>MD9A MBL6;N'JNJMD4"?!XE.2P(S>NEQAK)'GVKISP828!<<)Z].SF-L%PVQ.0&B O M7.8D[Z,)6)/4I#"=/C+6FC=52!*_N/TR>MX'10G!7IH\3WI^R8,J$D3L!!KR M(:/6 .EFQS[:WDZX=PDMD?E@,>UNP#[V+HQ3R!$?A#U?@N_!%)##79 $4! # MO5V.B#;R=WAHP;#TY\R#G- M84G#>'#BR=,])@ZH)ZXR0:NKNM6Y]$3J%;!/W.R'\4"#))GQP("YM(=+MA,? M$NVIS&M2%-9LH;U>Z)RX\OZ4ZK?M/LE$K MB>H=6[,TE=>)KY-:)Q?>L#&1F+!<@IS+O0/OXQ4@6+B:A<7G^GB6)A\\,OV466ECDQ[' YD%:DM@9+UV0VF%!' M9"(Z5C+_W&3PD< M?G$5Y]AH@6;FATGCDR)3NE(]',DX.#:Q) MW+JA]1OV;LR'[?3,Z/#= /M@67\L83A#DM^R=%H .*]_DIDD MVS=&E#OHT6S9A7(#, U:.4WL(9[+MSR.X@ N10&:FZ4(%DM9,5L=Y;O0P-C- ML4':"RVL/RB.+=PN1T6S-%^J!6YR="74ZI;P]B((.^K5]?';C()E)V[[OL?K MG>-7D$UA\#Z+0^$3G-SR=-#:R1;B9KY1@VO-+"\CCJY%3;F$]BQN>8)D:"GU MEI*-4:YD!C%2.*Y,\*:)<3W3V6)(-O?U[+(AD_3Q)GV+SH*M#0^32PBBN+@)0OS*!N\4+JM"%SX[KBEN%P4I8C_2 MGC*DO,-F:2CU99%5I4!=G?:5:5!GCPG.CZ2EUEGT91:V2Z=G+\V3U$D%B161 M;+HW"E)#B@=AG.8WVFR<7KPG7\LF]P+<*DJ!N [NY"A7QL06!"_>EN_.A2_S MG0E2/'MGOM6L()GX6K=%)Q@/O-2-SXWZJO#B^?E6XDM'M49K5!VNG>3U6330 M*[84X<5+][[T"U\6!'\ZB/3)YI4%JS>W*)QJ\A% XCBWCDM^F1%L64IB$QH6 MEN^S.)Q]!Q!0P""Z0@:#;>>QCS."WB"(L2+T#E MMHF0-P7'<;!E44E]'< 4$;B6]TXA^-G4)["SW/EYS\GNPAF(R@0=\3JBD$8N M&OT04=69@\A'XURSYQ9+VG*5*=[U*+Y8LAN0[)$M?I52XL%NVE9/8W;K/A3J M0PI1MICWP5S^#J2L*L7I>K/=!Y%MNA!#/S[$]=OO![YLKKWO$$;?,3!X:4SV MUK\CSO*GY]];W HSZE&D3G-R*(].V86O")X/>06JZ"- Y'QX%^;WE-:AR)S& M_'0D3@[-7J;5^RP%U>=_!! &(N\*<04JK-,WZC1Y4,1EP(N10\(C^K'$QH?O M2A1PBJ\B95:FK#<&C;9/3\E.LWCU=. WJRZQ MSR3#JGB(A7H+ MSP3)9O=PEDUR29[D7^Y2\3_S#CL8Y.2*/ M>;[_X>NO/W_^_%6P#>,LB0XY^T#VE9_LOF9__XO\(+GY]JNW[)_LIV_?'?WK M(7HY^N;M-]^2G]_^\8<_O/WA[3_\!_F_UY_^W]$1YR *XU_NO8P2QG&<_?F+ MQC>>[]/HJR1]^/J;MV^__;IL^(5L^<-S%K9:?_ZV;/ONZW_[=''K/]*==Q06 M8E14O!L5W;OOO__^:_%7UC0+?\@$_47B>[D80RM?1-N"_^NH;';$?W7T[INC M;]]]]9P%7_ Q2).(WM M$9__(7_9TS]_D86[?<39%K][3.E6S4.4IE]S^J]C M^L!GD??_/>__W7>\_]\4O[[P[FGT!>$M?[PYUXKS?:NO@NAK(!ZO:1HFP5D\ MCMDN-2S7M[F7YA/X;M)#<7Z7Y%XTBN?G94^"=]'_ M7Q5M:O%:W*0T2PZI3P>))@>L_57O7O55MCBQ%GQQIO'1C[=?_)/X._FY;/$? M_RA[JY@[3MNCY:5^^27VHX6[HL77?L)6QGU^U&)TFR8[[>@4GTRT@GR]U%26 M;LAYO$W2G5B4[[S[6@\ZLZIO#C3!!GZ[;-'/8:0,TB5W.NK-8_9WP!EC3 MJ!R_YCPJ!V]!7:SV:>^9QVM1RDY;8.WL]UQ9T MUON<:J:]:$A$2\*:XDZ\9H3[,Z\9WB7B<8PDTU; MK@"V0V@;[E8*0Z?*$.75Z#...TZ$M#YU_*M 4*C/3F]"K0\Z/\7GZ@ME1,!+">@UF&70NA* B@FQ# M)"%I4")[% [SHG O'"9ER=@O<;^@^276V1M\<.B;Z.I&VQEX%@STHN9E;,=31\8Z#ZFR>?\D<%R[\5FCT-# 6I(=%QK+$C9G,CV MI"# -1S&D>];#..P+P:/XR!@,YB=)@>V'3+CHML4%! ]/C5(*-IM2-$2%P+J MT>W/O7IHEW,UI$LC+1"#W&WNY=J I)D$UKW0\:US+(KM:45 ) 6R0V$W/N&I$EYOGG1=%)XXU$TU;T;*=LASK1I8Q62K1G6!V;ZE_B%EWWOWS?U=F&MSR/K- M@.99P5]WDL7O2;(E[[YY<_\E*2FPIEDWHLTYU@WG A-\F;#-!=]?WK[L[I/( MD#JB; DTS6HNNS-]F9"B&9'M4--)#"/;G&O#L"XPW:UO:2:ZTP9HBKN<]=2X M-;-8DZHF.MC_#T!GII(%PG6>Y%_R?<6VV*F@ ##EV>;8B0[0DC6('5,(V[%A?*05\B M%X5_,J6> 0SM)E Y)VV^>GDF8KK9WU'G5S5XK6P2Q<@M,(?\>G9T_9C$]/*P MNZ>I9A[[S8#F4L%?=SY%$R+:$-D(:TYU@]F<5]U(+IH=9)S;?C/PO"#MW#:2 M@I#G5C>8ZG0@H+DM#'[QGXLPIN]<5N5V>XQ%N<.Q;4TN?B"\/;F*U[$HJT9= MNR:KAGPQ6-QYS^MF]X/F0 M'3UXWEY"@49Y5OZFQD3QB[^*( -GXNQO!YE[MF?.2IQGQ\^AZDC/D0X )ZX2 M]$R):$;J=N1GWA+E:OB@62BA,V@*0$#48>!]LO-"5?#(TAX0-#J.;6 A/\NF MJ&@Q#G<7)<:Q!D%'(Y_U$]5X)H:V@*A0<=HO-%-G').?9;,>&B9S&M!M&(M< MSX^',"@*LDUA^RH-PMA+7\H%LI=K=/B>+%= MP$68\0ROK#R%TJS?-@)0_U_#L\;Y+UMOZN-!O)7;;>#[GK]IU)? 1O$9[9*L M:@2%@2YOO7FOIAEQT=6/8FMRE4.X1'F7(-4NHIV_0Y5U:7#4*^GR_F:YE29O M%/\;SMF.IFSO'9/W;,^5A7FU-**N,\H9;A6?Z4XO[";Q:ON!>1&Q'WK1=2+O MHABJ!0XCQ]@RFN7II:>49#R/L"(D)25R]<$QDZ7=4CK,% SR_$<:'")ZM;VA M3S0^T.P#$_CLF>E^[$6GARQ/F")GQW%PD<0/%^$3#8ZSC.:9KM;A7!U#HG7J M&/1P7'3(85QV23B02-DIJ7HE7AP0WN^1Z)C(GC&K+M]/B7]2468QME6="A1;L6Z* "$SQJ M?-P:5U0UA@P?J7BU 4.SM8%!])P<@\9AM*CH!6*TD("UT1>&:KNFQAA6^<)0 M8;?V@4UE=8'M\72&42QQ#Q-:$]P#! AXI6/CL,'K-@0$;8_'WD:_<%BU>S,8 MK#KRB8E+]71W,:F>:T \%G>:G6'9:P^.SC['ZLG?5+?.UX%6.]\EOYYH_P,^ M>C7@4(-8@PQX++MB& ^[=LS.#]3&FSFCF10/[Q"_!=/5H-0)G;"[+2][/(X# M_A^>-_#D12*?)#_UTO0EC!_^XD4'4U3-D1YR3^8H4<^R,0(1^Q(_-$@WQ,M) M24T$.=+>;:ID/O^!UJ0X&CQ6C$*S=<(P72>I2*>C 0ECDC]2DI7NM-C-;JL M_KZ(<*/E0F -@:#81LEG5)LXR.CT]O=#+ Z(#;UBXYRZ+N^JQH#64L7;% M6$NHP>S_(D#KDG$_,+J@(@&'GY)OW7ZM;KR2,(,3]ZS1T>G*MG%ZN*@1K<<* MM&-2<^+FFS3;X[@G+8[-'DK=%-U)<> Z9L!>3WS"B!&#.] '" RD]_PI=N;F M7U OHS?APV-^M?TQHX(I$[3-=) 0MTC0 TW9G@B"#1$D1\GVB!%)%4!"_4!! M*KX/C&\)?+9;C?BKSB1/2%+)&?'^<)7"!64]Y7"!&(B2G,#ATST.]ET97R$P&B&(+_UV$VR$'+26(^[+ 8E\%U!UM< %42 :<1%Z]V$4YB'E^=HB!? QB0(V MB_)2M$.0Q[T+0$T9(%=O':A)*XW)7] #03-*E/%+7 7Q[X0FX53Y'@O"KC8- M12"T9@V*F5KH<'3(*?[8:+^J$.I0.9IQU*BF78F&N$=4G9 $%U95LF.+K6J( MH .L.M[5\4J-(B"&6H?QW]Q9K$0![ A21EZ-\'&!?G#_E',\?_OVNV_?RAOF M[#?PC 7T8K*K[[O"8"HJ*;*(FWS+8VC)L->P.MT<%V5?-J<%SXX:Z;_ANF[N[ MAA/U!-JOMG?>LVZC-KH[J.W;>'E[68]U3Z3HBI1] MD49GI.Y-I 5<;7FQ<>":9R_B-9(7XO@L#F;AE_6S)+,CW3*=.T9\;Q\B7TW2 MVPR[^P5[?R0(Q!52+[KVPN \/I5C9[!P6@K(VR-:KGN+3=62\*;\.NFI&AXP M,![%^9XU/6*>V_)2T; MR;IFF[GO\G\O68WI W?1;( >QG$F.7[W^^\WW__Q&Y'WPG_^X_??DJ0L])_) MLOF>N.G]KX>8DF_?;@C?6XKV[ZDO"@F3;]^)WWZS(:SYGFT(PB<:O8@R!WZ2 MH6:?Z2'751 ]WD!TXX;F7AC3X,Q+N3^2-7SS]W0;^J$I$N5"#*@[3K+T;G,4 M1*2D(F^:^Y."$"FQ?I1$3?8#V0I3%=P1UE4-=WC!>$KUYT46 W^9AFT]:)PQ MN\/?O][1BR3+#"<3U!>E:#I33A3V:NM/H@LA/RAG?SI;S*DB#$K)81.)$E M'%H"AZ(35*=M''1[SMPXW$*_U62M]=1KBO-2D[;.4>.AIL*YVY#S+#O0 *E@ MDYWGJ[;SMB&__WF^S_\7OAR MW_]^\^[;/V[>_?X/E==WR!^3-/P[#>2-@E#(S9U!YM8-=@97\N22N1"0!H[0 MB33NY2E-1#@I-?:"CZV\FK54JQPDP7J3GQUK5]IA,W_NI[Z0E1,5FMA0T@*:D>+H J9O?B9;*O8-H38KF&R((EJM6YYCM-DP*\6?FYHFVN/6-[-A1 M[&ILP$&YCN-8@Q%IV;)S[7 +![\DXP#.5Y;:;(&+[>(-!L('@1L9UT[ @ 'S MP$Q]UYKB*\&Q.X21T:M)'78PTQ9"_+1\@^DSY.0CNRB#9;E]3-)\Z73\88>G M@V6XH%GV0Z7"O$2VHOSW"C+Q;:N1DTI +TINJQ'6,F1>?]"7'>UZ8V 2:9UQ M6&!65>[%#9<:TA65=S$CN%'6!1W,KNSW$"Z$4%T*60GTC?@:6L$%YT%"ZP/) MG888#Q%J'S"NW_13OT,,L_6=SB=L+JUJYK5/#L*_9]PXP1.JG\G#6K@AX'[*/X+Q)M_8+_3,D_6DJL"C_&S%@5>*!M^[677J5B MF0E$HL8U305#;G9>3XUC\PW2F.T_(R1)2B2I3$\BC%BJ"/IR,%RLUM)0I2JM M9'6P8Q]G:74;SJ3K3IG7)^OA[(?'3:? MV@WKL,F$>4" YG4^MP&0G7:03P=T..R5$:1Y^Z;!JBZXNW ?L3]AG:VY\B>2 MQOCSK/*^.@MW;X9^^\Y[/G/3,_](3& M=&N\_:>E 'U11\=U_[$980M84U*T)6^*UC->[AMV^CN8^[Q_20KVC1PC1OK/ MXA@! @+K\NY@N?EY'T:'W+CWT%( PEK/=:\R1WEKM=J!;TC1&L<8N[->_$64 M]A%K"5M#Y)Z#>)VENEGD!5,!+&CJ*H %2B *\!/E#[C1X)BM_-X#O3SPVU)7 MVX(5N2^Z.N19[HD:+P;%&-P3H,(,E[*+QK('4G1!9!]\*U+LY!OTR#HVH[1> M(6U<25OL^I.:GAPR*@JG\&NM!Y$UU5#5G4B>1JUY.!+C774="7"H.%IW8^AP MT=Q(!1M',W"O"$*Y7!??K&I'-TS$(A.W):AJOP<<8;-!3!%AL^$+-C6W\#0S MAUB:@08C(5?!N3X7MVR,?H%U'/NT:+R*O%4=9+0IJSJ\X"!]",)QD>V$Z*6V MXG.-L)4/OPD<;L\]%Q'!P'NS .N8GBI3 * M9@S6PDH):#OL4G0A4U"(]-LV36E:L()\TV3QVK(LIKN.YP*CA?GM;]Y]]_9/ MBME9@VX[*DU7TQTU!N:,F4:LNP?&RRPJ_C'UNOA M0*_CAO%41>N?P5BT JL2942;K(^/C M/7VB42)>GK8KL84.M/ZF68)^Z4W9OBCD55%@:_,D.8*&'-A:/=N$K$&QG?2C M7T+403G@JGMH"B;>4#_RLBS)\S78)8J M%?E#Q;DJ?[7>I?HH."?0U4A 1UE=*Z0=PGXCF?B2<#8VHJ8PKSA<]$AXEQO2 M9:_YK@_7!L(YW!!OF[/^T:JEX@_PL9\?O#1D^Z,'+XPSF=E#LR\)?Q=HMX^2 M%TK)O>R+#7;]<,P*RK7 Z[^R# R\\J.;6-6319Z?2V&&/D6V] =78C GC9F+ M7>P<[:E?.9-?%"Z)^M4S_!+28(/XP?1:5A!NMY3_FKX2LS==)X=8M^D*"7O MXY1_K6R-<\Y9^P'OC2,E8[S?CO!W7GM1]F;T\JYLV&7I[VB9>%O@&1 M _O!O]6@E7#BG0;1S:IN- R7]-=\G\&,;,?;#&98H]S)LRFHICWB?3P=#%6W M\1"URI5M\?O7? _/J A&^$ 7 #GULL*?W,=#T9 !,7Z MJG=H)\-0JD,[$S"F<[NE/N/B[-E_9$-.;QA?5S'GB?^/5V5]\B+&9W;#7/\T M])G]YW\XCH/V+QHMV9XB.O"%X'V8[9/,BSZFR6'/$R;"3#[+=*!!O1$QV>D5 M, >Y**Q W/X*))CBBE>R13A?_'"<[C*J9PS-]'E86] M[7[(,I^#?))MF?'J92;5G^'.E7S9N/M7? M7?*JI^N;<"C#F%;#6&U0V&_YS\(V;IDO1O;-83R4PU@_\N)5WT7=UR^IM[U7 M[1946J@2=([L&4S7D$Y@B]>YRZ8J9S;0>* 5N9LFY1@%1R[Q-A"RBOIO _&Z M,EUT<"?&=+9*W32L82-T%+V6PRR"GY8JFU51]M4MP^/1/%Y=49;0,MQ)15U9 M&F?*O)AF;$Q# !EKU/'UM91G-9 M:*#QU#.JYS4&GYW>I%YA6'=<.4/5.(Y.CSI74 MI"#?$-'!6M3-4;B63(6<3+B<-^=.&J=%N_ _?-3^ XEE:5UNV<3SF]EIA(J9W"77O9IK<6DR6W3'7MK%PBQ[K MY^C),3^UYIV2JRUAW1+1+[3WN\ XR,6]O;:+5^N;R[I8YE,A?K+EH9=B^4>[ M%C2##K0N#ZU% 9RN&"VD"$WCK,/"BP8)*#>7NH,@KN?*940(:SJZ<2/'W8>H MY''=@E)R0D2SBM+ ]6N R(MF@,&!WV'%HD M8FI6;6/J=6&X@JE[P=AUU$@3=">X\XTZ.$GZGNY3ZH>R5,0N2?/P[UY11(+M)M(#CW;S M[+ '&OMJ_9NA3RB'?J+D^LP>\6Y@V<.&WS:J MI1;U?@NI?9/48$[\',AO>?&K@;V3&[\L_(,12!CLQ;N8M)NJA%=1W^OJ/@H? MM.G^0SM ,586F0Q3PXA)34T*6!59Z\@#VR8X(T\,'7N MYK82?=U980[8=LP*4I(NXDDS6W:D(16'(@I0(6H3E>Z1(%=^RA@':4CT$6ZU5&AQ83@OT M+ !+FP#+JXGJ FQER_(LR_%*E^%YEM]5795PE](?L]Z^CN5V^C(+&IQO6IKE#\C=K7E)1?R%TE60D20DG%-5:!"E6WN@HH>?Q$\WFNH1K[ Q_UV>6=>#NK^KL M%01?APEN#;Z&E>CK#KXZ8-MQ5^@ ;)BEL%B2[Y)CGYD07M*9,R9^9UH$C620 MRY^9_]["5_J/;)=3$) &!5;"XT I1*,LE+7;V?K63*K:5J\$X"&#K!U!J3;"XZ5-)OQ..!N:S95W6R M&K4:(F97R?:5B/M:1%IV('U-X4[O"S=M59IG!:]5#ZW(79G3.8NSN5(G("!JS_EA4#CXH'^9B8-/ MP6O*)$-1H_SD(;T@15?MTIGGK0RM0OG*8P\PILII=I313>.X1J3QQ555XXN4D?Z2$ MLK_Q\Q?VHV1T(?EO MB]GK7_2Y5:RN@+\)FG?>M2)*9"8XI !T&T(^G=3E ML5<-5S18R8MAZA'MO4&C'$Z8]V!\_[ [B'32.YYZ$\F+R=5=PD^4O_UH@()K M!Y!OMKC*U#]'J@CY75X:/I3!1/^%-.Y7'G?>-KSV1(3G9]DQ4OK'+%)7TC:Z M*!9)K7B@SZ ,@FOO89-!6(76/UD9*-GM4_K(;^P^%6]V#U%!6Q\X6FB5K ?) MJ]/SU6O9<*D:BE;4\&I2%X]UDS>1>.=I9>KFADZ#QKE!$^BM^=P+8QJ4S[M: M-4Q' /H.O89G1$^WH1^N8\TQHZ7_GKT)*D!O_)4W M$ZZ]D&TVBFQK^SIBI@-]=<\L0;_V1747@Q,$-A7Z!R0U7]. MS@%6((K1NJ9M50=E:T E4'.KO>@OFB'#?5:6(8%M0$87S@98P+_@JM$M\7[. M???]G!LJTR3I+4V?0I_*8!1_X/$A%KW\Q8L.II<&EO\TULNNRXQCS[I?GY]N MB/7UJ2J"S>LXG2993AI]8ZUCX(-UN[(7K*#TSO@:ZX)*!_.L'#>:_$(<#=X? M4N8?2YX$(Y?TL_B+*:W!D1[RT3E'B7KP%FN?)"22LCC!VA!!O"&,7#9 >Q1D MK'#U-=4M2=(@C#W42D2CT-=[DVX(]&:IKZG7]^-(],AK FX;V^:/;.?)7V>^ MU#\&,E?O\)4Y)XZ&Z:GPNX1T-EZDL?&JN^?/@S2C%/P+A'^"/]..6MIS[L&I M168:[#5$+A]27T5EX3D41%,:=#7:,;!NZ-JU!#[K6?A&V=4ASW(OYH?L)O>B MWQ;Z_=H.ITJO.-N01BN\1$47AL_$'\B]%PF'X(VDF?%IT>'9A2YLGU3)@#;. MP5_156%9^8"N"LAP;^#5KH1@[]HJY='G7=KO897_G$+B?] MDKOXLLJH]XRSKY\DF:\_O41_A]<1?1VAA[YA;D4B;V@H6HWC^CFYS:='-'7RF+D M74E-6XC:_8D+Y*M2O<&R&PYUUA$GS>T>?\)%*_!#1/MX#XFRA_+UC, MNY/U0NH.Q?7)1I=$B6/>+1']SI^RYWC(/_-@W#U2$?/T8E17;0Z(=[5W#GQ/ MR QH?.CLB>_!V,?OZGK9C#,V]G*=>A]F?I0=4FI8$V;H$RH+8*+D/2^NH96R M/_%L<+/'L@9$<:F\ZA5YY9D-!ZUC[]6 P.FP>T$P4 D&;KES!1CD&2,OBR1[ MG>M)W3$2F=;C.3I=LVJ;EA^%;GO.NKWD:FQ/YT$8BE=EP[3K\\KPOI@5L9#?K-BFJ MQ+9DCN@#'6MJR=QA5],CKGR+BK@^=3*@T4VS#%"U#7T7,K9Q M!\3+%=MV>3PT?"%>/'0QES9"<.P89% C:$,J$B)I5F X1\C";V,SB KLH)I- M-RRIU< &)*BWNGA!+Q[N./;]].!%+OM^(Q7L:UP&[A7/;XG68F]2MD=_)W)9 M&8"?SK)A2?%6E@U(D-D;6<%/R0X-+D+O/HS$ T'#(A>C>X3/^Q@AM28I)"-% M5S4\:4 :O:TKR#&?_'>I%U#24LZVA]_H<04I,F-QKLF?&0MRN.S*QR0*&")D M9=_+)'?9)-@(H?,E33(H$R,+@M\53Y(33K.2I<)M4I19@-890435L"5B0!_H M6',S@WK80=G](954Q@K)DTXK(5>2!3\$BFYJA6VWZ^]?;=MEE$0= UZ(*ZL+ M+96/KCK8]:D= ^KBY#$P5?%2%#M;R>HPS]1W83[/O*\+^R=-5EW6G,D]KQ'] MVE$8#'_T+8DE1IP]1EV'WJKB"Y-$+ C&KKV MN(-/J4;NR)M2HK=12O.:K8U)'-.HU%OKQ1Q7:K 2NZ[2F*O$5J0-HXQ[GV8Q MP?!*WPX"7KNT+3SJW$K7+H8^ ;Y[3@U_OR79[4)9)XEG<#>=W4%I@P/[@;R1 M,%#"_@:@HI>9^]J-S2HQTV MWW5N^B] NDT,*L"&F?5!O:P =FY&SH# 55GS&:3DS1_#?48^A_DC:0J.''\= M@4]7?<.V[>4+L&QK(LX!'6RZG@10J0Q\]QYW*)\89FUE_4/TD[[U[^3M6TK!JT#LMH&_I>EJEEW%'PXI2FK:=!1(PQ MY:L/&72O>0C_91' +>M9E$@Z98XC;=<)6Q/T[1G6-@A!EIGM5,5\D?\_H*"L MM0/XTK%VF;1%8FO2C2P$^T)^+OZ[ F]BNGS-\J@KJ #KB#Y-K5='Z(&HTR7] MW& G36+VHR_RB+.ABC6\*T 5&R%G%XS\Z>1FO>56)Z!J%]!M*%_;_G@( UX_ M?UG)M5(3+TCV/.H3QH2G-&"JYE@D=Y5T+(Q!U/7'C%YMS[(\W'FY,1&UVQ!0 MU7H\=N'THW2#JB9K7+)2 M.3J%2G":*ON@Q87?/B6L3U)TNB)]660P] ,A7^8C,1N/%S8>Q?*#ECLUBP:T M4JK6 W^G3*LEU,"K9W_?GOW.M&_(7G2(\/ZW_TB#0\1O:2D+:M[Q0A).89F! M'4'&:H;*V O@%!WP9=)0IUCTLZ@)G+-DD_>VG@&!IU[0(T4NHL5S]P*DB+-\")I"8M\O5HW2QB MWM",,L5X;,B+&UD=ALE^H'48((&7/$7)U.'+G;T3E*7.03;3,J>IZKL279LD M9:UM"B'7L<2Y E._O+FB$JW$:UF2[.63EQ]2]E]GU1O5&W(Q6+NTCA5B-U7I MNI<-*3M;C6+.(WI30[OU<3\<6_U91Z"[ M%*5U1#F03C.&>!F/ 7JKH0#531W7RJK&&\+;KDB]7+EON93\S2/$NWF.B.DK M@!$N4QZ4JU;)V\-^'XF0C!?QG>"'*/E\'C/W=-]=N&_L.3OV&HZF#I);ZW??4#ZXJ1Z/" M<;GK<2SV8J*$KL)AE$)=?:-!LJFVLMC7#("$ 2^_84>9LNR&'6(HBN+LN=L( M$=7$:NMZP$+W&$:+THM?12K[B\]O+)RVGD96XG+C9*E-BO M3@JC'\!IR/T+$52K49(10C6VOK<_DF,_#Y^P2X*[X4L?S36""UA%SG;[*'FA M]):F3Z%/ZR*NS3*OS;HU-]1/'N+P[S205P5$[==ARC7[-U'45.6 M_PF*X_U]R+Q^WO^&'.]XJLH*]1Y@U!I[:T5U9M3"5F#ZIS<^"RD?3.D>;C&O MMC]Y7 GRJ_0F?'C,CY]#4\*Q@0:R((^!\U["CEBR&7R+UB1)B6C/]DZ, JO, MSH(2@);9L6&H5U''!B \Z+]/=E[8BSS9A"VIL.%?<3\ /I)F32HPHQ3H:M#& MDY,BM,$$[+Q*+R>K5ZCS^,2+^+VCVT=*W<\R1_>(XG@.E=JT3RSZ(G5G_,I4 MT1T1_4$XD:X/2\TW!K636 8FVR7NN$=]F<1'ONJOZW =1Z%?[QB.@CZPPK?K MT;.98+OHNCS],%5W[@M%R=TE-:EWYZT0#FP>$VH^P[&Z'>($R6NE_I0\R4>' MF#6[3I.G,.-5LM:AMP-!K-?8@0B>)<>B4W/^CS;-*9^E T5%:) M!TU F)=UA,P #5XT9_Q+@F7@:?U\(S^+WAE+AY^\?#C$HA#@T%RFD=W"Z_!8 M^8W.KZVJ^LD+*3M&7RB7&H]ZS1PR'"NP+),T0F-_\-5AH)7"5HO?_N;==V__ M5.A&/CYM:*K]N^0IU'1FZZ?N='6V3R/[U"F6W;XRN^/M%;ZO,+22'-SI[]Z!#0X ,3G!\0'_)"^<9405[B8S@1 M^/G&RFB:&I\A]7=(^2'"X4@:GQ+5JU2%FVU+.%( >V;(&6+;,^,-NIA+$C&Y M$AYA>**-#"#^Q,LE&W7-GYL/! @(..GF?!_#*0HSWUCU'PIJT+:>MN>G1_-&+29M(JN)*]&]N6!G*L\R,J2GO6>YH&OI>_)[NDRS,V2Y J'CVB>[N M::K0$"CZ">CXR00)?].R.]T!5RL=QTLL..@)=\;IZ2X9QKD!05-_ M=?+4"Y)VP1C=$R "ATNY!#97D [4]:6F>+H M.DT>4F_W(4E/'\,H2&E\_$"#$YI_IC3^P!!TEYQ%](G&9D]G>K]0OM ,(] % M=='EW2=2]DF*3@GKE93=$MXO*3HFO&=^FUKVC>E6O;(1 ?/0YM*5E@^W*D5Q M\O(6A8=?PF-?P&/+X.&7\/ X/.X+>&P+>%#1]TP.8Y;FC>6=_:M>VMD__BJS M//T7C6_8;P)@Q11\]5;9XL^(?IQN]$IET W=X*G,J/_50_+TM5]T)J>S_%<] MG>5O_GH<1<6'^>O&NKL0YN8 TVSAM[>UBB)2-T-UDEQ&NH2!RS"#O4(6!B'? MPWK5;5O+EM! _P*F8[SWCF!U[SHC;_+LXZZZM4NXY##@*7^]J6W8S\V?'7K M[2H78DCXN,ABP=$*=F3N4]*#E/-\P%S9FQ[TO@AC>I[3G?&"ZZR?@;P4.._X M+!&@X/T3\0'?Y!UQL;?GK+C T\(+!G>W>?TB#CR0N<%WY1CQ^T M[G9)+)9 _P=: '5P$62+IQ*&ID"4U*)ZYR"3OHS.&HQ29X/+7FNS/) JHDS MWKKJX@RV"<'P3D#K+@W9SZ):B2[,;:* "F ;N>Z7$^B$7T5SS7O- +'FY9@' M"PO;4=,*^ )!QBF4.V[TR]!L+D9_+]HC/%+&E5XNG^\/*7^?33 BE]5+^EG\ MR1BM<>P TI5SE:GG%XE]MZ0DDK10BTV1X+(A_/$YV0&2GX0QB0*& /[B7_YRF>14_/9V'X7Y:1(_L3_QNNIV MY6105] +RS YE5:XZ.)W1';"7^ZEFR+J*SKBCZ.471'1%^)BLPZ!P1>@$7A6 M+D4CP+S8P?L-CQ0:3MT;?PM.;O%WI)2[.3B$@IMRCIN 4T[P]"2V>*D2$W$0. MP2"GFN,6Y%03O!CD^$(@3/]'RH-@^T>^)!C\$D-[("B:..Y.>K,)LK-B'>@F M!JRCO!P>Z$/WN]J$'TM[*#P8.#;C =G7L0YU"Q&V<8;)W?&RQ^,XX/_ANZ@G M+Q*I$/+!\S!^^(L7':A#X8V!_4!FWPR4L'>HP!^7D^].L!\:76R(EY.R%R*Z M64FMCE&3VLN3&3.C()@]\>)?KMCF/DB];6XZ/^DV!$1=C\5H;*+Q#=BM0VH?L,"AQ.V2?,. DYV@I;LL'&HC MA\6-'3[%D1?N4#=@JLGNYT#W9QH2B44QV^*I(SLDN^WAL=GC6 ?2HF'UP#PJ M7IVYIBMXA-2(#0V"U<"8X'H(3;ZA/F7[ION(9GJ(FIM#N2%Z?M4VJM$4!Z&C MN$[KIFANB049+><$ A9.+LJ$@2;%4W,(!?1*?TK$L+=)^ME+ UO!6!,19"D] M$^_=,:^W!:39? U56>UST"N59YT //!<.-Q;MQ%B@^C"<+=<"Z2+=5P8=YL4 M)T3U9F3..$-M*9TC#DT2M-A#BV^'*$3##9A]]9?7N&YS+\V'A26,0EPQ/X^? MW][+)T 7XOHL#F;D^31*,@//> &5/LS-H96%,#XNR.*&]3KS&'I'4&4N\'8* QB_VI+/CR%C_*AZ0WF?I*BOP]F 8E8[M%W#&+0T M%&[LQL%5VZZ]%RZ"- 14>_703H>F?7T)7+2PH"(EV1K4T2[)4<5WJN$;3QTU M2#*KY9(P&J>> ^#44--]9UH6T]?CX#\/62ZJI\=!69I3%&J*A)QGVRU5GN1. MZPY-NYWE=5'ZNC-RS+,;RP*LC?Z([' -YF"TZ$=-07D:9UF_D^0-0:E24#S[ M,0S99K." .MQUF8ZO!M&R'.>]<7,TV42#_7?FR1H9J;%MXLI802E;[8&6V'D MO^',LW9'_EH=^CYXS%J^$'+&:;(;@FIMW9"XAM!\^L@O@-.*J>JA>_Z'^&"( MQ-GHX#33*D%_< 5)4SLK*E*0H>CH8$G^9X/Q5,TXH':Z0:FCHH XKN^>:+L<4DT'@782/,2:#O_4J$4^^7,=?PM\EQG\D1"V3\(R,%:> M@Q[ODD.!/J%B?P+%28D.H)84CD#:$4ZWB,1S'F7&"57]:0,!5QK6L[^5V M&P)"I\>C4Y)&R_8@5ELRCW07&^IAAKE/6H9(+JB7T>S#(3^DM"@#59RI9G6Z MD7Q_H)?T.;_[3*,G^BF)\T>3FS:^2T"P3Y"["W?9 MU89T8+\A57\;_H;L/66X#]F2_>_,J)&K&.DII!D%7T$NW5PP[FKN5 PC+%(5 M>\ZK4(,";9EI M9%:U2''+>O>,KT?L7PKM#6)2I8\=PB;UT)W_*YJD9QA=5SE MLCAY/9Q?#Y/H^:KF.H4@#Y*2K4R=76I5J4ZJL=Z(G57" ?GL\BKEP#L&'P\.EN'X,C0 M=#H"GQ.BG=45_/'W((>??7..5;O1UPJ7[Z:D\^QK>6>O M8&>KD5G(\.UK6,9[&)VTNVT"%%\5?XR#,/-Y^@P-SIY]UE2FY8Q51WU_:U%) M@\1CU++9'9']%4XAJA0$J-X%[ M :H2KX3UO*)#&'?4#HI(&2 +HIJ?O/],TNN4N^/YRVGD,?M@3O#4$0"JF9;G M_GN)K"$I6Q+15)/7":,O2W .J1)FM'2!;X8*$KRM2:AZ$E2(:]-.U5#19)MB MP7P>[G&A;DZ2M<$&*#O6B\XR_@JB0WYLMREHAFR/SWZ.K!<1V0;I>=29F87- MW57CH)^]JP;!U%N;XL:=%H*:=J#W,]L<&IYU00+?G)S"WAA5S'W_FNA2$^]^ M-W3:L )%O=A^X33)W'V'1#.ZDPBEQ M7KQ_H-MR:=K!%4;I<=A?]]@^O6R#N#\QCFBG7HAZ.&>:2>WN0ML28S:UWGAG M/A'=<,O(:N=TN-/M,*MF3T;5$F-6#=YI:U:QO03]R&IG%?UV6<&(5;P"7[X6[OX914'0*EK@*XX CL7>,/4?*YTLAC/P^?PCRD MF3Q5==AY#>@#^(5D5\F4CT]SXF;:0$V_(44.USIV<8/G4/40\J )1/ _R@P< M9P>D)D#S0!H\6UV0:TU*-(8/XL2WSW4D.>1;!IR,I#3B:2T\P:V3V(B:Y&W& MD-DMZ0((!/0G\JV=VT=*\PO^!;8N6,ZC]22 P#?PW850T92(MJ1LC'HJO13W MD%"W(:<+=AMLT.!N/9\V$2%#7AM7TL$&]91Z20FPH6\^J[9#:$+@[#W=TC2E M05'NV!P[TS2&"I_I>.W.?MFN+.Z->2@XF.=S$1Y90>#/B(Q6[&]Y6#@=% X> MZIEK==]YSV4B;VB+0JO; I9^57&J*I'7:(>I1C-S#%EV58N);EG590'A6C;5 M=9BCNMU<"G2VVT?)"Z4WQT08I4FSG5%3\0(WZ M:F:]%^_53#E0IKI8.*Z]-)<5\SV?:UIV\M+\BR7V.Z03T.SV ;+UDW7DBBK: MH(:%%Q<#-B-^*-[ZN?)#P0:N2-;8L:HQDF(8,B(^:V/;2-W&S!&MZ9.8&Z MU004.EKM+\"#G2JM&+P^@!88.7<(F4=P+A"=QW[*TQ?.R[=QV5(=\&0&7KW? M$DEPHX6"G:,DW=$LR4@85Z\*"DI2DF(&(N"% M/ (>+_O76B G2:S=QWQ[]LS1.;17MR M7]VJQWL*=\!,=#U4AVF8L%SY%YL5!U1)J*5!RV9MYWH@4K3!M M_(S<@AEO/0Y:IEH/ IAT=0[]0A$N#&\A6]I#IJ%K..ZEG L+5=DL[/>/G0:\ MET=N&FV8EQ?I;I^D7OIR]K>#*-N87J6WO+I#\!?^R,DU306 #8AQ[@'R)49G MJ7JA^)*22%*>9YZ2)"62G AZ7D&-B!YP8DSCQ;M,^-V92+Y@@_JNY##<]=Z7 M' 8Z#%42#&3'A_PQ2<._T\!=A?J4>*JCD,*N,I*(U%2K4!,'4:2+X1T9)QE_B7,?UNFG3W=O-39IK MZ&A!Q>QILN.7M.4MD0;C)R]UFV(ZC_D#O@-B"U._@1.)F#PRQKA%0TF:_3-Q#:4VR0>45Q7KF ='ALC(/" "42_Y6?8!2VY'IQT@S+L<=J$J$<8;H*9G M3&834AF4L]X%M'+*@7V:H0I4\QP'UVS\+[T=M:9A+/,Y%']HUO$R01@U#V0] M\N*X?O-KA=XQG%\E@/*PF*\:^CD-1 #PQSC,LYO;'QWJ\!KI0+.SS!+T\Y[* M]D745E"0-XPF^Q*]9N\LLBPFA&-UH EB9$*,@U$,V)PT!_WHIZ(>I72\&R20403;"RGT9/11M$D :(:L6=PV05877L3W1^48NA\1S=+ZFK8?+6)CLGB[B9 DX MK>3$>CZH#/;0G7&R;IV11RSG,?,\1)9<)NY)W3UZ<;&&?&1=Y-EY?$W3,#&= M!,*Q\!KT;_BXSJZEF^)0DS2X(/)F8<[X*)V$#9&L\!Q&RYR[+O3@(XX=B;-C(!H>45[EC/9.]A=D;J>VS&<>1JO[*3>B' M)-W2D*$(U8HJN/A5&%+5Z.+9THJ;)%R._2F_XV\I7-1@,UL]."G]-PB2']L9$0<33V@79AC0(YP\7BTF^ MS;TTMUF'$4+56OU94F5MU3ZA#V$< =5?[/55-KY!?Q# '$X-66 M(VN=J0TP'Y"6?S5#8ETO7H4':+-'L[EZ-F.T;K-M=50OD_A)^*K+F?/A/+P& M,S]B9/$VQQ4OKWAIF&' #1OD7\%"L>P _3J6C;'V$"YRH#&&ZUYFE.=R'],D M6R3)QO2UU[!T&$=KR3U"]PB?_X9]]96=Y \:/B>7^-=U?&]7QKF=8X,FO@J[ M51Q['1C6ESPC,GWM%=DM]6@M:;<:7WS%!SR#AL_);OW:CLCMZCBWY3+HXH0* M:B>WQT6XUU)=4]$0JGZ:BL?> W_DEAR7ARDK*">I'==60;)E!]6I4*33X-XV MAW;7'UK@R@Y56K\L-*'1K"@JWD:\VMY0/WF(>:T5J3BG298/J" YZ_=0*C[, M.V*#[QV=/?./L+^RY:"L&LC[WI#C77+@!9C5!1^ W'NH83KL=KPT$U\I&R.V M+YYJ)E2.TLI*?2Z@;/I2& MH&NS]PDE\7SC<]YG]2QAW&6<;I04LT87^)A", M.8(:I9/F*&6%X,Q%]W;KN.0WKRIIKP;.JTK6!!@$.1(GDN]JB4"D?W(M"T2UUK8Q4@.IB MYEY1UI^U)E5S4K9'+8&UK R0RN& I:Y&. )4PVL1; L=/BJH"W39 2:I6J MY>58@4J8RT@Y@0HFV$0CUMW#<1Q\\M)?:,Y^+A8I:]T8.RED",@N1\_SD"1B MAU01E5X4>NV8,0)Y$\8KD6 M+YQ3J%5ITP#X*8H!NF)OO"9E:=[0(O:O6H/8/_YZ%^;\E.$\#L*G,#@PS5;O M]@UM ;3#Q&GOP0_>CI\HU2T1]\/6,2Y!81U@. C\%.:/XAUEGF3Q&.[ODK,X M#PVO<8_J!0LV5NF< (6XGYPP9T:PN4T8R)K.;V!S#]X<>6RU ERCV]QUX5+\ M%36..(5#R,53,<_=15(QR9 0M$;].NW@8:BU6]4TH\;PIG*) $=S1$XYX1/R M#957S,^>:>J'&;U.0Y_>\),[C2T/Y=CU&N!B9Q3P2P3NIB*37:EKFF<\8/<.!#W):^3+$]I M'J;B1.L]W88Q#4YHS'[(^7LG_!:E?TA3?MP5>O=A%.:AT[N+,W\'T)6;>X2Z M""E;O6Q(T1LINB.\/\/+C#!.XGKEAW0_%]&3KONZB)* F)&+),M.DY@[WS3V M7XY]/^4ALOR46;T7]DOQMK+!/#C2 ZJ]JT0].#,ZTB D!>7\RIOD7F13WK%2 MW/'.B5]1,EQAEFX8*\9I4X!FJ85[[(IN,TE45-?0B -I( =9@*[A&Z3^B :M MQ4]M?0<;-FT_Z 9.+Z'-T&U*2R>JXA1T."[+5-'8'X^*ORYL QUS'Z8*Q#:4 MGQ]#_Y$T)%N?L;!HEYO1L*C66HS'Z1R6XW2=9N-TC,TX7;G!T MU^LHLA5Z2 MRDQH)F-E)N)TLGTX13 ._7WJ+A0RQMA_]R]NR+[]YX.94<:,\"72BA3BJ*YJ0(-)+ *;5 M@W#64FQXD#GI]B2P^0VP>078#IVI@C\)==@NR%(*Y[&?\C=_WE/YWVE[>%V? MZ]K2:R5WM2:;HK@@*?L@;\I>OESMGM]9ZAO*MN>9%XF3_D/&7O31"^/L. [XWVEV M%2OR)9P]^2%=HOGW@^1VT)ZB/R(Z)*Q'(KLD5[$R,P=CGS_O(-0R/PB9^67& M2,JI-3 M3X(*<>VU#S544"][+L4]+M3-]T%ML)ERBRV)V)>25-9!?$AI40,NRXYS7BPT MHOP/YED[@*I\LW\0GJ5D$="2H\G@UFE MA+ND-P*J[3MZ6#AUNZ*WS%1&O9F<:\\G+_>4(;'L//:C&\K?+63;4/[:D-EH MN%)#F0MG:7K9AN(]U9J2'PU%I$6+:2$FRK6OY0H9Z5>W*%-$M_0M80SN O$SK*E-WBMJ$I.&AEJ3(=?3& M2R8O?9+ZIB=)JLS%==31&X;$WJW603"6M=Q11^1W( MY5*4@]@R_\N-H).5=Q[)N=RUJD-S19)>,W!H:??S#7!A%PS1#*8:8%A%/P:, MZ&Q%<5J;F#BX"'U>:;3ZSI! @IX:)X1@D,82/.!GT)*T$4A =YV'S95A)PTR M42/VT*,G3!R<%A/FS:TBPDO?4_ZI^$&^O?#.N$GNM07=$O')X/%!?V^HTPA*D[J\J4O^E U@RQ6Y,XBF&\JI;6G$Q MZO77:1(<_/PJ+9XM-;Q?H&X*5(=>PV;"2^W:(G\>H%I@)OUY$VCN_3L M\_S,XK.9\94"0WM8'"@Y=@(#\LL#UA%78$(_W!/6P>*=E.SDY<,A]NV)$/KV M4*NC@>/NS)=-R?T+*1MC'E0NQ3K8TFI#2VN5!8&*TX([<=QGS\ FF-+IY;RG+HI/NI"23!W6":MPF M?NA%M]0_I&'^PG/#T_#^((Y5=5IB)(%2&#/?O?="16N2% M3+D#K>M5[[-DG)ODC3\FL2] V3<1*4NZ;E9V#0UFF)F9@E;''I MY8=4_T*QL35\R*+#K6GW*9NN(UPQ']L(H0H50C2!BL7@,3!,,6"\8]$4/N69 MC<"CE]':&IP]^]&!7Y:^2.('!JY=_:<[[SXR%=\:TQED*O0867M1Z*(34C?= MD*H?PCLZXCTU_DY^%IWA)A2/GN=>NF+*=.XVPHL?-#E MKK?EJQJ@W+L>S"1O@1<*4,YU>_>_W$2[;?@'CN5%70GN,U ME0$[.5HWH!JT8:5'#QM5^(M3IU[V>!P'_#]G?SN$3U[$]PB6$AHF(D"OP,A[ M+_F6M1*!<_%#H_T*JE+8)Z&[E-MG *@Z19:GH9_30,V0^K?6RWC3N@6MF3W2\Z,7VF82J'AC&]VLJDR0^>+Q[AM%A)/0EDK5 ]W[T"3S0. M:$HNO=T:*O78!KQ73-,RVF@HD<-JK=IC)T5&34>._M.T,>5%VHIL\I)J0PI8 MK<&"N4Z/"[94WQ7"=D]:6 W1"G+8@LTY,/2]S[8R[!<'/8W&MI_'1]Z*H MQ-UC44%0.J.4&R(\)Z*EX10 A8S2KNFZ!\ M^X!7_$Z$P(WC+!)(@=GOR5XI,)B]&(WDE@'!A;&319EU?LOI=9Q=A! )O[;+ M0.]%MK!(IR%D**3+H_+NL6A _H5&P0HK\]YOBC+W6N>\ M-_LK<,9UPZM'P'!G&_:0U6(>1O2UUB-6W:6O,2>LZ(9H]!Q/.E\%-V>#N+-: MO%&]K17.^HMK8P"] MLZ8:XG@7JV<$C?P[R1;P5<>VG^6S%GLQ5GESK/CA3O$N*V\I4\=XV)1O<'+#6"%N8F?0 M/,L&=RUJ-W+S^TH@!;]SOO4?:7"(F-C'<1X&873(PR=:W+8):297$AI\8!#D MU:&K,%)KNFJO M5R)3HY?XFV, %'5U#@!"B K(TRNLNVL[*;HJM.1PQ/.F2"Y9P0[9=7+>T\ ]MMBWK$:R/I1V?BWOWGWW=L_ M624 V[A98=/:A,%@QFE#-=,$S)6/<,W^>(C92O.3D_)IFT.IGI[??AFNHB59 M#VHMH]W"+,10.R%VTI#O1%OPO?A$K^K"D(@V_R?0O9M1X^+JU0_>;5_@)L,M M!:&9'?\>?EZ#7AWO^(O&RRE5V?_KT:AJ1!92IPV17WC%FM0&SNR/\']KCYYY6E=12Z<2>=>C: M(5LMR9)F>M<.AX(BH2KNL$@=7M2JX_!_-RZL(EF%*PDR0%0#BRR]Q M2R0R_^6_O2^C3V\HS<(D_OLODU_W?OF$8C\)PGC^]U^*_.7S[)?_]J__^3_] MRW_Y_/D;BE'JY2CX]+SZ='YY=?/IWT[OKS]=Q5GNQ3[Z=)[XQ1+%^:?/GQ9Y M_OJW+U]^_OSY:_ 2QED2%3G^0/:KGRR_X-]_9Q_\=+__ZQ[^3_RO_G^I_^]=_2WKWM_VYO]GT__]^[[__O\F?0@"N,_GKT,?<(]CK.__U+[ MQOMS&OV:I/,OT[V]_2_K@K^PDG][S\)&Z9_[Z[*3+__V_?K!7Z"E]SDL86QJ MD69X]2;'Q\=?Z*^X:!;^+:/UKQ/?RZD,E?WZ)"Q!_NOSNMAG\J?/D^GG_'[+J2CW#O?W M2.W_>I9@DN^\.2Y(&OGM_JK14USAN78@#%&(J( 7&W>[7K-C M)Q[">1R^X,$6YQ=O!#-6S,?4BS//IWIJVC5U>UW5 RL:&3SX?P@/;UY$OF), MO*"5CIV[Q3-7>E:D9 X[R3)DWC%>"QT[=8WP\HP5/$\Q!\8=VJ[=5>E3+T!W MWLI[CA#1C3K>Z]![#B.\#"#C7FHWVW6X=)YR>IA(:).GF*8 2V#99CCP6N@^ MC>=X5XYWYRWHW*K<=52R53>>7^&CPM)X2[E3O6-W3J*HW'W?OMQA+4CB&$47 M[Z]D(3*6E**QSB0NEV'>2J4:53MVXQY%;->T"%^S'V&^H'\@RIJVF2R4S76= M#G-!!Y7Q=-NHV[$CY0K\DJ.4;!FB)$.W+_A?^ -A$IAV3=6:M>W0'=Z) MM9DU>"WTLMMXI,N,G3W'NBWK.X]VG12W8W47TJYS_#:&V9&TZ[%AX]8W NUZ M+6['YJ:@Y2CB-6%W@]!RY/ ;Z7.ST*ZC6DU:7 );CG5."SV?=6NK6782!-0> MY457\4N2+JF\SE'NA<9&,&N?[64M>RB62R]=W;Z^UF*L%)9!R7\@G50%L>B8>-6]SR5 M.JQ7"OI[=EGD18J^AW&X+);K!?<>^0@/ 3SOM0-J]=/]B.$>?VR][%@%R6NX M'P@/Q2NN3*3F16L+>$V-RG/E8W);I%N2MPJX>S>&V4,W)\3:#Z>K&X]H8CNI MV/[Z,,*P.*O9^*)UPZC-'919X]9/4=7,DA4G>-/VAGO0 8EVV_T!V?VIG#"M MPU)^R3I(VXJGW[C-T_%&@.4X;OR(Q_A-$O-^:;E)M_CE7H3P/7FCZ]M5W!M: MQ2=LPK*HH?KMVK61[.XHV=];;LO-&N_3IK+YMK34Z>JRB/WVM/72!1?$TF4? MUT,'[-U_61VS>JWV>VMF$5"7+UDT-&Y4A%T$+9/X(4_\/VK&I!^+T%_\0"FZ M>/>C(D#!99HL26DO\HNH5*KS,"IPYV]07F^\Y8%MZ.Y1<;ZF*".'05+A&DNO M(5?TGJ,8M[V6+.FGL7,E]7!-_$;#=%@F:9,QTFZ&&Z:>HQGR?YTG;U\"%'[! M+$[)/PB=4THE_H\G^H63YXP><-B8H_S?8G!X=''(9.TF:GO=1?MXW_N4-/TP>W+/'EE?I-?O878;1A M]@5KCTILY8<3 P!%ACN4O+(1_]DP;+++/<\][9>2A*,_6?ZE8+/_PM''L8V=(X6HA /@(:@IO0YE/$Q\&DZ=(VFDR 5SI6-WQFP?4!R^'+>)62WRWPNCDRY MR%&:H>N>">%,&OBLAJ[P8B^: F55V%PS&]4DJ(6'S^G,M?&UQO*(6U301XJP M YA;:]:N[,64-3#P*3IVC:(3W/& =/XR\N:B:;!>A@(\VAL=27P0@G/[GFLT MK4$SE[B+.#C'!R#%D&J498@!MQ<=QQ8?C("^@>TN^O1=AIGO1?^.O/02_T6U MI&V59JC=LJJ84"B"(R!Q8(.**8E,(?5IK)5GR %WDU:(Y $24#FP^43WH'V/ MYB$Q_<;YC;<4S::\H@POD VL X%2+ +NC"TFPW!WAHC#7W05!^C]?Z"5E+RM ML@SQUY&R)P(CH,\]TPA%<1E&Z*:0'+VWBSU-]O>.][Z.[W @!B)@S#DK2>G8 M5"W?\NVGJ#C3U,/1$:C$(^#1V,(RT,3)X-RCUR0EECYRE2+2-EMD9.X="0>GWR: ME52DLIB-SWQC@$S LK.VG/]9>"E6VVC%UA"%$6"K]--T+P6'2$> 8^.&G0>%BB*-E'@)%-MO2#!>K W MO@L-"1(!:XZ:!;FOS,%SKT<6LPG1VK64<.24"HH\:=DR# TL_. MDB+.%>>19E&&=WPKHA2+@#OGS#SE?++THNBTR##J3&X5:)2DPAGMX.-#$1#G MJ%V'O 9+\=I-H5/_V%(1SY) ?K-/>4T4_X/D<5$ M9XJMEW^:[$_V)B-TXM! )"#340/0>LW _[Q-'Y.?0E]1?NGR,F'D1/+P"/SP M';7YE$#NDBSWHO\5OBKG7%Z%$OSX'#QT( GX=,ZZ0W3Q)$6>A,%ZD1+@^$[^ M?! "EIPSVUPGQ %ED<3R2^3M8B70\3ENB($(&'/.0/. _"+%.C>9/C^&N?"E MZ'8QMAD?WR6C$(> +^=,,R1\$KD672V?DTA 5J,,17@\OIT('X2 )N<,+FL] M6[\/D3BR\8HRO..[5I)B$7#GG,'E)FGHGL0!GU.232CCN_"501$0YZC!Y=%[ MOPJP &@86])G#7\V01UR>IU.]\>WS&FB$A#;R<#R93N@1[]!/HRSD@&$<.!T M0Q(VQ*3ZTVQZ>'APU'I,M8+E+U!01(C$+GU#<8$R$OGE I.88BTZ*[(\6:*4 M!%^[3N+Y=?B&@EIP?AG@3@TS40!-O*TX:PY;RU(8?^"3L\C+\ BFWBFZ04^V MZU!Q0)GA+#,J4!W"I'(T;X3P]-HU94@L148!FAX MWJ7)*TKSU5WD87!Q0!:85[+%O$$R@F75J&@.@<^Y2M[X=&OALA5,!FJ);60Q MN@_GB_SVY;<,49')5EM9/284N0),'/,.)=WYM49Z("/B.WU $C?+:BU\#OL2LYZ6VSJ_)4&%"A;;H.>"D@ M6_%M@-BM28,BE!"[792) ,B'OR.G0BRVXMV [KZ5>VT&UXD3D]'.>M-O6T%N M@&BJ9PJ, WI-TLRYISXTZ39!13:#OD,T-44;H[,5+0=H&J[AU3=5BRLQL0 ? MJHPY5*J""*6ML#I01B_?)\_'LC*M*$TQJF$"$]=B@@'>6FOP)ICJ-8#9BL?S MAM+G!/Y8O9;52L.*+:W(! 1L,FO-O"8V6X%[VI*_FQJ-_(58@]["#'?J,DEW M1SO:D[T[6EC=D& MEJT@14!\MKH'D0MP!O66V3+;&BAMA3:"WBE(10,6(,&"(3ZT0 MC:W81E"W&D$0LK[?>6%P%9]YKV'NR;R&!#680,!?PK6D5P7*5FPD()8?4WPH M+-*5UL#=+YN>HV,GAE)".D4+5"1+G1ICLD(^/!FK!!6$-L*/04TA^P*S>@\Q\0 M;&QK/1-(\-@*3 5O?N$>;3LX+S(1N6-WLV2HD6.U%X/%^#J>#8=>+8M^Z4,6-4H2,/60S_),I*I:+[EHAI_0"DV6Y"-9!*3D:0; M5(I7C\;0.]@'MZEPJ5+P*L5;@&FWXJ)J9 M]SL21/04EBWQ YM+%-0HS=O;6"Q%A0)S*N@<$8Q,>,!N8NWFX%T,EH)$#3\N M&S;<4EEI,E%=.W:]SM/L\.OTP)5E=9)VDD4?%+DBR0-_UF=<.7$;]=B<@$W3K95EA1C*KP>3ARMK*S.IH7CU+% EP/%;H-H> M68*7C5%*/ MR09XME4S)QK#.LBZFIJ@/>L>4(2;FV.0W[WT#U23DVQ=%59B<@&^*V_+N :L MKK8G:+J_H1C+)L(03X)E&(=$+CG>4ZHY5]1D$@)^W]"6>%UL70U/T.SOR,=D M_:92F *;D]LR+$;3U<;4Y/01QOMI Z_RYM2AMBK-Q#&V;;8,"&C@N\H MNWC'$Q;&B<62KJCTR&-87!/CB*@N8RPHDYVM>OPJ)68?_/F:X40PA$"LA4Z' M62(VT,LA>(KW/"_2=S."&DP@#EXK:VB(&$SG$.G0>[L;E&LM_HUR#+Z#=\52 M+OD0K$4V!]K"25[F\-YIX#TOH2D.3)^]]/O!I\G^WO%D,K8%I&]AC#PPNTP\ M]\@G"38WB;$K,9"U^.3V[.J.5*'2HNW<)?C(AO(PI0R5$S')6J+S<&_@GI0, MCFVU Y.2M8CU8"X;VR+3T$E)K5(R8UMAM1"-/.S]^KGTVKWLU,M"7\(RM_S3 M=')P=#";@H=V,:98#6?D4>Q_()(-"04G;_@,.$YL@#WF\/A/,P*G*IFYZ@1B64L6T7= #9"G+OUFQ0 M(MW1[ +45%=]Q[TZ2U_@R2GX".7)N/F_FM;E3C2C"9'.K MX+B]:G+DRO0JDZ2FY8J"L>2,"?;TK#I!9H\)/EXFL1]&J('U,2&BHC%^\5 \ M7?V&!]55O+F_._'S\(U%)=#(T-O#YQ@7KMRKF2M6KS*QY&<*II]8#/:TS[PQ M)D?H_'9]*HAPLFLK*5!W65'@JHW\C3;/]B'3H9N74U:X!_W8W,.8'H'K)E.7:5252*29<@^?P^_)!='M"UZLZ7PI.KQV:)+)"O@%:6*1NS;CO5PY M-$_\?Q1ABK ,\##)5\3#-<=S,0DT2I_^2Q1&OQ$F-F!7D YL\]6G!?[.GL+0 M2QF&Z",4T!=G#UZ$;E]::8Y^*Z7G+?".V;[NM)& -=]C1R8=)C[Z-Y-IIE:- M2=E-.Y[%B86'N+.CI1)SI>Z/8-TGY?BC?I!(0VN3T*YG[D.B'MS;QY^ZWJ/ M7LLU]O:%FBRODWC^B-+E.7K6W;A*VV!" W9_Z\"U>M>J!U^@,[#67BZ,VY=& M$'Z=+8JH+D,/;("S1KXY; 'I8TFH7,=*PG>30#ZW*3NE*?/JJ2M3<[FC&Q$[ M4X,"MT ]C(VN8*[5=:SKL]IEDM)9D"-!36W1:(ER /VNNE?5,1&"0(_&8H/5 MEZ.5#2P3FYNFDO:ZTP*_0&W,'66!7O"_O" ?+[T7[_["B^?H'A\%;F,B!/)_ M9*I]PY,N'D+W^ 28AGZ. O(#N5]M_*%6\BKVHX*\9CP/L]:SL&(HJ***2=01OG/5@TQW,AJ8GM$EN-9O\2=6Q(0"!AAF;[5^I MCF-(:?Z7GFV)>;SV67L"$.B9L9V?Z=E%W+@B="PB!9W-\2:'/I1:)!&&FI6F MFJ'S1VO<.C0+8H68[1_,!AV^[5.%S0Z@';X$TN,/)T'_QY\)S&HN>BH65R+U M-)E2T"J%,]I4878RT5,QN!*$44J4X!@L1?4G34-/X0.;-N3$"/8U0B1CST%_ M$@0AZ_R=%^(S9_DZ0LFMM!Z3#O!QJ0W/>JC&':N@<>NIY)E3FLD!^(%/&W9E M6,8=A> >Y1@^"M91(96T\BLP:0#[?;1A5@%GW-GG3WR_6!81.3:*@H2KIVO= M-JC,H(.GMYJZC1&..WI #2\WH8&)2D@:8-("/EUUU <=>'VEMA_X8'W=,L7V M_F3F3 (0HR/T+@9;C_HAS"-X7]*T_\E8W"Y,C4E?77G0N$N,B$DA#EN/[4'O M&DSB5.\&:":B.'3%MJ5-J1!&Y\?P+C#:-@PR5FI7[%FZ3/(A6'MW[EYFI([I MC#895ZBH7+G'TV7;"-G(WY#398>X^J+@O$CQ',6<+G[WH@+=H)_T%_DF2J,^ M$Q;P>;K=BJP-S5;Z*# +J N6\3.0^*922ZMP\TK5O+&V5PSY.U12J C ]O2 M%$VH(W\0WH@1(S <__!2?/;,F8BDUG3#MLIG]6.;6CK@''EJ*]FDVK!+X^&B MTA;CMMB0<\5]S<8Z)(,VBP+]:=L( ? M?A +^*'0 F[^%IWK!3T:^_?H-JY"&+8>C\-[M3\N$-GG>/&0/NIE,&\R"291 MZ&OFGA-66L^<1_O#^J^3?+P9B9E74^ CQEI!D>(_SW2X_8JI.(WYD#QO- M5J( WD)ILL4?>-8DT%]ZQT$':0WYQ1OU6XZ9,P06)WT+W?5HH/K [0N>)]B& MA3S5C?"1'4F&;. OGN90/\2( MX^1D4*9 1LKE7+F MCQE-9!]BV-"$8F5R,;)OK<\7]?Q;@P:J7W>&)EWV(IWMFZ06(6RR.7@,:NE9 MIVVK$DC79&JVDVO9(@,/;!31(4=P<]D1]8<8HZ!Q-7:M^S=)KK/(R2MNS%63 M8^ ;&M(KLZ&HW48%$MS129L+W3L>'<@?Q0RY20"^#I ZX/BK9'S[TO3,H#?I M9TF69Y7OQKJ#&N.S6\-XACW>FTT&';O:/6YPI3.B.[;,A '\S,42G_SQ;TM M'V(]/J,A.^K;.K&N!#6>9H?3R<#6S*VN5 HE>Z4@KL0@ -LK M5>(5'"_5H#[$,-D9/Q M)JI#XW1NS(==+C.DXE'>>.O59KT%WO^I9M;2*.[ Z-VJ*WZ>%CO,*T.:MU=&S7$H *G?6I'CN ^NQW\#S%$Z;&2N,XL MPM?L1Y@ORG/FG9<.?!M1^_"J[M.C,5)55GP\K/E3U">SD6G0"M7+/>![ M0&TF^".Q#=P/,0S)217O"JAA9\A0WF44O/6G=8)Z"ZI09J?#CK'MONB,*&$= M"F ?>/PHIZC!/580"@'U.II"NX;E."^A#K2_4(9_V<8<2/*!A@T8-.@AN3Y8\D08W]+TC Z\1M9>RZR/%SB/:OL M;J59D.*'3E#9FF,!%DLI*,"XO$$_:R))DQC_TV=I=TQ'NFE35(;0]VNM]:$U M6DMY+0+T$K+X&-^*,"#9F"U8LB6@;I+\WU%^$N">XW.JIFIT;Y2*#?J]NK&2 M6,3=7_8,!UYMT3C&'^;MUL!NAOX"!05)ORZ1K=;QQJ@A"A4Z/)$F&X*33SN\ M'^(XQ'FK8S@$!WO0-7#"O(U2"$1D-I)4C5"(7X%&D:[X5<-'&V1?0V&/N"YPQSTEEX,N MRPU4@UN#R0/:Q[;AH7A]C>AIV(O6.;2O8KQ:+.M>_X_) M]AM9%>%]?(:)%#C&FJ&6]"H'2S:L4;Q+'GQ)I_VH=6"]&=/T+1?77#^<.YP! M!,O8EJBV7[FP8@4'>/DV$3M_*C< ^B',$)QW7$./,IU)&W!D9:/U](0C ;?-I]%7I;=OI3I(V[3^W"^R$FB=IGA6U2' MBF/B2KJN)D-\.M500+?,_=#+,H&:$KS)'XKE AVQ3+*1L!9]FBV1:4(G0VH MJ]Z88OT0E]);(2I@3-C]1$>93HR,8\I[J.T0,LH;I:T*K$_ P?WT^.]@2_U*J7"N]T@C(H\?$,/R"=>85CF%^]^5&"2+K$.$T-'D9=Z MUR:V@/V/T9Q%T/&N](E5GEYMBZ6'.TBG\J[5@AMD5>+?FL?2.X2KIA#K MXG++C2%+\YJNXO^J]!3_Q],]P2-P56C\SN!!Y\/MC[6FFO"A6]H*#LCL=[1\ MYJ8OWRK!(!["L,L7MH"0K?Y:\C08AI+O81PNBZ64E$89!A/(""82^2XQ_#Y; M96LXL=[5_-3+\.P J7H,>"'V^=Q7_4_XK;Q_K^:VA7^=MSR3!; KI:# M+6IZHK!TO3Z\Q\^NP#R^C(3CNV5+5'3'P!8R.:E\16B+DZ\B1[VKB."L^7OH M97^$<;X\PV7Q:2&Z2Y-YZBTOD_2," V+[V2.@E.4_T0HODR*]#&YB! ^40@U MP4J[3%[0,59:4B$OS (O73UX&TVX>[#9> MDM\0F1%?%V1VE%A5A.4I_F-HY^(AK2QJ40A4P5&#V@.:;Z,1#GMI>88?R/U7 MCQD.FTHT C8=-:*Q)Z?^2C*6ZT482N"4O8,.7RYZ <<#6^4RY/\Z3]Z^^&47 M&<_K_ZIX7O^%9-0IX9!$':)!*RO.) !HK^/2T61-J_\"!L?P[F<]:Y7OU+1V MYZ(Z1![3Z9_ETD-?' +U,+8=@CW5I9!TGW#6"C,)0!_7E/SP>97 $1#:O]5/ ME/IMB5)R[WN.7I,LS,E)@_AKB$UW&K4HV'W@P2SA@&-QT00D8,_8( ?UOKK[ MM':M\5+7YF>8*>O/N9$H'7)[TPSFQ($Q.P(>+_?"RN\ MR6@7MH [8S.=51?J+>OT8QKB?[-T/@)"Q34H4O"HS ,1K"$&@0>,L5D.++(# M7G:OLJQ P7F1DO#Q%!Y;5&_03_J3_*2@TP 3%_#J,(#6M)2*0(G&$B23P6)P M[_#V#&WR[$GT1E2'"04Z%,R JJ(4A$ [QA(LB(Z%11+A7FHE.*>O2<3@#=EH84(GT!2+0FNX.C0XDC-D$F3]-D?=' MD/R,15D\3-^'=+<.\'.2L"CX>*_QNQ<56MG73=IAV4F,'O]: :KH/^L6]'FS ME2 %%H4Z*!??XS91/J)T6=KB>*<$10T&%-AX;(,]79PC#_NH(ZFN$PZ3%; _ MC^T1K8_:5J#()/>BX37DU(O_N,5;S"#U7K@3 K\@17\$;52RR+D GH,/0)P< M_D?01S:0X7]D+]HD=!+&W=Q.F_WTSD^#[Y]I#Y2IXR2EGVBZ,1N!<.ZQ^+%J M+C:9K$1[J)V"-+D5^,6[3#B<'9($Q;C3!-VEZ-4+ XQ+:BRO%V-R CZYZ/,G MA3#N;6T)J8Q^4TY-:A:;Y9DL1C,<];" 1BV7Y?^\1S["2RD)VR/F2U:<000^ M91C.GBHHX]Y=UH2A'H*[A:D4H.^ES<>?!(BMU\C;)T%7-H([FX$1;@19AM%A M$PASLYZJ@N&(*Y48')P*-\+E#QT=2&Y%GNE*\K6&3Y^\(I/,$?!EE@YS!IQS MT$'%I=$]YE6KN/:!KZK"8$+GHM.E0N<8R,-F:>_YRAQOU [Q&Y1$>; MWF]"<9(?8JX)3*O>.OO>T=Z8J37 "+IAU1VJ928WIJ)(Z#&IJH>E-ID<0=]4 MVART0H"@871T:3T)_J/(4'BP(LMFUM'\MR; #^Z ML*D'+:#WE;#&L34:]_3CT,S#9BGL#5NC+^*@-RYODEAA)Y)483/;$;!+JDTN M>=A 0]#H\FA*8A/E!YIT=X!9"@\#G$UFQUK49T1FSM<4\9;%-3;[V@,C8Y!V MST3V'5GQ33;O8R#%-Y&9R-ZM@/6Q##RJB(VB.I5(((-3Z_!E8-;9 >96L.&N M7)-X3\KW]HJ:E7A554JI$!.;2WG9B-A_?.H#]$2N)KY&6(Y/ DN]6:!^/:IDU_SRX+DBNKC/A>&D6SREHR M_*VV4?=,$@(:-4A>B>W-AKT:W\0!4N:&:12D787>0G64,G_1%> T R+ 7H0$1*COC<2N" ^F)V)O6[]Q])>I)++ M5Q2E8L#R*S!I %OBC4:K L>X?39WP2D'K*@*DPBPA5Y!EB[#6XC&G5;F'GG1 M14947L-VT2S*) "40TN;'I&Y0H#%Q;OKRGM2'@YRNQP!-8&^I#8D2 [$THTT M],Y69G 2%V82 [84MMO+[F(8=TJ4:X25$S7/=->A]QQ&8;Y:'^?."W2#WO/' MGRAZ0]^3.%_(^&[;)!L;KFR(=XGF:T9GM'U=B+NE/_^.O/3Q9V)!;W. @S MGUSWH>#BW<=%V>5?6^T0M<>$"9U.Q*JJ**%VSB1SS/0F1G/<;W.?:(FQI,),#V(6/V56!LI8*!>H?/AZ?Q)E]:D8D'.A&8):ZW,75.%N/HD":1 M9=OR7M5E8AK+/M$"_,.I;[)G*%NBHG0%2\-*XHB0]E;%AD7 MW.?N\;?*>%/#Q\XN^Y3E&GYO.V4)/_N3/9@K(5.7MOV#Z1[PP4HL0,5M4!/" M:-_X6'94(^)PY;#49$A!IQ#*:%_T=/91(P)PY3 DI(=/JP0.U/,G>>M^5_>$N.SI'Y&THX_8!^X;GH^L$[Y5B8@8*8TK&[0M%*F%75HU) MQI6=B2[)6H@L^6M!9SX0&#T>BM?7B K-BT@JB,LH^5F+:'*/(F+X?TQNBW3K M(1A(>C'2O4T_3OP\? MS#)-=?&JF%M-J@])_, 6<;M=7^]KS[;H"ZSJPFX.Y MH'7FX1V(?3T8''1H/J9>0*#1X.DG<5!_'[V^W\$5FIE*:C^0N5BLI2+ MY6N4K! J]Y>UJ4MN[%'5J\(X U\Q:?#"L009P7,Q2O5Y^>4RJK:<3&YA*IXC MX,FV'7MR/"Y&GW[TWK6''J\L!3<#]I-I1Y84CK-O:<_1VH!,.X+:F"S9639%N:!9A&_F9U&Z4!R948'+SF,J*V@:2WAZ4N6E>M!'1WVZ*Z?S 2 M%U'25> -JZXX=2VJ%-"X+:JE4>+.2W,67A7+ 2/)3E?U7Q0V5OU&F-1"JW7>J<9N46YH MTZE;80=:R*1D<'@S!@5J*G7!%+?_U95WHCI[% F&<1M5UXI[CM8*?.+3=XQ9 MJ;Q4D27LZC50Z;Z3QCI*))_Y%O@L&6>A71\?%EBBBR3"O<\N_E&$>#OGQ&&? MOE1J].LFR76\&.45-S:&PE:^$;[U+0&BN3;NGVI MG9Z5Q@!UY)#\*[9:L<$$;#34R\@=%7M& M5X6^RHKR?=YJ>"O(IELG*=Z:S:E1*WM,;I]Q1^)O21(0KXT'E+Z%/LITK".M M&GR:38\/#R90%I--G\^2)7EK7@Z%'UY9](0R6BM8>3K\X1$9 MYK?I/0E\K-CI".M4(H'V41UHYZ,GB=%&K./"TXVARJM5B05XU=$CSH!T#CZH M&'>"JZO3AY.RRPHGOIV"%2K@S:2NY#DW5G)0EHQ9 #?.JNE--+OI7&QU;YQ- MG]";AH$6 XOBLO1*=$3ZR"S,5S'>F1>4"?K:Z''AQ6S/15Y8ON%].PIN"L4V M=K ^,+J@+_/M:9UEM6XM3ENO9E]1&B;XC.>EN8,&I-9B^T97L:OXCL(#&0C- M+C#BH'V2QCL.!-*$36+K\ "X3-(7%.)Y W0,[/2"$@?^\F&\PT LT,[Y?*%S M]O4GM-_I @HZ$)I=8*1!I_\:[R@02+-S!N./.P1-K&\"YIK5 RVFX)IK^UE;1MRHR_CI2=1&=K937X[2F<4TLW](D MZ^7B0_RUZKKI+SM9-^&-/#-W5_&45I(":T^?IW[QURHR_KKYZ":\SJG#1WNF M=VM_\9>QJHOH!'[>+6_KMO;)KKP&VOVIS'\X^-N@\S#SHR3#D\KM2YW.,M8> M2>&>T=X^UWNK\4:H6\-4!6<'PTX_&\>.C9,F>^4B4/@H*L/LW[[<(S^9Q^0U M*YN7*3K]=T,6O\<$!^PB8XE[P?33J]C&'4#V*L:S#ZH"5^EEY9+4HG(YAE[1 M>F6DPVPO5B'.R/6M["-_NT/PO)JY/!3$APZ[%ZJ18MC6I= MA##:]T@]/3MVW3&A"]=\]=(3BJ5W0F"K5D]A#8AD/V18 ZG*Z EEY"GI[.P1 MKC5>/UK^$MMI.O,4NFTFB>!\_4:XG[@6\J9P7LGD*Q!/!N.^="P1*6U"C7(,.[#MF,>%E+6MOH_[ MTM!N7"\BD\E'/;M(QK-:(N.^3K0?X(O*!7CF5[-FP/86+DMWAT!\MXYE#/\( M!V#T\Z4P[HP7'^*JB# ![.+&UXTAKXI*(8P[R8;=^R(J$^CK[#[)-KTK6@ND MKV0=H[XEPK(Y@':4'5Y9](1BZ6+1IL)D:5Y3%OQ?E:+@_WAZ#'.R.[B*@_ M M# HO$FQQA&7)#1EXRJXAMSEJ2=BZ*[1DLC+5@!]AOJ!V0?*(:1&^/B87<4[R M^8AV+2U:8;("6G/4#&HPKHD/[+I-$,Z8>UB[>$>I'V;H#L]PZ)Y,HH)9P+0) M)@;H@#X#3@ZM!63K3FU@/1'.">:-,%$ 1:8K$5TPO V;&)2VD,X98O!0%]6:;' ME>#\*<=E*_X6H#?K&)W-CL"#< +,.7W)T58P,%>MON,)GP2LU'TI6$O+<4=) MVHH--C:U'F&,_0UMP/;MD0R +N+M+<+8H&ZA9TE,O%I0[.,_;P+9G!4I8;GQ MXTDL]A%.:A5D)LJ]_!.CS[>K WZ-1WC:?RBJK5B>^GA1>=X:/Z"O_I=R\J M4$FH1 KZC3"(P&MO/Z3Q)YX6HAEW)!H-P)4\N^E4U0Z3'?#K/L?4BB.=<;N0 M\C&?Y W4QAJU59_)"CCM*+PFB:1BRYDUR;W(L1W-]^2-RO8\AJL(D OSL M0T&6+L-;B,;]&(1L1!"UVQ"(%=ARAA/G@S9K@$CK$/K!L9)*O@88(@1]]B'R M=,#+D_>/LE)$F M;R$Y=F17L1]1]\["SXL4[X3E7.O5I@* =HMLP[(AO)$_Z]B$R-/)Z[Y3F$H! M/#.)R9Y,@F'<+R(&LY8<@J?[$E/8T>1Q*,[?97R) YKVB(]X,ZD9J\&F)I,2 M=(PL.PJP"PKT]8)@K>;W_;<,]Z6R_8F6:JW*##ZTHZ$NIRUP=7Z.T,R7\^C2 M!-^8P]B=--ZQI,@C*4;8_W:[=.&W265[\#'F 1.XMEXS##!%W*#\*L;?P7M7 ML^FA5I'A_@!3 P]3;U&\K'*9%UX:>M$W?&HA#A?D=Y3=QIQ;(6V6]9MDLG)E M?]^._Q9H;3U%L*H9ETF*PGGI;N.O+MY]>M]PCX7#;AZ$"J"N29%_A0[58,2S M 2A;+P4^_,GN*_0;^/Y.=E^M)_0&R+B WFAG7X M=2S;PVX0;;F\V(='QS!6=$,_EDUW@8>0CCBU M'%;J@*#"E@JVSYO[.MG+_D:A"@WP7:5$R)R-L1B#)8<3ZXS(W]!O%:L0 6U+ M%$*6,<)!8,E!Q%K4@\85-][AACZ)?+Y!8.(%(*I=X0>*BZ$D17GWKP7-DJ\' M8#R#EI?"&R&X4+>N#C8B=<_:4&?;]A5"';8EIY& V##I M!OY;$09>[".($\7M*R+38CPOLRZN'>RW_C[XL8(Z\K!OXPF[S.&A\\A/7I&< M"*<;'X@NB^TZ_>RC]WZ&*0]S]DW1ZBHH_C39WP?>H&H*C+.LRC&!^KW+?.>: MFCT1,<8K2Z5Q .S&WIXP*210CW8!7X_DZ=$]>D-Q(;XA:11ZFNU/CJ&?E[1G MB(_E0SSDJH<'P*MLEL0QBM:RV:P[TE*GJ\LB]D',7)OUT&0I$M5Y(CE&I\.^ M'6_]7&M_,@-?HI2"U#)PK:&XE9-'$>#T+DV"PL]OTS+VAB3"+:\H!>V,KT^3 MAR9I2@10%K NM!&GA1)+)HU *RS/X ,-0"4G0@HE0!RSFNTN+G([F:@\Q?<5 MR"JF)WG.AD.)9MRY;C8S3QG6E(8_UXWLN5V'35RNW)C*YE)]**,UB]41Z28O MJA5F G#E0;*0'CZM$CB6C%/CLUM3 ;CB[&@T-G%EE;F-I/;;)AXYK*F:+3Z\>)$OOE< \EQY0%)%\BW'PW4O_0+4SFFST M"BLQN;AWM2"G6@./I<=)8#Q_0S$^@D<8XDFP#..0'+_S\ VIR5;49!*"SK%@ MRK@N*%NY5,!XW[&\F)B[F!A<\;_1Y58,H[?W0^.SP]YX>9$"W I:M\*:W06" M6F$/@9]XJ 6I;84]%#_L<'^3:]^F<.C*YK;)4!N;PJ%P4PMEJ!W8IG#HRNY5 M2(^13>%0N'F%RNTSP'W)H2O[4=EX5")PRX5QT/N20Z ++R4GIO MG.9K>/ B+Y4$C-DNQ_;EKJQENV+F##$A!-!DU@)>'A(_]*('Y!'AZP;- BZE@FHK2N;(_):1(7&,*H.GKQ[D=%@+MY MG<1S/,27U4^J*POSQBCD"?"U1CN2^".U@PA&>QUBA%EQ36+<%A,?=(JZ]JQ; M4*.&&$9[]6($67DWTZ(U)D+@O5][XBTHTI82B>LS ( MO50T?CFE*!;H9$?6AJP,H*T;.KM7XYN^RN-#;I=CJ"!#"PJD+.5CJ^^V+ML MCLXD4&).G[8HCLN-@@PY\.VW_2,R'Z.M^S-(=M7.S5M%&7K@RW$!(2KVMA#8 MNC.SM;I5EPQX;:[N(JXE;GA:]2C@ ^#+%;LKH#9D6TE#;'&\'4_R*J8APFH8 MSFEZTL=%&8!21+IQ0^O(E4>@BZHV<1S2NT&VE38$]LW>/8IHF]DB?,U^A/F" M_@$%=UZ:.Y,)H-:GU6/JQ9E'X\GHO-%357V:'P>]C$3AM^.@S$5T%3-_ M[]L7K&/U(OJCM,-'*G4&OH/0)DEK$-N22%]A1@<=WR0P,9Z\J /7Y@DN1DTF MN22F;[)JAO4?B]!?_$ I8FLI"BXQ5Z2T%_E%5#[:/0^C LOW!N7UQ@>?%"Z\ M-,:3\Z8#&I.!J KQ>CH>.CF(OT!!$6$=/(ES?-C#,@W?4.GQC"FL,T"<[HJ\ M%/\V".5[7ZL?HJ*: >_]E#SR-^X]26*T_C4=I7"ZXC>@..#W^%5&"?23YWZT MC*_20PASM)X_?&PWWA(IK12JJDPXP/BG> M^$F<,^05&$+@VW=M&CC[9C6R<+82D SMI46Q_A:'>7;_\)N!&Q:G'I,2\/5L1Q70 VC)R:9M9#'!U'V' M?RS((?B'UL0M*+X^X,_V@'>)7:9N'6RC=:[IN*F176[8_@3EZ!CZ4=^(CAN[ MDANM(U!'29PLDT*:<-E*^TS,P*XJUG6F%]7<$E@/?DI'-D4$L! M A0#% @ @(3_5@;6N;;R"P ;IX !4 ( !624! &1B M=G0M,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0 ( ("$_U;,XK%]H2X .[. M @ 5 " 7XQ 0!D8G9T+3(P,C,P-C,P7V1E9BYX;6Q02P$" M% ,4 " " A/]6IGH=<$Y0 !I@00 %0 @ %28 $ 9&)V M="TR,#(S,#8S,%]L86(N>&UL4$L! A0#% @ @(3_5DR@]16^/ J=$# M !4 ( !T[ ! &1B=G0M,C R,S V,S!?<')E+GAM;%!+!08 1 "0 ) $4" #$[0$ ! end